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 The Insulin Receptor Substrate (IRS) proteins IRS-1 and IRS-2 are cytoplasmic 
adaptor proteins that organize and propagate intracellular signaling downstream of 
specific growth factor receptors, including the Insulin and Insulin-Like Growth Factor-1 
Receptors (IR and IGF-1R, respectively).  Despite sharing a high level of homology and 
the ability to stimulate Phosphotidylinositol-3-Kinase (PI3K) and Mitogen-Activated 
Protein Kinase (MAPK) signaling, IRS-1 and IRS-2 play distinct roles in mammary 
tumor progression.  Specifically, IRS-1 promotes growth and proliferation, whereas IRS-
2 promotes motility, invasion, survival, aerobic glycolyis, and metastasis.  To further 
understand the differences between IRS-1 and IRS-2, I investigated the mechanistic basis 
of IRS-2-mediated PI3K activation.  I identified tyrosines in IRS-2 that mediate its 
recruitment and activation of PI3K in response to insulin and IGF-1 stimulation.  Using a 
PI3K-binding deficient IRS-2 mutant, I demonstrated that IRS-2-dependent PI3K 
signaling promotes aerobic glycolysis through its ability to selectively regulate the 
phosphorylation of the Akt effector Glycogen Synthase Kinase-3β (Gsk-3β).  I also 
performed a rigorous comparison of IRS-1 and IRS-2 signal transduction and their ability 
to regulate functions associated with tumor progression.  These studies required the 
generation of a novel model system where IRS-1 and IRS-2 function could be compared 
in a genetically identical background.  Using this model, I confirmed a role for IRS-1 in 
growth regulation and IRS-2 in tumor cell invasion, as well as expanded the 
understanding of differential IRS protein function by showing that IRS-2 more  
vi
effectively promotes Akt activation.  The model system I have established can be used 
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 Breast Cancer: Progression to Metastatic Disease 
 
 In the United States, breast cancer is the second leading cause of cancer related 
death among women (1).  In the past two decades, new treatment strategies for localized 
and regional disease have significantly improved 5-year survival rates for women to 99% 
and 84%, respectively (2).  The same cannot be said for the treatment of metastatic breast 
cancer, where limited successful treatment options are available and the 5-year survival 
rate for women with metastatic disease is only 24%.  The mechanisms that promote 
metastasis are still not fully defined and understanding them is key to the development of 
effective treatment strategies for metastatic breast cancer.  
 Tumor progression from initiation to dissemination and metastasis is a 
complicated, multistep process that requires adaptation of tumor cells (3).  Many of these 
changes, the so-called “Hallmarks of Cancer,” are essential for cells to successfully 
disseminate (4).  Following tumor initiation, transformed cells begin to rapidly grow and 
divide, evading the growth suppressors that would normally cause senescence or cell 
death.  As cells proliferate, they begin to grow into the luminal regions of the ducts and 
lobules of the breast epithelium, forming carcinoma in situ (3).  These cells are subjected 
to many different stresses including intermittent hypoxia and low nutrient supply due to 
the insufficient and disorganized vasculature network supporting them (5).  These 
stresses select for those cells able to withstand such harsh growing conditions; a subset of 
these aggressive cells can eventually acquire the ability to invade through the basement 
membrane and intravisate into the vasculature (3).  Cells then travel through the blood 
stream, where they extravisate from the capillary bed into the site of metastasis.  To 
2
 successfully colonize a new organ, cells must be able to survive and grow in an 
environment very different from where they originated.  Adaption to a changing 
microenvironment causes cells to become more aggressive and resistant to conventional 
therapies.  Understanding how and why these changes occur are essential to effectively 
targeting metastatic breast cancer.        
   
IGF-1R Signaling in Breast Cancer 
 
 Aberrant activation of growth factor signaling is a common event in breast cancer.  
Increased expression and activation of several growth factor receptors have been 
observed in primary tumors, including Human Epidermal Growth Factor Receptor 2 
(HER2), Vascular Endothelial Growth Factor Receptor (VEGFR), Epidermal Growth 
Factor Receptor (EGFR) and Insulin Like Growth Factor-1 Receptor (IGF-1R) (6).  
Targeted therapies for each have been developed, with the drug Herceptin that targets 
HER2 being the most successful to date (7).  
 IGF-1R expression in breast tumors was first demonstrated over 25 years ago, and 
several subsequent studies since have implicated IGF-1 signaling in breast cancer (8,9).  
The IGF-1R is commonly overexpressed in breast cancer and IGF-1R tyrosine kinase 
activity is increased 40-fold in malignant cells relative to normal breast cells (9,10).  High 
plasma IGF-1 levels in premenopausal women positively correlate with increased risk for 
developing breast cancer (11).  Additionally, high levels of IGF-1R expression correlate 
with disease relapse following chemotherapy and radiation (12).  Despite a clear 
3
 correlation between patient prognosis and elevated IGF-1 signaling, IGF-1R targeted 
therapies have had limited clinical success, presumably due to constitutive activation of 
signaling pathways downstream of the receptor (13).  Fully understanding the mechanism 
of signal transduction downstream of the IGF-1R is important to finding novel ways to 
target this signaling pathway in cancer.    
 
IGF-1R Activation and Signal Transduction 
 
 The IGF-1R is a ubiquitous growth factor receptor tyrosine kinase (RTK) that 
transmits intercellular signals in response to ligand binding to its extracellular domain 
(9).  The IGF-1R is expressed in nearly all cell types, with the exception of T-
lymphocytes and hepatocytes and Igf-1r -/- mice have severe growth defects and die 
shortly after birth due to respiratory failure (9,14).  In addition to its regulation of global 
organismal growth and development, the IGF-1R also promotes cellular proliferation, 
migration and survival (15).   
 Several factors determine IGF-1R activity and bioavailability.  First, to generate 
the functionally mature IGF-1R, the immature IGF-1R pro-receptor polypeptide is 
proteolytically cleaved into 135-kDa α and 90-kDa β subunits (9).  Next, the α and β 
subunits are joined by disulfide bonds to form the mature, dimeric IGF-1R.  Insulin Like 
Growth Factor (IGF) -1 and IGF-2 bind with high affinity to the IGF-1R, while insulin 
can stimulate the receptor only at very high concentrations (16).  During the post-
translational processing of the IGF-1R in the endoplasmic reticulum, subunits of the 
4
 Insulin Receptor (IR), can be co-incorporated with IGF-1R subunits to form hybrid 
receptors that have high affinity for the IGFs as well as insulin (17,18).  Additionally, 
IGF-IR activation is limited by Insulin Like Growth Factor Binding Proteins (IGFBP), 
which function to bind IGFs and sequester them from receptors, limiting their bioactivity 
(19).  Therefore, many factors influence the activity of the IGF-1R, including hybrid 
receptor formation and the availability and concentration of ligands. 
 Transmission of signals downstream of the IGF-1R is a multi-step process that 
requires the kinase activity of the receptor as well as recruitment and activation of 
intracellular adaptor proteins and kinases.  Following ligand binding to the extracellular α 
subunits, the signal is stereologically transmitted to the largely intracellular β subunits, 
activating the receptor’s tyrosine kinase activity (20,21).  This leads to 
autophosphorylation in trans of tyrosines (Tyr) 1131, 1135 and 1136 in the kinase domain 
of the IGF-1R (20-22).  Phosphorylation of all three of these tyrosines is required for 
signal transduction as they mediate the association of the IGF-1R with the Insulin 
Receptor Substrate (IRS) proteins (23).  Mutation of these three tyrosines to 
phenylalanine (Phe) blocks their phosphorylation and abolishes IRS association.  
Additionally, mutation of Tyr950, present in an NPEY motif in the juxtamembrane 
region of the IGF-1R receptor, abolishes association of the IRS proteins and the adaptor 
Shc (23,24).   Following their recruitment to the IGF-1R, the IRS proteins are 
subsequently phosphorylated by the receptor and recruit factors required for activation of 
Phosphotidylinositol-3-Kinase (PI3K) and Mitogen-Activated Protein Kinase (MAPK) 
5
 signaling.  The recruitment and phosphorylation of these adaptor proteins following IGF-
1R autophosphorylation is a key requirement for activation of downstream signaling. 
 
IGF-1 Signaling and Breast Cancer Progression 
 
 The positive correlation between amplified IGF-1 signaling and breast cancer 
spurred studies of the specific outcomes of increased signaling downstream of the IGF-
1R.  Early work using mouse embryonic fibroblasts (MEFs) and NIH-3T3 cells done by 
Renato Beserga’s group clearly demonstrated that loss of IGF-1R expression blocks 
transformation of these cell types (25,26).  Mutation of Tyr950 to Phe also inhibits the 
transforming ability of the IGF-1R through loss of IRS and Shc binding, highlighting the 
importance of adaptor proteins in mediating IGF-1R signaling and transformation (27).  
Similar studies using human breast cancer cell lines have confirmed the role of IGF-1R in 
transformation as well as implicating it in promoting tumor progression.  Expression of a 
dominant negative IGF-1R in MDA-MB-435 breast carcinoma cells decreased adhesion, 
invasion, anchorage independent growth, and metastasis to the lungs, liver and lymph 
nodes following mammary fat pad orthotopic injection (28,29).  Expression of a 
constitutively active IGF-1R in normal, immortalized breast epithelial MCF10A cells 
disrupts acini formation in matrigel, increases growth in soft agar and invasion and 
promotes tumor initiation in nude mice (30).  These studies show that the IGF-1R is not 
only sufficient, but required to induce transformation, tumorigenesis and promote 
6
 metastasis. Furthermore, the recruitment of adaptor proteins is required for the 
transforming ability of the IGF-1R in breast cancer. 
 Of note, the functional outcomes of IGF-1 signaling are dependent on Estrogen 
Receptor (ER) status.  IGF-1R stimulated mitogenesis requires ER expression, as MCF7 
cells (ER+) respond to IGF-1 with growth, while MDA-MB-231 (ER-) do not (31).  
However, non-mitogenic functions, such as adhesion, motility, and invasion are increased 
in both ER+ and ER- breast cancer cell lines in response to IGF-1 stimulation (28,31,32).  
Therefore, hormone receptor status is an important factor in determining the functional 
outcome of IGF-1R activation and could affect the outcome of IGF-1R targeted therapies 
in specific breast cancer patients. 
 
The IRS Proteins: Mediators of IGF-1 Signaling 
 
 The IRS proteins are cytoplasmic adaptor proteins that serve as a key link 
between the IGF-1R and activation of downstream signaling pathways.  The IRS family 
of proteins has four members, IRS 1-4.  IRS-1 and IRS-2 are ubiquitously expressed in 
both humans and rodents and are considered the primary regulators of mitogenesis and 
glucose metabolism in response to insulin (33). Irs-3 is expressed only in rodents and 
IRS-4 has a more limited expression pattern found only in the brain, kidney, thymus and 
liver in humans and rodents (34-36).  The expression of IRS-1 and IRS-2 are hormonally 
regulated at the transcriptional level, where IRS-1 is an ER responsive gene and IRS-2 is 
a progesterone receptor (PR) responsive gene (37-39).  These data have been confirmed 
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 in breast carcinoma cells lines, as it has been shown that well differentiated, ER+ cell 
lines predominantly express IRS-1 but less differentiated, ER- cell lines predominantly 
express IRS-2 (40).  In addition to hormonal regulation, IRS-2 has also been shown to be 
a hypoxia responsive gene as its mRNA and protein expression are both increased under 
hypoxic conditions (41).  Importantly, loss of ER and/or PR expression, as well as 
increased hypoxia, are common events during breast cancer progression.  Therefore, it is 
important to consider their effects on IRS expression and how this may serve to limit or 
promote tumor progression.  
 The IRS proteins were discovered in studies of the events following insulin 
stimulation.  Using phosphotyrosine-specific antibodies, a 185-kDa protein was shown to 
be phosphorylated in hepatoma cells within seconds of insulin stimulation and termed 
IRS-1 (42,43).  Irs-2 was subsequently discovered as an alternative substrate of the IR in 
the liver and muscle of Irs-1-/- mice in response to insulin stimulation (44-46).  
Subsequent studies determined that IRS-1 and IRS-2 also serve as substrates for the 
similar IGF-1R as well as the interlukin-4 (IL-4) receptor (46-50).  Specific integrin 
adhesion receptors have also been shown to use the IRS proteins as intermediates to 
regulate intracellular signal transduction (51-53).  Limited studies have also implicated 
the IRS proteins downstream of the VEGF, EGF, growth hormone, and prolactin 
receptors (54-58).   These discoveries show that the IRS proteins serve as adaptors for 
multiple classes of cell surface receptors, many of which are dysregulated in cancer.    
 Unlike many proteins involved in signal transduction, the IRS proteins do not 
contain any intrinsic enzymatic activity and instead function as adaptor proteins 
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 following their phosphorylation by upstream receptor and non-receptor kinases (43,59).  
Recruitment and receptor association are mediated through interactions of the plextrin 
homology (PH) and phosphotyrosine binding (PTB) domains of the IRS proteins with 
phosphorylated tyrosine residues in the cytoplasmic regions of the IR and IGF-1R 
(24,49,60,61) (Figure 1.1A).   IRS-2 contains a unique region encoded by amino acids 
591-786 termed the Kinase Regulatory Loop Binding (KRLB) domain that regulates its 
association with the IR (62) (Figure 1.1A).  Binding of this region to the IR is thought to 
decrease the receptor’s kinase activity and limit tyrosine phosphorylation of IRS-2, as 
mutation Tyr628 in the KRLB region of IRS-2 increases kinase activity of the receptor 
(63,64).  Once recruited to the receptor, phosphorylation of the C-terminal region of the 
IRS proteins creates docking sites for downstream effectors including PI3K, Grb-2, SHP-
2, Fyn, c-Crk, CrkII and Nck (65-70).  IGF-1R signaling mediated by the IRS protein is 
diagramed in Figure 1.1B. In regard to PI3K activation by the IRS proteins, 
phosphorylation of tyrosines in YxxM motifs leads to PI3K recruitment through 
association of src homology 2 (SH2) domains of the regulatory subunit, p85, leading to 
activation of PI3K signaling (71-73).  Using a proteomics phosphopeptide screen, 
additional proteins were shown to be capable of interacting with IRS-1 and IRS-2 in a 
phosphorylation dependent manner (74).  Many of these proteins were similar between 
IRS-1 and IRS-2; however, there were several additional proteins that were mutually 
exclusive to either IRS-1 or IRS-2 (74).  Additional studies are required to determine if 





 Figure 1.1. Insulin Receptor Substrate-Mediated Signal Transduction. (A) Schematic 
of IRS-1 and IRS-2 domains (PH, PTB and KRLB) and effector binding regions (PI3K 
Grb2, and SHP2).  (B) Schematic of IGF-1 stimulated signal transduction mediated by 





















  IRS-mediated signal transduction is also controlled by serine phosphorylation in 
addition to the regulation by tyrosine phosphorylation described above (75).  Serine 
phosphorylation of IRS-1 has been extensively studied, while less information is 
currently available pertaining to IRS-2 serine phosphorylation (75,76).  Phosphorylation 
of IRS-1 on Ser302 and Ser307 disrupts the interaction between the PTB domain and 
upstream receptors, limiting both phosphorylation of IRS-1 as well as activation of 
downstream signaling pathways (77-79).  Additionally phosphorylation of IRS-1 on 
Ser662 and Ser731 limits the association of IRS-1 with PI3K and decreases Akt 
activation (80).  Ser662 and Ser731 are adjacent to YxxM motifs, and it is thought that 
their phosphorylation functions to limit tyrosine phosphorylation of IRS-1 (80).  
Many, but not all, tyrosine and serine residues are conserved between IRS-1 and 
IRS-2 and the differences may confer different functional outcomes (81). Using 
quantitative mass spectrometry, phosphorylation of tyrosine residues in YxxM motifs of 
both IRS-1 and IRS-2 were observed over a time course of insulin stimulation (82).  The 
role of Tyr612 and Tyr632 in IRS-1 were further investigated and were shown to be 
required for PI3K activation in response to insulin (83).  However, the role of specific of 
tyrosine residues in response to IGF-1 stimulation has yet to be addressed.  Additionally, 
no studies have assessed the contribution of tyrosine residues in YxxM motifs of IRS-2 





 IRS-1 and IRS-2 Specific Functions 
 
 Despite similar structure and ability to activate many of the same signaling 
pathways, IRS-1 and IRS-2 do not function interchangeably.  Irs-1-/- mice are born runted 
and display insulin resistance but do not develop diabetes (84,85).  Irs-2-/- mice are 
infertile, have impaired brain development and ultimately develop diabetes due to β-cell 
failure combined with insulin resistance (86,87).  These studies implicate both Irs-1 and 
Irs-2 in regulation of whole body glucose homeostasis as loss of either results in insulin 
resistance.  However, Irs-1 plays an important role during developmental growth, while 
Irs-2 is involved in brain development and survival of the endocrine compartment of the 
pancreas.  These data imply there are some similar functions of the Irs proteins, however 
Irs-1 and Irs-2 are not redundant.    
 In vitro studies using cell lines derived from Irs-1-/- and Irs-2-/- mice confirm the 
non-redundant roles of the Irs proteins and additionally indicate that Irs functions are 
often cell context dependent.  In Irs-1-/- MEFs, IGF-1 dependent mitogenesis is impaired 
but Irs-2 expression is sufficient to maintain wild type (WT) levels of PI3K activation 
(88).  In response to insulin stimulation, knockdown of Irs-1 expression in L6 myotubes 
decreases Akt1 activation, actin remodeling and Glucose Transporter-4 (Glut4) 
translocation to the plasma membrane, while knockdown of Irs-2 expression decreases 
Akt2 and Erk activation (89).  In response to either insulin or IGF-1 stimulation, Irs-1, 
but not Irs-2, associates with Grb2 and activates MAPK-dependent proliferation in fetal 
brown adipocytes, while both Irs-1 and Irs-2 can promote PI3K-dependent differentiation 
13
 in this cell type (90).  Irs-2 is the primary mediator of insulin-stimulated glucose uptake 
in adipocytes by increasing Glut4 translocation to the plasma membrane and Irs-1 
overexpression cannot rescue this function (91).  These data suggest that cell context can 
mediate some of the differential functions attributed to either Irs-1 or Irs-2 activation.   
 Some of the differences between Irs-1 and Irs-2 have also been attributed to the 
relative differences in PI3K activation mediated by the IRS proteins.  For example, in 
keratinocytes, Irs-1 displays higher PI3K association relative to Irs-2 and stimulates 
PI3K-dependent glucose uptake following insulin stimulation (92).  In contrast, Irs-2 
serves this function in fibroblasts.  The mechanisms that underlie the differences of PI3K 
activation by either Irs-1 or Irs-2 in a cell context dependent manner remain to be 
determined.   
 
The Role of the IRS Proteins in Breast Cancer 
 
 The established role of the IGF-1R in breast cancer and the importance of the IRS 
proteins in mediating IGF-1R signaling prompted studies on the function of the IRS 
proteins in tumor initiation and metastasis.  Like the IGF-1R, IRS-1 is commonly 
overexpressed and constitutively tyrosine phosphorylated in many types of cancer, 
including of the breast (93,94).  Localized breast tumors express high levels of IRS-1, 
whereas more invasive tumors have high IRS-2 expression (95).  More recent studies of 
the IRS proteins have suggested that the subcellular localization of the IRS proteins may 
be a more predictive marker for patient prognosis versus expression status alone.  In 
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 human breast carcinoma cells, both IRS-1 and IRS-2 localize to the cytoplasm, but only 
IRS-1 localizes to the nucleus and IRS-2 localizes to the plasma membrane (96,97).  
Nuclear localization of IRS-1 in human tumors correlates with increased survival in 
response to tamoxifen treatment, while IRS-2 membrane localization correlates with 
decreased overall survival (96,98).  Therefore, in addition to expression status, 
subcellular localization of the IRS proteins is a key determinant in the functional outcome 
of their expression in breast cancer. 
 In vitro studies of the IRS proteins have also defined their differential roles in 
tumor initiation and progression.  Overexpression of IRS-1 or IRS-2 in non-transformed 
MCF10A human mammary epithelial cells leads to increased IGF-1-dependent Akt 
activation and disrupts normal acinus formation in 3D matrigel (99).   In response to IGF-
1 stimulation, IRS-1 is required for PI3K- and MAPK-mediated mitogenesis in ER+ 
breast cancer cell lines (100-102).  However, overexpression of IRS-1 in two ER- breast 
cancer cell lines was not sufficient to stimulate IGF-1 dependent mitogenesis (40).  In 
contrast to IRS-1, IGF-1 signaling mediated by IRS-2 promotes adhesion and motility 
regardless of ER status of the cell line used (102,103). These data implicate differential 
functions of the IRS proteins in discrete stages of tumor initiation and progression, and 
some of these functional outcomes are dependent on hormone receptor expression status. 
 Irs mouse models have also contributed to the understanding of the different roles 
that the Irs proteins play in breast cancer.  Transgenic overexpression of IRS-1 or IRS-2 
in the mammary glands of mice induces mammary hyperplasia, tumorigenesis and 
pulmonary metastasis (99).   Both IRS-1 and IRS-2 overexpressing tumors display higher 
15
 levels of PI3K and Extracellular Signaling-Regulated Kinase (Erk) activity relative to 
matched normal mammary gland tissue.  Another model to study breast cancer drives 
Polyoma Middle T expression with the mouse mammary tumor virus promoter (MMTV-
PyMT), which induces tumorigeneis specifically in the mammary glands of mice and 
these tumors are robustly metastatic (104).  Despite no differences in overall tumor 
growth in PyMT:Irs-1-/- or PyMT:Irs-2-/- mice relative to PyMT:WT mice, decreased 
pulmonary metastasis is observed in Irs-2-/- mice (105,106).   In contrast, Irs-1-/- tumors 
express elevated levels of Irs-2, are significantly more metastatic and display increased 
angiogenesis relative to their WT counterparts (105,107).  Upon further investigation of 
the Irs-1-/- tumors, an Irs-2-dependent increase in PI3K/Akt signaling was observed.  Cell 
lines derived from these tumors are more invasive and have increased survival and 
aerobic glycolysis relative to WT tumor derived cells (107,108).  The opposite is true of 
Irs-2-/- tumor derived cells, which are less invasive, more sensitive to apoptotic stimuli 
and have decreased aerobic glycolysis (106,108).  Using these tumor derived cell lines, it 
was determined that Irs-2 positively regulates aerobic glycolysis through a mechanistic 
target of rapamycin complex-1 (mTorc1)-dependent increase in Glut1 surface expression 
and glucose uptake (108).  Together, these studies highlight the differences between the 
IRS proteins and implicate IRS-2-dependent PI3K signaling in multiple functions 





 PI3K Signaling  
 
 The link between IRS2, PI3K signaling, and breast cancer is not surprising, given 
that the PI3K signaling pathway is one of the major pathways activated in response to 
RTK signaling.  The lipid kinase activity of PI3K was first described in the early 1950’s 
when it was shown that radiolabeled phosphates could be incorporated into phospholipids 
following acetylcholine stimulation (109).  Phospholipids were further linked to signal 
transduction in studies showing that the break down of the phospholipid phosphoinositide 
(PtdIns) was linked to membrane-associated receptors known to regulate intracellular 
calcium trafficking (110).  Pioneering studies in the 1980’s lead to the discovery of a new 
form of lipid kinase activity directed at the 3-OH position of the inositol head ring.  In 
transformed cells, this lipid kinase activity was discovered following 
immunoprecipitation of pp60v-src and PyMT (111,112).  It was initially thought that the 
product of the reaction was PtdIns-4-P, however thin layer chromatography experiments 
in Lewis Cantley’s lab clearly demonstrated that the lipid product was actually PtdIns-3-
P, ushering in the field of PI3K signaling (113).  In addition to its association with viral 
oncogenes, PI3K activity was shown to co-immunoprecipitate with the platelet derived 
growth factor receptor (PDGFR) and the IR following ligand stimulation (112,114-116).  
Further study determined that PtdIns-3-P levels remain constant in cells, while there is a 
rapid accumulation of PtdIns-3,4,5-P3 following stimulation with growth factors such as 
platelet derived growth factor (PDGF) or G-protein coupled receptor (GPCR) agonists 
(117,118).  Transfection of the IR into Chinese hamster ovary cells also results in 
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 increased PtdIns-3,4,5-P3 production (116). From these studies, it was concluded that 
PtdIns-3,4,5-P3 is the true second messenger generated by PI3K that leads to 
amplification of intracellular signaling.     
 While there are three distinct classes of PI3K (Classes I-III), all with kinase 
activity directed at the 3-OH position of PtdIns, their structure and substrate specificity 
set them apart.  Class I PI3K is the only class that can generate the active second 
messenger PtdIns-3,4,5-P3 from PtdIns-4,5-P2 (113,117,119).  Class I PI3K is further 
divided into two classes; Class IA activated in response to RTKs and Class IB activated 
by GPCRs (120).  Because of the role of RTKs in breast cancer formation and metastasis, 
further discussion of PI3K in this dissertation will focus on Class IA PI3K and its roles in 
amplification of RTK signaling.   
 Class IA PI3K is a heterodimer comprised of a regulatory subunit and a catalytic 
subunit (121).  The regulatory subunit exists as 5 isoforms (p85α, p55α, p50α, p85β, and 
p55γ) where p85α, p55α and p50α are encoded by PIK3R1 while p85β and p55γ are 
encoded by PI3KR2 and PI3KR3, respectively (120).  Structurally, p85 contains two SH2 
domains in the N and C-termini connected by an inter-SH (i-SH2) domain region that 
binds to the catalytic subunit.  The catalytic subunit also exists as three isoforms (p110α, 
p110β and p110δ) each of which are encoded by distinct genes PIK3CA, PIK3CB and 
PIK3CD, respectively.  The p110 isoforms are structurally similar, each containing an N-
terminal p85-binding domain, a Ras binding domain, a PIK (Phosphoinositide-3-kinase 
family) domain, a C2 domain and a C-terminal catalytic domain.  Under basal conditions, 
the association of p85 with p110 stabilizes p110 and inhibits its lipid kinase activity 
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 (122).  Following RTK activation, the SH2 domains of the p85 regulatory subunit bind to 
phosphorylated tyrosine residues within YxxM motifs of upstream receptors and adaptor 
proteins, inducing a conformational change that is transmitted to the p110 subunit, 
releasing inhibition of p110 and rendering the kinase active (122-126).  This inhibition of 
p110 is mediated by contacts of its N-terminal p85 binding domain with the i-SH2 of p85 
(124).  For maximal PI3K activity, both SH2 domains of p85 must be associated with 
phosphotyrosine residues as mutation of one SH2 domain impairs PI3K activity by 50% 
and mutation of both abolishes binding to IRS-1 and activation of PI3K following insulin 
stimulation (125,126).  This mechanism of activation, the disinhibition of the catalytic 
subunit through the binding of SH2 domains of the regulatory subunit to pYxxM motifs, 
its similar across all PI3K Class 1A isoforms.    
 While binding of the SH2 domains of PI3K to p-YxxM motifs is required for 
activation, different classes of proteins serve as binding partners for p85.  PI3K is 
activated in response to ligand stimulation of many RTKs, including the IR and IGF-1R 
(116,127,128).  Downstream of the IR and IGF-1R, activation of PI3K is mediated by 
pYxxM motifs in the IRS proteins and loss of IRS expression abolishes PI3K activation 
following insulin or IGF-1 stimulation (129,130).  However, downstream of other 
receptors, like the PDGFR, PI3K is directly activated by association with pYxxM motifs 
within the receptor and does not require an adaptor protein (72,123).  Therefore, 
depending on the RTK, the mechanism of PI3K activation may require recruitment of the 
IRS proteins or other adaptor proteins.  
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  The mechanism underlying the intracellular functional responses following 
generation of PtdInsP-3,4,5-P3 by PI3K remained in question for many years. However, 
the discovery that PH domains associate with PtdInsP-3,4,5-P3 illuminated the 
mechanism of PI3K mediated signal transduction (131).  The first PI3K effector 
identified was Akt (also called Protein Kinase B (PKB)), which is recruited to PtdIns-
3,4,5-P3 through its PH domain (132-134).  PI3K activation of Akt leads to increased 
survival, growth, proliferation, glucose metabolism, transcription, and protein translation 
(135).  In addition to Akt, the generation of PtdIns-3,4,5-P3 by PI3K also leads to the 
activation of Rac signaling through activation of Rac guanine-nucleotide exchange 
factors (Rac-GEFs) (136,137).  Activation of Rac-GEFs increases the rate of exchange of 
GDP to GTP in Rac’s nucleotide binding site increasing Rac activation (138). Rac 
signaling regulates cell-to-cell contacts, actin cytoskeleton rearrangement, cell adhesion, 
transcription, translation, survival and entry into the cell cycle (139,140).  Through Akt 
and Rac-GEF activity, PI3K signaling is able to regulate many cellular functions 
including cell growth and division, survival, protein synthesis, motility, and cell polarity 
(120).    
 One of the specific metabolic pathways dependent on PI3K is the regulation of 
glucose metabolism, and type-2-diabetes is associated with perturbations in this signaling 
pathway (120).  In response to insulin, PI3K stimulates glucose uptake and Glut4 
translocation to the plasma membrane, as these effects are lost when PI3K is inhibited 
using LY294002 or wortmannin (141).  Loss of all three isoforms of p85 in insulin-
responsive tissues such as the liver and muscle results in an impaired insulin response 
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 (142,143).  Specifically in the liver, loss of p85 results in hyperinsulinaemia and 
hyperglycemia, while in the muscle it results in decreased glucose uptake as well as 
whole-body glucose intolerance. Conversely, loss of Phosphatase and Tensin Homolog 
(PTEN), the phosphatase that antagonizes the actions of PI3K, results in increased insulin 
sensitivity in the liver, fat and muscle (144).  As with other signaling molecules, the 
effects of PI3K can vary between tissue and cell types.  However, perturbed glucose 
responses are one of the key results of impaired PI3K signaling activity, which occurs in 
several forms of cancer and promotes tumor growth. 
 
PI3K Signaling and Cancer 
 
 In addition to its crucial role in normal cell biology, PI3K is considered an 
oncogene and is mutated in many types of cancer including colon, lung, brain, gastric, 
and breast (145).  Activating mutations in the p110α catalytic subunit of PI3K (PIK3CA) 
occur in roughly 25% of all breast cancers and are localized to two “hot spots” in exon 9 
and exon 20 which encode the helical and catalytic domains respectively (146).  These 
gain-of-function mutations, E542K, E545K and H1047R, lead to increased PI3K activity 
and constitutive activation of downstream targets such as Akt, Ribosomal Protein S6 
Kinase (S6K), Glycogen Synthase Kinase-3 (GSK-3) and Eukaryotic translation initiation 
factor 4E-Binding Protein (4EBP) (147,148). E545K and H1047R are considered 
oncogenic as they induce anchorage- independent growth, growth factor-independent 
growth and protect against anoikis in MCF-10A cells; they also induce transformation of 
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 both chicken embryo fibroblasts, mammary epitheial cells and human colon cancer cell 
lines (147-149).   The catalytic antagonist of PI3K is the phosphatase PTEN, which is 
frequently lost in tumors that do not harbor outright PIK3CA mutations (150).  The 
phosphatase activity of PTEN dephosphorylates the 3-OH phosphorylation of PtdIns-
3,4,5-P3, reverting it back to PtdIns-4,5-P2.   Loss of PTEN leads to accumulation of 
PtdIns 3,4,5-P3 and aberrant activation of PI3K/Akt signaling (151).  Germline mutations 
of PTEN result in Cowden’s Syndrome and predispose patients to developing breast and 
thyroid cancers (152).  Interestingly, mutations in PIK3CA and PTEN are not mutually 
exclusive and can coexist in the same tumor suggesting that their alteration may not lead 
to the same functional outcomes (153,154).  In addition, there are other mechanisms that 
alter PI3K signaling in tumors exclusive of PI3K and PTEN genetic mutations.     
 PI3K signaling can also be amplified indirectly by constitutive RTK activity.  
IGF-1R signaling is commonly amplified in breast cancer and leads to increased PI3K 
activity (9).  Another common event leading to increased PI3K signaling is HER2 
amplification (155).  HER2 is a receptor tyrosine kinase in the EGFR receptor family that 
can activate PI3K signaling and is overexpressed or amplified in ~25% of all breast 
cancers (156,157).  Interestingly, PIK3CA mutation and PTEN loss are observed 
following development of resistance to HER2 targeted therapies, including trastuzumab 
and lapatinib (158,159).  Thus, it appears that tumors resulting from aberrant PI3K 
activation will evolve new mechanisms to sustain pathway activation in response to 
targeted inhibition of the pathway, suggesting that active PI3K signaling is required for 
tumor maintenance.   
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  Multiple groups have reported the occurrence of mutations in the PI3K pathway 
and their association with breast cancer subtype, however some of the results are 
contradictory.  PIK3CA mutations have been shown to be associated with ER/PR+ 
tumors, while PTEN loss is associated with ER/PR- tumors (160,161).  The relationship 
between PIK3CA mutations and HER2+ breast cancer remains controversial, with some 
reports of a correlation of PIK3CA mutation and HER2 amplification and others with no 
correlation (160-162).  However, triple negative breast cancers (TNBC, ER-/PR-/HER-) 
infrequently show PIKCA and PTEN perturbation suggesting that these tumors do not 
rely on PIKCA or PTEN perturbations for amplification of PI3K signaling (159).  Due to 
the overlapping nature of PIK3CA, PTEN and HER2 perturbations in breast cancer, it is 
clear that despite functioning in the same signal transduction pathway, these nodes of 
PI3K signaling are unique and should be viewed as such.  
 
PI3K Signaling: Akt 
 
 Akt was the first PI3K effector to be described and it is a central player in PI3K 
signaling downstream of RTKs (133,134).  Akt shares considerable homology with 
protein kinases A, G and C and therefore was classified as a member of the AGC kinase 
family (132,135).  Akt is rapidly activated in response to growth factor stimulation and 
this activation is dependent on PI3K, as either PI3K inhibitors or overexpression of 
dominant negative PI3K block Akt activation (134).  Additionally, expression of a 
constitutively active, membrane-targeted version of PI3K promotes Akt activation 
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 (163,164).  Studies using 32P-labelled phosphates determined that Akt phosphorylation in 
response to insulin or IGF-1 stimulation occurs on residues Ser473 and Thr308 (165).  
Phosphorylation of both Ser473 and Thr308 synergize and are required for maximal 
activity.  However, mutation of one site does not effect phosphorylation of the other site.  
Together these data indicate that Akt phosphorylation is a key step in its activation in 
response to insulin or IGF-1 stimulation.   
 The PH domain of Akt plays a critical role in its activation in response to PI3K 
signaling.  Following growth factor stimulation, Akt is recruited to the plasma membrane 
through association of its PH domain with PtdIns 3,4,5-P3 and treatment with PI3K 
inhibitors blocks its translocation (166).  Plasma membrane targeting of Akt by tagging 
its N-terminus with the myristoylation/palmitylation motif of Lck tyrosine kinase leads to 
constitutive phosphorylation and activation of Akt, which cannot be inhibited by 
expression of a dominant negative PI3K.  This result suggests that the targeting of Akt to 
the membrane is sufficient for its activation.  However, phosphorylation of Akt is the 
primary mechanism leading to activation of this kinase, as deletion of the PH domain 
does not impact kinase activity, providing that Akt is constitutively targeted to the plasma 
membrane (167).  Membrane localization of Akt leads to Phosphoinositide-Dependent 
Kinase-1 (PDK-1) phosphorylation of Thr308, thus activating the kinase (168).  Akt is 
also phosphorylated on Ser473 by mechanistic target of rapamycin complex 2 
(mTORC2), leading to maximal kinase activation (169).  Following these 
phosphorylation events, Akt is fully functional to promote signal transduction.  
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  Following its activation at the plasma membrane, Akt localizes to the cytoplasm 
and nucleus where it phosphorylates many downstream effectors, amplifying RTK 
signaling (170).   GSK-3 was the first identified, bona-fide Akt substrate (171).  Peptides 
generated around the Akt phosphorylation site in GSK-3 ultimately lead to the discovery 
of the minimal recognition motif of Akt’s kinase activity (R-X-R-X-X-S/T-B) (172).  
This motif is distinct from other AGC kinases such S6K1, which can tolerate K 
substitutions at the -5 and -3 positions, distinguishing them from Akt.  Since the 
discovery of GSK-3 as an Akt effector, many more Akt substrates have been identified 
and Akt signaling has been shown to regulate many cellular functions including cell 
growth, proliferation, survival, metabolism, motility, invasion, and angiogenesis 
(135,173).  These functions are often regulated by Akt-dependent phosphorylation of 
more than one downstream effector; glucose metabolism, for example, requires 
phosphorylation of the Akt substrates GSK-3, FOXO, TSC2, PRAS40, and AS160 (135).  
In addition, phosphorylation of GSK-3 and FOXO by Akt also influence proliferation and 
survival.  Thus, Akt signaling does not occur in a discrete pathway and instead branches 
at many places, eliciting numerous effects.     
 The substrate specificity of Akt can be modulated depending on the 
phosphorylation state of Akt and through its protein-protein interactions.  For example, 
Ser473 phosphorylation is required for the N-terminal phosphorylation of FOXO proteins 
but it is not required for Akt phosphorylation of other FOXO sites, GSK-3 or TSC2 
(169,174).  Interestingly, Ser473 phosphorylation is not required for response to growth 
factor stimulation but does increase Akt kinase activity 5-10 fold (165).  In addition to 
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 the phosphorylation state of Akt, protein-binding partners may also direct its substrate 
specificity.  Proteins that have been shown to interact with Akt, some of which have been 
shown to regulate its activity, include Hsp90, JIP1, Grb10, and APE (175-178). 
Therefore, it is important to keep cell context in mind, as Akt interacting proteins may be 
differentially expressed and likely influence the outcome of Akt activation.  One 
particular Akt interacting protein is Adaptor protein, phosphotyrosine interaction, PH 
domain and leucine zipper containing-1 (APPL1), which promotes phosphorylation of 
GSK-3β, but not TSC2 (179-183).  The proposed mechanism for this APPL1-mediated 
substrate specificity is the partitioning of Akt activity to specific endosomes containing 
GSK-3β, but not TSC2.  Thus, subcellular localization is an additional factor that 
influences Akt activation. 
 It is well known that Akt translocates to both the cytoplasm and nucleus following 
its activation at the plasma membrane and many studies have confirmed that Akt is active 
in the nucleus (184).  The use of fluorescent Akt reporters has shown that Akt activity in 
the nucleus occurs more slowly but is sustained relative to its activity in the cytoplasm 
(170).  The larger question of whether nuclear Akt is phosphorylated before import into 
the nucleus still remains in question, however the factors required for Akt activation 
(PI3K, PtdIns 4,5-P2, PtdIns 3,4,5-P3, PDK-1, and mTORC2) have been shown to be 
present in the nucleus (185-190).  Based on these studies, subcellular localization of Akt 
may regulate the effectors that Akt has access to, but further studies are required to fully 
understand this regulation of Akt substrate specificity.          
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 Akt Isoforms 
 
 Akt is present as three isoforms, Akt1-3, which share 80% sequence and structural 
homology despite being encoded by distinct genes (191).  Each isoform contains a C-
terminal PH domain, a catalytic domain and a N-terminal hydrophobic motif (192,193).  
Initial studies of the Akt isoforms suggested they functioned redundantly, however it is 
now clear they have non-overlapping functions.  Akt1-/- mice are born runted, Akt2-/- mice 
develop diabetes and Akt3-/- mice have developmental defects of the brain (194-197).  
Interestingly, the Akt isoforms have distinct subcellular localization patterns.  Akt1 is 
present in the cytoplasm, Akt2 in the mitochondria and Akt3 in the nucleus; importantly,  
knockdown of one isoform does not impact localization of the other two isoforms (198).  
These data suggest that each Akt isoform has specific functions, which may in part be 
mediated by subcellular localization. 
 The most well defined Akt isoform-specific function is the regulation of glucose 
homeostasis by Akt2.  Loss of Akt2 expression, but not Akt1 or Akt3, results in glucose 
intolerance and decreased glucose uptake by the muscle and fat in response to insulin 
(196,199). This is due to Akt2-dependent regulation of Glut4 translocation to the plasma 
membrane in response to insulin and cannot be rescued by overexpression of Akt1 (200-
202).  Glut4 translocation to the plasma membrane is facilitated by the phosphorylation 
and inhibition of the Rab-GTPase Activating Protein (GAP) AS160 by Akt2 (203-205).  
Currently, there are a limited number of Akt isoform specific reagents available and 
development of superior reagents is a requirement to rigorously understand the specific 
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 roles of each Akt isoform.  New conditional and tissue specific knockout mouse models 
of individual Akt isoforms will also be helpful in determining isoform specific 
contributions.    
  
Akt and Breast Cancer 
 
 Just as PI3K activity is amplified in human cancer, Akt signaling has been shown 
to be hyperactivated in brain, breast, prostate, and ovarian tumors (206).  Unlike PI3K, 
few somatic mutations have been described for Akt.  The best characterized is a gain of 
function mutation of Glu17Lys in the PH domain of Akt1, leading to constitutive activity 
of Akt1 through its targeting to the plasma membrane (207).  This particular mutant 
occurs in roughly 4-8% of breast cancer patients.  Amplification of Akt2 expression has 
been shown in only 3% of breast cancer patients and currently no studies have shown 
amplification of Akt1 expression in breast cancer (208).  However, increased Akt kinase 
activity is commonly observed in many different types of cancer and often predicts poor 
prognosis in patients.  In one study, Akt1 kinase activity was increased in 40% of breast 
tumors (206).  Akt3 kinase activity has also been shown to be upregulated in ER- breast 
cancer (209).  In addition, patients with tumors that scored positive for Akt 
phosphorylation were more likely to relapse and have distant metastases (210).  Together 
these studies demonstrate the importance of increased Akt kinase activity in breast 
cancer, but suggest that Akt depends on upstream factors to promote its hyperactivity.    
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  Studies of Akt isoform-specific effects in breast cancer have focused mainly on 
Akt1 and Akt2.  Initial studies of the isoforms used overexpression of constitutively 
active Akt isoforms, leading to some controversy over the specific roles of Akt1 and 
Akt2 (173).  However, more recent knockdown studies have more consistently described 
the roles of these isoforms.  In general, in vitro studies show that Akt1 inhibits migration, 
invasion, and the epithelial-to-mesenchymal transition (EMT), while Akt2 promotes 
these functions (211-214).  The mechanism of Akt1-mediated inhibition of migration has 
been well characterized by Alex Toker’s group, who has shown that the actin bundling 
protein palladin is specifically inhibited by Akt1 leading to decreased invasion of human 
breast cancer cell lines (215).  Studies using invasive variants of human breast cancer cell 
lines determined that Akt2 expression was upregulated in a Twist-dependent manner and 
that knockdown of Akt2 reduced Twist-regulated migration and invasion (216).  Together 
these studies demonstrate that Akt1 and Akt2 do not function interchangeably to promote 
breast cancer progression.   
 The use of mouse models has confirmed results from in vitro studies on the 
isoform-specific roles of Akt in tumor formation and growth.  In HER2-driven mouse 
mammary tumors, mammary specific expression of a constitutively active Akt1 
confirmed a negative regulatory role of Akt1 in migration and metastasis in breast cancer 
(217).  Other in vivo studies have also suggested that Akt1 functions to limit invasion and 
metastasis, while Akt2 promotes these functions (214,218).  Additionally, Akt1 
expression has been shown to accelerate tumor formation and growth, while Akt2 
expression inhibits these functions (218).   However, one group has reported that Akt1 
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 can promote invasion and metastasis (219).  The studies of Akt1 loss were done on 
different genetic backgrounds with total body knockout of Akt1, which may explain the 
different observations between studies.  Little is known about Akt3 specific functions in 
breast cancer and further study of all three isoforms is required to fully understand their 
specific functions in breast cancer progression.  However, studies do clearly implicate 
Akt signaling in many functions associated with tumor progression, including the 
regulation of tumor cell metabolism. 
 
 Tumor Metabolism: Effects on the Microenvironment and Tumor Progression  
 
 In the early 1920’s, Otto Warburg first noted that cancer cells consume glucose at 
a higher rate relative to normal cells (220,221).  He observed that cancer cells 
preferentially metabolize glucose using glycolysis, not oxidative phosphorylation, even in 
the presence of oxygen. This phenomenon as been termed the Warburg Effect.  Warburg 
proposed that this metabolic switch was due to defective mitochondrial metabolism in 
cancer cells, which has since been shown to be false (5,222).  However, the principles of 
the Warburg effect have been rigorously confirmed and are now considered one of the 
“Hallmarks of Cancer” (4). 
 Under normoxic conditions, in normal, non-proliferating cells, glucose is 
converted to pyruvate and then shuttled into the mitochondria (223). There it is 
metabolized through the Tricarboxylic Acid Cycle (TCA) cycle, generating NADH that 
can be used to generate ATP during oxidative phosphorylation.  However, under 
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 conditions where oxygen is limiting, cells switch to anaerobic glycolysis and convert 
pyruvate into lactate to generate ATP. In comparison to oxidative phosphorylation, 
aerobic glycolysis is an inefficient way to generate ATP, generating 36 versus 2 
molecules of ATP respectively (5).  Interestingly, following Warburg’s discovery in 
cancer cells, others noted that normal, rapidly proliferating cells such as lymphocytes and 
thymocytes also preferentially use aerobic glycolysis (224-227).  It was clear that both 
normal rapidly proliferating cells and cancer cells use aerobic glycolysis but the reasons 
behind this metabolic shift were still unclear.   
 Why rapidly proliferating normal and cancer cells preferentially use glycolysis to 
metabolize glucose remained a biological conundrum for many years.  Studies have since 
shown that glycolysis proceeds faster than oxidative phosphorylation, rapidly producing 
ATP when glucose is not limiting (228,229). Aerobic glycolysis not only supports 
increased cell growth and proliferation through ATP generation, but also supplies cells 
with biomass required for their proliferation (223).  Cell division is a huge metabolic 
challenge for a cell and requires the synthesis of nucleotides, amino acids and lipids.  
Aerobic glycolysis meets these metabolic requirements by shuttling metabolic 
intermediates into biosynthetic pathways.  To maintain high glycolytic flux to sustain 
ATP and biomass generation, cells must convert pyruvate into lactate using lactate 
dehyrodrogenase, which is then secreted (230).  This explains why tumor cells secrete 
high levels of lactate, which at first glance seems wasteful, but is actually required to 
sustain flux through the pathway. 
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  To maintain high glycolytic flux, tumor cells must also sustain high levels of 
glucose uptake from the blood supply.  In breast cancer, the expression of glucose 
transporters Glut1 and Glut3 are increased, along with their targeting to the plasma 
membrane (231).  Of the family of five transmembrane glucose transporters, Glut1 and 
Glut3 have the lowest Km values and can facilitate glucose transport at a nearly constant 
rate (230).  In response to growth factor stimulation of Akt, Glut1 expression and surface 
localization are increased leading to increased glucose uptake and aerobic glycolysis 
(232,233).  The expression and plasma membrane localization of Glut1 are just two 
mechanisms by which PI3K/AKT positively regulate aerobic glycolysis.  
 Aerobic glycolysis is a fundamental response to the constantly changing tumor 
microenvironment.  As a tumor grows, cells eventually reach the oxygen diffusion limit 
and become hypoxic (5). However, the diffusion limit of glucose is greater than that of 
oxygen and therefore the supply of glucose is not limited.  It has been well established 
that fluctuations in oxygen levels occur frequently in tumors and ultimately favor the 
survival of cells with increased glycolytic ability (5).  Consequently, tumors use 
glycolysis even in the presence of oxygen due to constitutively upregulated glycolytic 
pathways.  Hypoxia triggers the expression of hypoxia-inducible factor-1α (HIF-1α), a 
transcription factor, which up-regulates the expression of glucose transporters as well as 
glycolytic enzymes, promoting glycolysis.  In addition to hypoxia, PI3K/Akt signaling 
has been shown to positively regulate HIF-1α activation and promote glycolysis (234-
236).  Akt has also been demonstrated to regulate the activity of enzymes that participate 
in glycolysis.  Specifically, Akt has been shown to stimulate phosphofructokinase activity 
32
 and increase hexokinase association with the mitochondria, both of which increase 
glycolysis (237,238).  Studies have also shown that tumor cells will undergo cell death in 
response to glucose withdrawal and treatment of tumors with PI3K or mTOR inhibitors 
decreases glucose uptake and induces regression (239,240).  These data implicate both 
the microenvironment and PI3K/Akt signaling as central players in the regulation of 
aerobic glycolysis in cancer.   
 Aerobic glycolysis also supports important functions that promote tumor 
progression.  In vitro studies using breast cancer cell lines have shown that more invasive 
cells such as MDA-MB-231 cells consume higher levels of glucose relative to the less 
invasive MCF-7 cells (5).  Persistent glycolysis leads to acidification of the tumor 
microenvironment, promoting ECM and basement membrane degradation through 
increased matrix metalloproteinase (MMP) activity.  This allows tumor invasion through 
basement membrane, giving tumor cells access to the vasculature, promoting 
dissemination and metastasis.  Cells likely encounter regions of hypoxia at the site of 
metastasis as they proliferate and occlude the blood supply.  This once again will favor 
the survival of cells with constitutively up-regulated glycolysis.  It is clear that aerobic 
glycolysis is important in multiple stages of tumor progression and targeting the factors 
that contribute to this metabolic reprogramming could lead to more effective treatment 





 Rationale for Thesis Work 
 
 The IRS proteins are required for IGF-1-dependent tumor initiation and 
progression.  Despite their similarity, they do not function interchangeably as IRS-1 
promotes growth and proliferation, while IRS-2 promotes survival, invasion, aerobic 
glycolysis and metastasis (101-103,106-108).  The mechanisms that underlie the ability 
of IRS-2, but not IRS-1, to promote these functions associated with tumor progression to 
metastasis are unknown.  The downstream signaling events following IRS-1 or IRS-2-
mediated PI3K activation also remain to be rigorously characterized.  Determining the 
differences in signaling downstream of PI3K activated through IRS-1 or IRS-2 is 
required to fully understand how the IRS proteins mechanistically differ.  Potentially, this 
could implicate novel drug targets to better treat metastatic disease.  The goal of the work 
presented here was to rigorously establish the mechanistic basis of PI3K activation by 
IRS-2, as well as the role of IRS-2-dependent PI3K signaling in functions that positively 
regulate metastatic potential, specifically aerobic glycolysis.  Additionally, I sought to 
generate a novel model system to compare IRS-1 and IRS-2-mediated signaling and 






























Rationale and Strategy for Model System Generation 
  
 Achieving stable expression of Insulin Receptor Substrate-1 (Irs-1) or Irs-2 in 
mammary tumor cell lines derived from FVB MMTV-PyMT:Irs-1-/- or FVB MMTV-
PyMT:Irs-2-/- mice was not possible, with little or no IRS protein expression following 
antibiotic selection and cell culture passage.  Additionally, Wild Type (WT), Irs-1-/- and 
Irs-2-/- cells were derived from discrete tumors and are not genetically matched, thereby 
limiting the conclusions that can be drawn from their comparison.  Therefore, I sought to 
generate superior cell culture models to address these issues.   
 My approach was to generate mammary tumor cell lines from mice with 
conditional alleles of Irs-1, Irs-2 or both Irs proteins.  To induce tumorigenesis, I 
employed the MMTV-PyMT mouse model of tumor progression. Mammary gland 
specific expression is achieved by driving Polyoma Middle T (PyMT) expression by the 
mouse mammary tumor virus promoter (MMTV).  This model of mammary tumor 
progression is robustly oncogenic, driving rapid tumorigenesis and metastasis (104). 
MMTV-PyMT is also a well-characterized, representative mouse model of estrogen 
receptor negative (ER-) human breast cancer in which the role of the Irs proteins has been 
previously characterized (106,107,241,242).   Following establishment of tumor cell lines 
in vitro, Irs expression was knocked-out through adenoviral Cre-Recombinase infection.  
This method allowed for the generation of genetically identical cell lines differing only in 
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 expression of the Irs proteins.  Additionally, stable expression of either Irs-1 or Irs-2 was 
achieved in these cells. 
 
PyMT:Irs-1-/-, PyMT:Irs-2-/- and PyMT:Irs-1-/-/Irs-2-/- Cell Lines 
 
Mouse Models.  Irs-2-/- mouse mammary tumor cell lines were previously isolated from 
FVB MMTV-PyMT:Irs-2-/- mice (106).  Irs-1fl/fl and Irs-2fl/fl mice were a generous gift 
from the laboratory of Morris White (Children’s Hospital, Boston, MA) (129,243) and 
were backcrossed through 10 generations onto a FVB background.  Irs-1fl/fl and Irs-2fl/fl 
mice were crossed with FVB MMTV-PyMT -/+ mice to generate PyMT:Irs-1fl/fl, PyMT:Irs-
2fl/fl and PyMT:Irs-1fl/fl/Irs-2fl/fl mice.  Females of these genotypes were observed for 
mammary tumor formation.  All mice were housed and bred in accordance with the 
guidelines set by the Institutional Animal Care and Use Committee (IACUC) of UMMS.   
 
Tumor Harvesting and Cell Line Establishment. At 85 days of age, mammary tumors 
were dissected from female mice and placed in 3mls high glucose (4g/l) DMEM 
(Invitrogen) with 2% FBS (Sigma), collagenase (2mg/ml, Sigma) and Pen/Strep (Sigma).  
Tumors were minced into roughly 1mm3 pieces, placed back into the same media and 
incubated at 37°C under constant agitation (220 rpm, 3 hrs).  Periodically, tumor digests 
were pipetted up and down to dissociate any clumps.  Following collagenase digestion, 
cells were pelleted at 1000 RPM for 5 min.  Media was aspirated and cells were washed 5 
times with 10mls of PBS containing 5% FBS.  During the first wash, cell culture plates 
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 were coated with collagen (8mls/10cm plate, 50 mg/ml, Advanced BioMatrix) and 
allowed to sit in the tissue culture hood during the washes.  Before seeding cells, excess 
collagen was rinsed from the plates with PBS.  Cells were resuspended in DMEM/F12 
(Invitrogen) containing 2% FBS and Pen/Strep.  Approximately 4x106 cells were seeded 
per 10 cm plate.    
  Cells were maintained in DMEM/F12 containing 2% FBS with Pen/Strep and 
media was changed every 2-3 days.  Once cells reached confluence, they were passaged 
1:4 using trypsin and seeded onto collagen-coated plates as described above.  
Contaminating fibroblasts were periodically removed using differential tyrpsinization.  
Following addition of trypsin (Sigma), cells were monitored microscopically for 
detachment of fibroblasts, while the more adherent mammary tumor epithelial cells 
rounded but maintained their adherence to the plate.  Detached fibroblasts were washed 
away with PBS and fresh media was added.  This process was repeated as necessary to 
remove any contaminating fibroblasts during the crisis period, which lasts approximately 
4 weeks.   During this crisis period, growth medium was switched to low glucose (1g/l) 
DMEM (Invitrogen) containing 10% FBS.  Following crisis, cells began to actively 
proliferate and tissue culture plates were no longer pre-coated with collagen prior to cell 
seeding.   
 
In Vitro Knock-Out of Irs-1 and Irs-2 expression.  PyMT:Irs-1fl/fl, PyMT:Irs-2fl/fl and 
PyMT:Irs-1fl/fl/Irs-2fl/fl cells were infected with adenoviruses containing either GFP or 
GFP and Cre recombinase (Gene Transfer Vector Core, University of Iowa) at an MOI of 
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 10 in DMEM containing 2% FBS for five hours.  Virus containing media was removed 
and cells were placed in DMEM containing 10% FBS.  24 hours post-infection, GFP 
positive cells were isolated using fluorescence-activated cell sorting (FACS).  
Representative FACS profiles for control cells and GFP-Cre cells pre- and post-sort are 
shown in Figure 2.1A.  During and after sorting, cells were kept in 2% FBS/DMEM 
containing Normocin (100µg/ml, InvivoGen) to prevent contamination.  Cells were then 
screened for Irs-1 and Irs-2 expression by western blot.  Irs-1 or Irs-2 expression were 
successfully knocked-out in PyMT:Irs-1fl/fl and PyMT:Irs-2fl/fl cells (Figure 2.1B).  
However, following three rounds of Cre infection with subsequent sorting, PyMT:Irs-
1fl/fl/Irs-2fl/fl cells had residual Irs-1 expression (Figure 2.1C).  These cells were subcloned 
to isolate cell populations with a complete knockout of both Irs-1 and Irs-2 (Figure 2.2).  
Five subclones with no Irs-1 or Irs-2 expression were selected for further screening and 
showed no significant difference in cell growth (Figure 2.3A).  Additionally, these 
subclones were also screened for invasion (Figure 2.3B), glucose uptake (Figure 2.3C) 
and lactate production (Figure 2.3D).  In contrast to the cell growth data, the subclones 
varied in their ability to stimulate invasion and aerobic glycolysis.  The level of Igf-1r 
expression was also determined in each of these subclones, with subclone A having the 







 Figure 2.1. Establishing novel models to study the IRS proteins. (A) Representative 
sorting profiles showing the fluorescence of non-infected cells relative to Cre-GFP 
infected cells pre and post sort. (B) PyMT:Irs-1fl/fl and PyMT:Irs-2fl/fl cells were infected 
with Adenoviral GFP or Adenoviral Cre-GFP and cells were sorted for GFP+ cells 24 
hours post infection. Cell extracts that contained equivalent amounts of total protein were 
immunoblotted with antibodies that recognize IRS-1, IRS-2, and Tubulin.  (C) PyMT:Irs-
1flfl/Irs-2fl/fl cells were infected with Adenoviral Cre-GFP either once or three times and 
sorted for GFP+ cells 24 hours post infection. Cell extracts that contained equivalent 
amounts of total protein were immunoblotted with antibodies that recognize IRS-1, IRS-





























Figure 2.2. Evaluating Irs expression in PyMT:Irs-1flfl/Irs-2fl/fl 
single cell clones. 
42
 Figure 2.2. Evaluating Irs expression in PyMT:Irs-1flfl/Irs-2fl/fl single cell clones. 
PyMT:Irs-1flfl/Irs-2fl/fl cells that had been infected and sorted were single cell cloned.  Cell 
extracts from multiple individual clones that contained equivalent amounts of total 











































 Figure 2.3. Characterizing five PyMT:Irs-1-/-/Irs-2-/- clones.  (A) PyMT:Irs-1-/-/Irs-2-/- 
clones (A-E) were assayed for cell growth over three days.  The data shown represent one 
experiment.  (B) PyMT:Irs-1-/-/Irs-2-/- clones (A-E) were subjected to a transwell invasion 
assay for 4hrs.  The data shown represent the mean (+SEM) of three experiments.  (C,D) 
PyMT:Irs-1-/-/Irs-2-/- clones (A-E) were grown in 0.1% BSA/DMEM supplemented with 
IGF-1 (20ng/mL) for 24 hrs.  Glucose uptake and lactate production were measured and 
normalized to total protein concentration.  The data shown are expressed as a rate 
measurement (mM/mg/hr) and represent one experiment with measurements in triplicate.  
(E) Cell extracts from PyMT:Irs-1-/-/Irs-2-/- clones (A-E) that contained equivalent 
amounts of total protein were immunoblotted with antibodies that recognize Igf-1R, and 



















 Methods and Materials 
 
Cells, Antibodies and Reagents. All cell lines were maintained in DMEM (1g/l, 
glucose, Invitrogen) containing 10% FBS (Sigma). The murine pCMV-His-Irs-2 
construct was kindly provided by Morris White (Children’s Hospital, Boston, MA).  
Murine Irs-2 was sub-cloned into the pExchange-Puro vector (Stratagene).  Tyrosine 
residues in Irs-2 were mutated to phenylalanine using the Quickchange site-directed 
mutagenesis kit (Stratagene) according to the manufacturer’s protocol.  Mutagenesis 
primers were purchased from Integrated DNA Technologies (Y538F: 5’ 
GGGCGAACTCTATGGGTTCATGAGCATGC 3’ and 3’ GTCTATCCATGCTCATGAACCC 
ATAGAGT 5’; Y628F: 5’ CCCTTACCCAGAGGACTTTGGAGACATTGAG 3’ and 3’ CTCA 
ATGTCTCCAAAGTCCTCTGGGTAAGG 5’; Y649F: 5’ GGCAGATGATGGCTTCATGCC 
CATCAGCC 3’ and 3’ GGGTCATGGGCATGAAGCCATCATCTGCC 5’; Y671F: 5’ GCAA 
GAGCGATGACTTCATGCCCATGAGCCC 3’ and 3’ GGGCTCATGGGCATGAAGTCA 
TCGCTCTTGC 5’; Y734F: 5’ CCAGAAGACAGTGGGTTCATGCGAATGTC 3’ and 3’ ACA 
CCACATTCGCATGAACCCACTGTCTT 5’; Y758F: 5’ CCCCAACGGGGACTTCCTCAACA 
TGTCCCC 3’ and 3’ GGGGACATGTTGAGGAAGTCCCCGTTGGGG 5’; Y814F: 5’ CAG 
CGGAGACAATGACCAGTTTGTGCTCATGAGC 3’ and 3’ GCTCATGAGCACAAACTGG 
TCATTGTCTCCGCTG 5’). All cell transfections were performed using Lipofectamine 
2000 (Invitrogen) according to the manufacturer’s protocol.  For stable selection, cells 
were grown in puromycin (100 µg/ml; Fisher).   
 Human pcDNA-Neo-IRS-1-HA or pcDNA-Neo-IRS-2-HA constructs along with 
pcDNA-Neo (a generous gift from Adrian Lee, UPMC, Pittsburgh, PA) were transfected 
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 using Lipofectamine 2000 (Invitrogen) according to manufacturer’s protocol. For stable 
selection, cells were grown in Neomycin (500µg/ml, Gibco).  
The following antibodies were used for immunoprecipitation or immunoblotting: 
Irs-1 (Bethyl Laboratories), Irs-2 (immunoblot, Calbiochem or Cell Signaling 
Technologies; immmunoprecipitation, Bethyl Laboratories), p85 (Millipore), PY99 
(Santa Cruz), Glut1 (Abcam) and α6-integrin subunit (a kind gift from Anne Cress, 
University of Arizona).  HRP-conjugated anti-mouse and anti-rabbit secondary antibodies 
were obtained from Jackson Biolabs.  All other antibodies were obtained from Cell 
Signaling Technologies. 
 
Immunoprecipitation and Immunoblotting.  Cells were serum starved for 4hrs in 0.1% 
BSA/DMEM (1g/l glucose) and then stimulated with IGF-1 (100ng/ml) or insulin 
(100ng/ml) for the times listed in the Figure Legends.  If the following inhibitors were 
used, cells were pretreated for 1hr prior to stimulation: LY294002 (25µM, Cell Signaling 
Technologies), MK2206 (0.5µM, Selleckchem) and PD98059 (6µM, Selleckchem).  
Cells were solubilized on ice for 20 minutes in RIPA lysis buffer (50mM Tris, pH 7.4, 
containing 0.15M NaCl, 1% NP-40, 0.1% SDS, 1% sodium deoxycholate, 1mM sodium 
orthovanidate, 1mM sodium fluoride, and protease inhibitors (Complete Mini, Roche)).  
Insoluble material was removed by centrifugation at 14,000 RPM for 10 min at 4°C.  
Aliquots of cell extracts containing equivalent amounts of total protein were 
incubated under constant agitation at 4°C overnight with Irs-1, Irs-2, Akt1, or Akt2 
specific antibodies and protein A sepharose beads (GE Healthcare).  Immune complexes 
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 were washed with RIPA lysis buffer and incubated with Laemmli sample buffer 
containing β-mercapatoethanol for 5 minutes at 95°C.  Immune complexes, as well as 
aliquots of cell extracts containing equal amounts of total protein, were resolved by SDS-
PAGE and transferred to nitrocellulose membranes.  Membranes were blocked in 1X 
TBST buffer (50mM Tris, pH 7.5, containing 0.15M NaCl, 0.1% Tween-20) containing 
5% (w/v) Carnation dry milk.  Membranes were then incubated overnight at 4°C in 
blocking buffer containing primary antibodies.  After washing, membranes were 
incubated with HRP-conjugated secondary antibodies for 1 hour at room temperature in 
blocking buffer and proteins were then detected using enhanced chemiluminescence 
(Pierce and Bio-Rad).  For phospho-antibodies, the blocking buffer contained 5% BSA 
(w/v) (Sigma).     
  
HA Pull-Down Experiments. Cells were serum starved for 4hrs in 0.1% BSA/DMEM 
(1g/l glucose) and then stimulated with IGF-1 (100ng/ml) for the times listed in the 
Figure Legends.  Cells were solubilized on ice with a 50mM Tris, pH 7.4 buffer 
containing 0.15M NaCl, 1% NP-40, 10% glycerol, 1mM sodium orthovanadate, 1mM 
sodium fluoride, and protease inhibitors (Complete Mini, Roche).  Insoluble material was 
removed by centrifugation at 14,000 RPM for 10 min at 4°C.  
 Aliquots of cell extracts containing equivalent amounts of total protein were 
incubated under constant agitation at 4°C overnight with HA antibody-conjugated 
sepharose beads (Thermo Scientific).  Pull-down complexes were washed with lysis 
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 buffer and incubated with Laemmli sample buffer containing β-mercapatoethanol for 5 
minutes at 95°C.  Samples were subjected to western blot analysis as described above. 
  
Lactate and Glucose Uptake Assays.  Cells were grown in 24 well plates to near 
confluence, washed with PBS and then incubated with 0.1% BSA/DMEM (1g/l glucose) 
supplemented with IGF-1 (20ng/ml) for 24 hrs with or without the addition of the Gsk-3β 
inhibitor SB 216763 (10uM, Sigma).  Lactate levels in the conditioned media were 
measured using a lactate assay kit (Trinity Biotech) and glucose levels were measured 
using a glucose assay kit (Sigma) according to manufacturers’ instruction.  Total cellular 
protein per well was quantified using a Bradford Assay (BioRad) and lactate production 
and glucose uptake were expressed as a rate measurement (mM/mg/hr) normalized to 
protein content. 
 
Cell Surface Biotinylation.  Cells were grown to near confluence and then incubated in 
0.1% BSA/DMEM (1g/l glucose) with IGF-1 (20ng/ml) and with or without SB 216763 
(10 uM) for 24 hrs.  Following two washes with cold PBS, cells were biotinylated at 4°C 
for 30 min using EZ-LinkTM Sulfo-NHS-SS-Biotin (0.5 mg/mL; Pierce Biotechnology).  
Biotin was removed and the cells were incubated in a 50mM Tris buffer (pH 7.4) for 5 
minutes to quench any residual biotin.   Cells were washed with cold PBS and solubilized 
on ice with a 50mM Tris, pH 7.4 buffer containing 0.15M NaCl, 1% NP-40, 10% 
glycerol, 1mM sodium orthovanadate, 1mM sodium fluoride, and protease inhibitors 
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 (Complete Mini, Roche).  Nuclear contaminates were removed by centrifugation at 
14,000 RPM for 10 min at 4°C. 
 Aliquots of cell extracts containing equal amounts of protein were incubated with 
Neutra-Avidin Agarose Beads (Pierce Biotechnology) with constant agitation overnight 
at 4°C.  Pull-down complexes were washed lysis buffer and incubated with Laemmli 
sample buffer containing β-mercapatoethanol for 5 minutes at 95°C.  
 
2D Growth Assay.  Cells were dissociated using trypsin and resuspended in low glucose 
DMEM supplemented with 10ng/ml IGF-1.  Cells were plated at 5000 cells/well into a 
total of three wells and this was done for four individual 48-well plates (one for each day 
for the assay).  Media was changed every other day during the course of the assay and 
one plate was measured for cell growth each day.  Media was removed and cells were 
washed two times with PBS.  Cells were fixed with 100% methanol for 15 min at room 
temperature.  Methanol was removed and cells were stained with 0.2% crystal violet in 
2% ethanol for 15 min at room temperature.  Crystal violet stain was removed, cells were 
rinsed with H20 and crystal violet was solubilized with 200µl of 1% SDS.  A595 readings 
were measured using a spectrophotometer and cell growth was expressed as relative 
increase in A595 over day 0. 
 
3D Growth Assay.  In a 24-well plate, 200µl of Matrigel was added per well per cell line 
and left to solidify at 37°C for 30 min.  During this incubation period, cells were 
dissociated from their growth plates with trypsin and cells were resuspended at a 
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 concentration of 50,000 cell/ml in DMEM (1g/l glucose) supplemented with 10ng/ml 
IGF-1.  Cells were then mixed with matrigel at a 2:1 ratio and 300µl of this mixture was 
added to each matrigel-precoated well.  The cell/matrigel mix was then allowed to 
incubate at 37°C for an additional 30 min.  Following this incubation, 500µl of low 
glucose DMEM supplemented with 10ng/ml IGF-1 was carefully added to each well.  
Cell culture media was changed every three days and pictures were taken on day nine of 
the assay.  Colony size and number were then quantified. 
 
Transwell Invasion Assays.  24 hours prior to the assay, transwells (Costar, 8.0um 
polycarbonate membrane, 6.5mm inserts) were coated with matrigel (5µg/well) and left 
to dry overnight.  The following day, 40µl of 0.1% BSA/ DMEM was added to each well 
and incubated for an hour at 37°C.  Cells (1x104/well) resuspended in 0.1% BSA/DMEM 
were added to the top well of the transwell and 600µl of NIH-3T3 conditioned media was 
added to the bottom well.  After 4hrs of incubation at 37°C, the each transwell was 
swabbed with a Q-tip twice to remove the media and remaining cells. The transwells 
were fixed in methanol (10min, room temperature), rinsed with water and left to dry 
overnight at room temperature.  Transwells were stained with DAPI, five representative 
images were taken of each transwell and invaded cells were counted.    
 
Statistical Analysis.  In Chapter III, all p-values were calculated using an unpaired 
Students t test.  In Chapter IV, all p-values were calculated using a paired t test.  All error 
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 Insulin Receptor Substrate-1 (IRS-1) and IRS-2 are cytoplasmic adaptor proteins 
that mediate the activation of signaling pathways in response to ligand stimulation of 
upstream cell surface receptors.  Despite sharing a high level of homology and the ability 
to activate Phosphatidylinositol-3-Kinase (PI3K), only Irs-2 positively regulates aerobic 
glycolysis in mammary tumor cells. To determine the contribution of Irs-2-dependent 
PI3K signaling to this selective regulation, we generated an Irs-2 mutant deficient in the 
recruitment of PI3K.  We identified four tyrosine residues (Y649, Y671, Y734 and Y814) 
that are essential for the association of PI3K with Irs-2 and demonstrate that combined 
mutation of these tyrosines inhibits glucose uptake and lactate production, two measures 
of aerobic glycolysis. Irs-2-dependent activation of PI3K regulates the phosphorylation of 
specific Akt substrates, most notably Glycogen synthase kinase-3β (Gsk-3β).  Inhibition 
of Gsk-3β by Irs-2-dependent PI3K signaling promotes glucose uptake and aerobic 
glycolysis.  The regulation of unique subsets of Akt substrates by Irs-1 and Irs-2 may 
explain their non-redundant roles in mammary tumor biology.   Taken together, our study 
reveals a novel mechanism by which Irs-2 signaling preferentially regulates tumor cell 
metabolism and adds to our understanding of how this adaptor protein contributes to 








The IRS proteins are cytoplasmic adaptor proteins that organize signaling 
complexes downstream of cell surface receptors (33).  Originally discovered as substrates 
of the insulin receptor, they function as adaptor proteins for additional surface receptors 
including the closely related insulin like growth factor-1 receptor (IGF-1R) (43,49).  
Upon ligand stimulation, the IRS proteins are recruited to activated receptors where they 
are phosphorylated on tyrosine residues within their C-termini, generating binding sites 
for the recruitment of downstream signaling effectors, including PI3K, Growth factor 
receptor-bound protein-2 (GRB-2) and Src homology-2 domain-containing protein-
tyrosine phosphatase-2 (SHP-2) (93).  Following receptor activation, the combinatorial 
recruitment of these effectors by IRS-1 and IRS-2 is required for amplification of 
signaling cascades that regulate changes in cellular behavior.  IRS-1 and IRS-2 are 
ubiquitously expressed and are the primary mediators of insulin-dependent mitogenesis 
and glucose metabolism in most cell types (33).  Although they share considerable 
homology, in vitro cell line studies and distinct phenotypes of the Irs-1 and Irs-2 
knockout mice confirm that these proteins do not function in a redundant manner in 
normal cell biology or development (44,86-88,90,244).  
IRS-1 and IRS-2 also play divergent roles in breast cancer.  Stimulation of human 
breast carcinoma cell lines expressing only IRS-1 with IGF-1 increases their 
proliferation, whereas stimulation of cells expressing only IRS-2 promotes cell migration 
(102,103).   These differences in IRS function have also been demonstrated in vivo using 
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 the Mouse mammary tumor virus – Polyoma virus middle-T antigen (MMTV-PyMT) 
mouse model of mammary tumor progression.  Specifically, in mice expressing PyMT, 
mammary tumor metastasis is significantly diminished in the absence of Irs-2 expression, 
and Irs-1 does not compensate for this loss (106).  In fact, PyMT:Irs-1-/- tumors have 
elevated expression and tyrosine phosphorylation of Irs-2, and these tumors are more 
metastatic when compared with their wildtype (WT) counterparts (107). Cells derived 
from PyMT:Irs-2-/- tumors are also significantly less invasive and display decreased 
aerobic glycolysis relative to PyMT:WT or PyMT:Irs-1-/- tumor cells in vitro (106,108).   
Distinct functions for IRS-1 and IRS-2 in human breast tumors are also indicated by their 
unique intracellular localization patterns.  Tumor cells express both IRS-1 and IRS-2 in 
the cytoplasm, while IRS-1 also localizes to the nucleus and IRS-2 to the cell membrane 
(96,97).  Nuclear localization of IRS-1 correlates with increased response to tamoxifen 
and improved patient survival, whereas IRS-2 cell membrane localization correlates with 
decreased overall patient survival (96,98).  Differential intracellular 
compartmentalization may contribute to the ability of the IRS proteins to regulate distinct 
tumor cell functions. 
 The IRS proteins share their highest degree of homology in their N-terminal 
Plextrin Homology (PH) and Phosphotyrosine Binding (PTB) domains, which mediate 
their interactions with upstream receptors (61,62,245,246).  The C-termini of the IRS 
proteins are less conserved, and it is these C-terminal differences that likely confer upon 
the IRS proteins their divergent functions through specific interactions that impact 
localization and signaling (93).  With regard to signaling, activation of the PI3K and 
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 mechanistic target of rapamycin (mTor) pathway is enhanced in PyMT:Irs-1-/- tumors that 
express only Irs-2, and is significantly lower in tumors that lack Irs-2 expression, 
indicating that Irs-1 does not compensate fully for the activation of this pathway in vivo 
(107,108).  Similarly in vitro, mammary tumor cells derived from PyMT:Irs-1-/- tumors 
have enhanced Irs-2-dependent PI3K/mTor signaling (107).  The PI3K signaling pathway 
is one of the most commonly mutated pathways in cancer, including breast cancer 
(160,247). PI3K itself is an oncogene and activating mutations have been observed in 
many types of cancer (248).  In tumors that do not harbor PI3K mutations, other 
components of this signaling pathway, such as the lipid phosphatase Phosphatase and 
Tensin Homolog (PTEN) and Akt are often mutated such that PI3K signaling is enhanced 
(150,248).  One of the major contributions of the PI3K/Akt signaling pathway to tumors 
is the regulation of metabolic pathways that promote aerobic glycolysis, a hallmark of 
cancer (4,249). The overall goal of our current study was to establish the contribution of 
Irs-2-mediated PI3K activation to mammary tumor cell metabolism and to determine the 











Identification of Tyrosine Residues within Irs-2 that contribute to the recruitment of 
PI3K. 
 
PI3K is activated by the interaction of src homology 2 (SH2) domains within the 
p85 regulatory subunit with phosphotyrosine residues in upstream receptors or adaptor 
proteins (45,46,48,59,126).  To understand how Irs-2 activates PI3K signaling, we 
initially sought to identify specific tyrosine residues that participate in the recruitment of 
PI3K.  Tyrosines located within consensus PI3K binding motifs (YxxM) were mutated to 
phenylalanine to prevent phosphorylation while maintaining wild type Irs-2 structure (71-
73).  These residues included Y538, Y649, Y671, Y734 and Y814 (Figure 3.1A).  Two 
additional tyrosine residues that were shown previously in an Irs-2 proteomics 
phosphopeptide screen to be capable of binding to PI3K (Y628 and Y758) were also 
mutated to phenylalanine (74). WT Irs-2 and the individual Irs-2 tyrosine mutants were 
assayed for tyrosine phosphorylation in response to IGF-1 stimulation when expressed 
transiently in PyMT:Irs-2-/- cells.  Mutation of Y649, Y671 or Y814 reduced significantly 
the overall tyrosine phosphorylation of Irs-2 when compared with the level of WT Irs-2 
phosphorylation (Figure 3.1B).  In contrast, mutation of Y538, Y628 or Y758 did not 





 Figure 3.1. Identification of tyrosine residues that mediate Irs-2 recruitment of 
PI3K. (A) Schematic of WT Irs-2 and Irs-2 tyrosine mutants. Individual tyrosines that 
were mutated to phenylalanine are indicated for each mutant construct. (B-E) Irs-2-/- cells 
were transiently transfected with WT Irs-2 or the individual tyrosine mutant constructs 
and stimulated with IGF-1 (100ng/mL) (B,C) or insulin (100ng/ml) (D,E) for 10 minutes.  
Aliquots of cell extracts that contained equivalent amounts of total protein were 
immunoprecipitated with Irs-2 specific antibodies and the immune complexes were 
immunoblotted with antibodies that recognize either phosphotyrosine (p-Tyr) or p85α.  
The p-Tyr blots were stripped and re-probed for Irs-2.  The data shown in the graphs 
represent the mean (+SEM) of four (B), three (C and D) or two (E) independent 


















 was not possible to assess the impact of mutating Y734 on phosphorylation due to the 
protein instability of this Irs-2 mutant.  
The ability of the Irs-2 tyrosine mutants to recruit PI3K was assayed by co-
immunoprecipitation (co-IP) of the p85 regulatory subunit of PI3K.  Only the Y649F, 
Y671F and Y814F Irs-2 mutants exhibited a significant reduction in their ability to 
recruit p85 when compared with WT Irs-2 (Figure 3.1B), which correlated with their 
decreased level of tyrosine phosphorylation.  The association of p85 with Irs-2 was 
reduced by 43%, 57% and 70%, respectively, for each of these Irs-2 mutants.  Of note, 
the tyrosine residues that were implicated in the IGF-1-dependent recruitment of PI3K 
were also required for the recruitment of PI3K in response to insulin stimulation (Figure 
3.1D and E). 
We next combined multiple tyrosine mutations to generate an Irs-2 mutant that 
was impaired in its ability to recruit and activate PI3K.   These Irs-2 mutants included:  
Irs-2 Y3F, which combined mutations in the three tyrosines that individually contributed 
to the association of Irs-2 with p85 (Y649, Y671, Y814); Irs-2 Y4F, which added an 
additional mutation at Y734 to Y3F; and Irs-2 Y5F, which added an additional mutation 
at Y538 to Y4F (Figure 3.1A).  The level of tyrosine phosphorylation and association 
with p85 that was observed for the Irs-2 Y3F mutant was only marginally lower than that 
observed for the individual Y671F and Y814F Irs-2 mutants (Figure 3.2A and B).   
Additional mutation of Y734 significantly reduced the level of p85 association when 
compared with Irs-2 Y3F, indicating that Y734 participates in the interaction of Irs-2 with 
PI3K (Figure 3.2A and C).  The reason that protein expression can be obtained when this  
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 Figure 3.2. Generation of a PI3K-binding deficient Irs-2 mutant.  Irs-2-/- cells were 
transiently transfected with WT Irs-2 or Irs-2 multiple-tyrosine mutant constructs (Y3F, 
Y4F and Y5F) and stimulated with IGF-1 (100ng/mL) (A-C) or insulin (100 ng/mL) (D-
F) for 10 minutes.  Aliquots of cell extracts that contained equivalent amounts of total 
protein were immunoprecipitated with Irs-2 specific antibodies and the immune 
complexes were immunoblotted with antibodies that recognize either phosphotyrosine (p-
Tyr) or p85α. The p-Tyr blots were stripped and re-probed for Irs-2.  The data shown in 
the graphs represent the mean (+SEM) of three independent experiments.  NT, mock 




















 tyrosine is mutated in conjunction with other tyrosine mutations, while mutation of this 
tyrosine alone leads to protein instability, remains to be determined.  Additional mutation 
of Y538 (Irs-2 Y5F) did not provide further significant reduction in tyrosine 
phosphorylation or p85 association, confirming that this tyrosine residue does not 
contribute to the interaction of Irs-2 with PI3K (Figure 3.2A, B and C).  Similar levels of 
tyrosine phosphorylation and p85 association were observed for each of the combination 
mutants in response to insulin stimulation (Figure 3.2D, E, and F).  
 
Irs-2-dependent activation of PI3K stimulates aerobic glycolysis. 
 
 To establish a model system with which to study Irs-2-dependent PI3K activation 
and its role in the regulation of aerobic glycolysis, we derived cell lines from PyMT:Irs-
2fl/fl mammary tumors and acutely deleted Irs-2 expression in vitro by transient adenoviral 
infection of Cre-recombinase. These PyMT:Irs-2-/- cells were stably transfected to 
express either empty vector, WT Irs-2 or the Irs-2 Y5F mutant at equivalent protein 
levels compared to the parental population (Irs2fl/fl) (Figure 3.3A).  Similar to the results 
obtained after transient expression of Irs-2 Y5F, a significant, but not total, reduction in 
Irs-2 tyrosine phosphorylation and association with PI3K was observed when compared 
with WT Irs-2 (76% and 86% reduction, respectively) (Figure 3.3B and C).   PyMT:Irs-
2fl/fl cells expressing empty vector and PyMT:Irs-2-/- cells expressing empty vector, WT 
Irs-2 or Irs-2 Y5F were assayed for their level of aerobic glycolysis. As shown in Figure 




Figure 3.3. Irs-2-dependent PI3K signaling regulates aerobic glycolysis.  (A) Stable 
cell lines were generated of PyMT::Irs-2fl/fl cells expressing empty vector (EV) and 
PyMT::Irs-2-/- cells expressing EV, WT Irs-2 (WT) or Irs-2 Y5F (Y5F). Aliquots of cell 
extracts that contained equivalent amounts of total protein were immunoblotted with 
antibodies that recognize Irs-2 and Tubulin.  (B, C) Cells were serum deprived and then 
stimulated with IGF-1 (100ng/ml) for 10 minutes.  Aliquots of cell extracts that contained 
equivalent amounts of total protein were immunoprecipitated with Irs-2 specific 
antibodies and the immune complexes were immunoblotted with antibodies that 
recognize either phosphotyrosine (p-Tyr) or p85α. The p-Tyr blots were stripped and re-
probed for Irs-2.   The data shown in (C) represent the mean (+SEM) of five independent 
experiments.   *, p<0.0001 relative to WT Irs-2. **, p<0.0001 relative to WT Irs-2. (D,E) 
Cells were grown in 0.1% BSA/DMEM supplemented with IGF-1 (20ng/mL) for 24 hrs.  
Glucose uptake (D) and lactate production (E) were measured and normalized to total 
protein concentration.  The data shown are expressed as a rate measurement (mM/mg/hr) 
and represent the mean (+SEM) of five independent experiments. *, p<0.02 relative to 















 nearly 40% in the absence of Irs-2, and these activities were rescued by restoring WT Irs-
2 expression.  However, expression of Irs-2 Y5F did not restore glucose uptake or lactate 
production to the levels observed in WT Irs-2 expressing cells, establishing the 
requirement for direct PI3K activation by Irs-2 in the regulation of aerobic glycolysis 
(Figure 3.3D and E).  
 
Identification of Irs-2/PI3K-dependent Akt effectors. 
 
 Although both Irs-1 and Irs-2 are capable of recruiting PI3K and stimulating the 
activation of Akt, which plays an important role in regulating metabolism, Irs-2 
preferentially regulates aerobic glycolysis in mammary tumor cells (46,73,108,135). To 
investigate further the mechanism of this metabolic regulation, we sought to identify 
downstream signaling effectors of Akt that are selectively activated by Irs-2-dependent 
signaling.  Loss of Irs-2 expression did not diminish the overall level of IGF-1 stimulated 
Akt activation, as assessed by phosphorylation on either Ser473 or Thr308 (Figure 3.4A).  
Similarly, restoring WT Irs-2 or Irs-2 Y5F expression in the Irs-2-/- cells also did not 
significantly alter phosphorylation of Akt on either site relative to the level of 
phosphorylation observed in vector control, Irs-2-/- cells (Figure 3.4B-D).   This lack of 
impact on signaling is likely explained by increased expression of Irs-1 in the Irs-2-/- 
cells, which compensates for the activation of PI3K and Akt.   
 To assay for Irs-2-specific Akt activation independent of Irs-1, WT Irs-2 and Irs-2 
Y5F were expressed in cells that lack expression of both Irs-1 and Irs-2 (Figure 3.5A). 
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 Figure 3.4.  Signaling downstream of a PI3K-binding deficient Irs-2 mutant. (A-D) 
PyMT::Irs-2fl/fl cells expressing empty vector (EV) and PyMT::Irs-2-/- cells expressing 
EV, WT Irs-2 or Irs-2 Y5F were stimulated with IGF-1 (100ng/mL) for 2, 10, and 30 
minutes.  Aliquots of cell extracts that contained equivalent amounts of total protein were 
immunoblotted with antibodies that recognize Irs-1, Irs-2, pIgf-IR (Tyr1135/1136), Igf-
1R, pAkt (Thr308, Ser473), Akt, pMapk (Thr202/Tyr204), Mapk, and Tubulin.  The data 








































 Figure 3.5.  Signaling downstream of a PI3K-binding deficient Irs-2 mutant in Irs-1-
/-/Irs-2-/- cells. (A) Stable cell lines were generated of PyMT::Irs-1-/-/Irs-2-/- cells 
expressing empty vector (EV), WT Irs-2 or Irs-2 Y5F. Aliquots of cell extracts that 
contained equivalent amounts of total protein were immunoblotted with antibodies that 
recognize Irs-1, Irs-2 and Tubulin.  (B-C) PyMT::Irs-1-/-/Irs-2-/- cells expressing empty 
vector (EV), WT Irs-2 or Irs-2 Y5F were stimulated with IGF-1 (100ng/mL) for 10 
minutes (B) or 2, 10 and 30 minutes (C).  (B) Aliquots of cell extracts that contained 
equivalent amounts of total protein were immunoprecipitated with Irs-2 specific 
antibodies and the immune complexes were immunoblotted with antibodies that 
recognize either phosphotyrosine (p-Tyr) or p85α. The p-Tyr blots were stripped and re-
probed for Irs-2.   The data shown in the graph represent the mean (+SEM) of 3 
independent experiments. *, p<0.0002 relative to WT Irs-2. (C) Aliquots of cell extracts 
that contained equivalent amounts of total protein were immunoblotted with antibodies 
that recognize Irs-1, Irs-2, pIgf-IR (Tyr 1135/1136), Igf-1R, pS6k (Thr389), S6k, pAkt 
(Thr308, Ser473), Akt, and Tubulin. (D.E) PyMT::Irs-1-/-/Irs-2-/- cells expressing empty 
vector (EV), WT Irs-2 or Irs-2 Y5F were grown in 0.1% BSA/DMEM supplemented with 
IGF-1 (20ng/mL) for 24 hrs.  Glucose uptake (D) and lactate production (E) were 
measured and normalized to total protein concentration.  The data shown are expressed as 
a rate measurement (mM/mg/hr) and represent the mean (+SEM) of three independent 














 This Irs-1-/-/Irs-2-/- mammary tumor cell line was generated from PyMT:Irs-1fl/fl/Irs-2fl/fl 
mammary tumor cells after transient infection with adenoviral Cre-recombinase.   As we 
had observed using the PyMT:Irs-2-/- cells (Figure 3.3B and C), Irs-2 Y5F tyrosine 
phosphorylation and association with PI3K was significantly, but not completely, reduced 
in the Irs-1-/-/Irs-2-/- cells (Figure 3.5B).  Akt was not activated in response to IGF-1 
stimulation in the double null cells, keeping with previous reports that the Irs proteins are 
required for PI3K activation downstream of the IGF-1 and insulin receptors (Figure 3.5C) 
(129,130).  In the absence of background Irs-1 signaling, Akt phosphorylation was 
diminished in the Irs-2 Y5F expressing cells relative to cells expressing WT Irs-2 (Figure 
3.5C).  Phosphorylation of p70-S6Kinase, which we previously showed was 
preferentially activated by Irs-2, was also reduced (Figure 3.5C) (107).  Phosphorylation 
of the Igf-1R was similar in all cells examined, indicating that neither Irs expression nor 
the ability of Irs-2 to activate PI3K is required for upstream receptor activation (Figure 
3.4A and B and Figure 3.5C).  Importantly, glucose uptake and lactate production were 
significantly enhanced upon expression of WT Irs-2, but not Irs-2 Y5F, in the Irs-1-/-/Irs-
2-/- cells (Figure 3.5D and E). 
  Akt phosphorylates a large number of effectors, a subset of which have been 
implicated in the regulation of aerobic glycolysis (135,250). To identify Irs-2-dependent 
Akt substrates, Irs-1-/-/Irs-2-/- cells expressing either empty vector, WT Irs-2 or Irs-2 Y5F 
were stimulated with IGF-1 and total cell extracts were immunoblotted with a phospho-
Akt substrate-specific (RxxpS/T) antibody (Figure 3.6A) (251).  Although many of the 




Figure 3.6. Irs-2-mediated PI3K signaling preferentially regulates phosphorylation 
of Gsk-3β .  (A,B) PyMT::Irs-1-/-/Irs-2-/- cells expressing empty vector (EV), WT Irs-2 or 
Irs-2 Y5F were stimulated with IGF-1 (100ng/mL) for 2, 10 and 30 minutes.  (A) 
Aliquots of cell extracts that contained equivalent amounts of total protein were 
immunoblotted with antibodies that recognize Irs-2, the p-Akt substrate motif 
(RXXpS/T) and Tubulin.  Molecular weights (kDa) are indicated on the left.  (B) 
Aliquots of cell extracts that contained equivalent amounts of total protein were 
immunoblotted with antibodies that recognize Irs-2, pGsk3β (Ser9), Gsk-3β, and 
Tubulin.  (C,D) PyMT::Irs-2fl/fl cells expressing empty vector (EV) and PyMT::Irs-2-/- 
cells expressing EV, WT Irs-2 or Irs-2 Y5F were stimulated with IGF-1 (100ng/mL) for 
2, 10 and 30 minutes.  Aliquots of cell extracts that contained equivalent amounts of total 
protein were immunoblotted with antibodies that recognize Irs-1, Irs-2, pGsk-3β (Ser9), 
Gsk-3β, and Tubulin.  The data shown in the graph represent the mean (+SEM) of 3 
















 differences were observed.  In particular, one protein with a molecular weight of 
approximately 45 kDa showed higher levels of phosphorylation in cells expressing WT 
Irs-2 relative to vector control cells or cells expressing Irs-2 Y5F (Figure 3.6A).  We 
surmised that this protein could be Gsk-3β based on the molecular weight and its known 
involvement in the regulation of glucose metabolism (252).   Phosphorylation of Gsk-3β 
Ser 9, the Akt-dependent phosphorylation site in Gsk-3β, increased significantly in Irs-1-
/-/Irs-2-/- cells expressing WT Irs-2 relative to vector controls and this increase was not 
observed in the same cells expressing Irs-2 Y5F (Figure 3.6B) (171).  Similar results 
were observed using Irs-2-/- cells expressing either empty vector, WT Irs-2 or Irs-2 Y5F.  
Although Irs-1 is expressed in these cells, Gsk-3β phosphorylation in response to IGF-1 
stimulation is predominantly dependent on Irs-2 expression and its ability to activate 
PI3K (Figure 3.6C and D) and Irs-1-dependent signaling is unable to compensate for this 
phosphorylation.   
It has been suggested that Mitogen Activated Protein Kinase (MAPK) signaling 
can also promote GSK-3β phosphorylation in some cell types (253).  To determine which 
pathway was responsible for Gsk-3β phosphorylation in our model system, cells were 
incubated with PI3K (LY294002), Akt (MK2206) or MAPK (PD98059) inhibitors prior 
to stimulation with IGF-1.  Treatment of Irs-2fl/fl cells with a PI3K or Akt inhibitor 
prevented phosphorylation of Gsk-3β (Figure 3.7A).  In contrast, MAPK inhibition had 
no effect on Gsk-3β phosphorylation (Figure 3.7B).  These data support that PI3K/Akt 
signaling is the primary pathway that regulates Gsk-3β phosphorylation downstream of 
the Igf-1r in mammary tumor cells. 
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 Figure 3.7. Gsk-3β  inhibition is mediated by PI3K/Akt signaling. (A,B) PyMT::Irs-
2fl/fl cells were treated with or without a PI3K (LY294002), Akt (MK2206) or MAPK 
(PD9805) inhibitor prior to IGF-1 stimulation (100µg/ml, 10min).  Aliquots of cell 
extracts that contained equivalent amounts of total protein were immunoblotted with 
antibodies that recognize Irs-1, Irs-2, pIgf-IR (Tyr1135/1136), Igf-1R, pAkt (Thr308, 





















 Irs-2 regulates aerobic glycolysis through inhibition of Gsk-3β . 
 
 To determine if Irs-2 specific activation of PI3K signaling leads to inhibition of 
Gsk-3β activation, thereby relieving its inhibition of glycolysis, glucose uptake and 
lactate production were measured in the presence or absence of the GSK-3 inhibitor SB 
216763.  Inhibition of Gsk-3β rescued glucose uptake and lactate production in the Irs-2-
/- vector control and Irs-2 Y5F expressing cells to the level observed in cells expressing 
WT Irs-2 (Figure 3.8A and B). Previous studies have reported that Gsk-3β regulates 
aerobic glycolysis at the level of glucose uptake either by regulating Glut1 protein 
expression, promoting Glut1 retention at the cell membrane or increasing glucose 
transporter activity (232,254).  To address the mechanism by which Irs-2/Gsk-3β 
regulates glucose uptake, we first assessed total Glut1 expression.  Glut1 protein 
expression levels were equivalent in cells that lack Irs-2 expression, express WT Irs-2 or 
Irs-2 Y5F (Figure 3.8C and D).  Additionally, total Glut1 expression was not altered by 
Gsk-3β inhibition (Figure 3.8C and D).  Irs-2-/- cells expressed significantly less Glut1 on 
the cell surface compared to Irs2fl/fl cells and Irs-2-/- cells with restored WT Irs-2 
expression, confirming our previous data that Irs-2 regulates Glut1 surface expression 
(Figure 3.8C) (108).  However, Glut1 surface levels in cells expressing Irs-2 Y5F were 
equivalent to that observed for WT Irs-2, suggesting that direct activation of PI3K by Irs-
2 is not required for regulating Glut1 expression on the cell surface (Figure 3.8D).  




 Figure 3.8. Irs-2 regulates aerobic glycolysis through Gsk-3β  inhibition.  Cells were 
grown in 0.1% BSA/DMEM supplemented with IGF-1 (20ng/mL) with or without the 
Gsk-3β inhibitor SB-216763 (10µM) for 24 hrs.  Glucose uptake (A) and lactate 
production (B) were measured and normalized to total protein concentration.  The data 
shown are expressed as a rate measurement (mM/mg/hr) and represent the mean (+SEM) 
of five independent experiments.   (C and D)  The cell surface was biotinylated and cell 
surface proteins were isolated using Neutravidin beads.  Avidin interacting proteins were 
immunoblotted with antibodies that recognize the α6 integrin subunit and Glut1.  Total 
cell lystates from biotinylated cells were immunoblotted for antibodies that recognize Irs-
2, Glut1, and Tubulin.  (E) The data shown represent the mean (+SEM) of 2 independent 



















 3.8E).   Therefore, the regulation of Gsk-3β by Irs-2-dependent PI3K signaling likely 
























 In the current study, we investigated the mechanism by which Irs-2 recruits and 
activates PI3K and demonstrated the requirement of Irs-2-dependent PI3K signaling for 
breast carcinoma cell metabolism.  Our work identifies specific tyrosine residues within 
Irs-2 that are essential for its association with PI3K and provides a mechanistic basis for 
the amplification of PI3K signaling downstream of this adaptor protein.  Irs-2-dependent 
PI3K signaling promotes glucose uptake and lactate production, two measures of aerobic 
glycolysis.  The regulation of these functions is specific for Irs-2, as genetically identical 
mammary tumor cells expressing only Irs-1, which can also activate PI3K, are 
diminished in their glycolytic capacity. Although global Akt activation was not 
diminished in the absence of Irs-2-dependent PI3K activation, a reduction in the 
phosphorylation of specific Akt substrates was observed, indicating that Irs-1 and Irs-2 
regulate unique subsets of Akt effectors.  Inhibition of one of these Irs-2-specific Akt 
effectors, Gsk-3β, is required for the regulation of glucose uptake and lactate production.  
In summary, our data reveal a novel mechanism by which Irs-2 signaling preferentially 
regulates tumor cell metabolism and adds to our understanding of how this adaptor 
protein contributes to breast cancer progression.  
 Aerobic glycolysis is a hallmark of aggressive tumor cells that supports rapid 
proliferation, survival and invasion (4,255).  The importance of this altered tumor cell 
metabolism is underscored by the fact that aerobic glycolysis is regulated by many 
oncogenic and tumor suppressor pathways that promote tumor progression.  In previous 
81
 work, we reported that signaling through Irs-2 regulates mammary tumor cell glycolysis 
through the control of Glut1 surface expression, which was dependent upon PI3K and 
mTor pathway activation (108).  We now provide evidence that the direct activation of 
PI3K by Irs-2 is required for regulating aerobic glycolysis and demonstrate that specific 
downstream effectors of this pathway control glucose uptake, the rate-limiting step in 
glycolysis.   Glut1 surface expression is decreased in cells lacking Irs-2, but not in cells 
expressing an Irs-2 mutant with a significantly reduced ability to stimulate PI3K 
signaling, indicating that Irs-2-dependent PI3K activation is not required for Glut1 
surface localization.  However it is possible that the low level of Irs-2/PI3K/Akt signaling 
retained by the Irs-2 Y5F mutant (~15%) is sufficient to regulate Glut1 surface 
localization.  Generation of an Irs-2 mutant that is completely deficient in PI3K 
recruitment is required to address this potential mechanism of regulation.  Of note, 
inhibition of Gsk-3β activity rescues glucose uptake, but does not increase Glut1 
expression on the cell surface. Taken together with our previous study that implicated 
mTorc1 in the regulation of Glut1 surface expression, our data support that Irs-2 
coordinates the activation of signaling pathways to promote Glut1 expression on the cell 
surface and stimulate optimal uptake of glucose and aerobic glycolysis (108).  Given that 
Irs-2 is a hypoxia-regulated gene and its expression is required to sustain Akt activation 
in hypoxic environments, Irs-2-dependent PI3K signaling likely plays a key role in 
controlling glucose uptake and glycolytic metabolism in both normoxic and hypoxic 
tumor microenvironments (41). 
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   We identified four individual tyrosine residues within Irs-2 that are required for 
the recruitment and activation of PI3K in response to both IGF-1 and insulin stimulation.  
These tyrosines had previously been reported to be phosphorylated in response to insulin 
stimulation, but their involvement in recruiting PI3K had not been assessed (82).  
Likewise, each of these tyrosines had been shown to have the potential to bind to PI3K in 
a phosphopeptide pull-down proteomics screen (74).  However, this screen also 
implicated Y628 and Y758, which do not contribute to PI3K association with Irs-2 upon 
stimulation of mammary tumor cells with either IGF-1 or insulin.  A previous study had 
reported that Y628 inhibits Irs-2 tyrosine phosphorylation in response to insulin, but not 
IGF-1 stimulation (63).  We did not observe any difference in the phosphorylation of Irs-
2 in response to either insulin or IGF-1 stimulation when this site was mutated, 
suggesting a cell context dependent role for this regulation.   Combined mutation of all of 
the tyrosines located within canonical PI3K binding motifs did not completely inhibit 
PI3K association with Irs-2 or downstream activation of Akt signaling.  Although the 
tyrosines we identified play a dominant role in recruiting PI3K (>90%), additional 
tyrosine residues within Irs-2 may recruit PI3K through a non-canonical interaction.  
Additionally, PI3K recruitment may occur through an indirect interaction with another 
binding protein.   A rigorous study of Irs-2 interacting proteins will be necessary to 
identify these alternative mechanisms of PI3K recruitment.     
 The regulatory subunit of PI3K, p85, contains two SH2 domains that must be 
engaged by phosphorylated tyrosines to induce a conformational change, leading to 
disinhibition and activation of the p110 catalytic subunit (126).  Although binding to one 
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 SH2 domain can partially activate PI3K, binding of both SH2 domains promotes 
maximal kinase activity.  We implicate four tyrosines in the association of Irs-2 with 
PI3K and based on primary sequence alone, Y649/Y671 and Y734/Y814 could be 
predicted to form docking sites for two tandem p85 SH2 domains.  However, Irs-2 is an 
intrinsically disordered protein with minimal structural information available to guide 
predictions of physical proximity (256).  Therefore, additional potential pairings are 
possible both in cis and trans, given that the IGF-1 and insulin receptors are dimeric and 
two Irs proteins can be recruited simultaneously (257).   When comparing Irs-1 with Irs-
2, only two of the four tyrosines implicated in Irs-2-dependent PI3K activation have 
corresponding residues within Irs-1.   Y612 and Y628 (human numbering) in Irs-1, which 
correspond to Y649 and Y671 in Irs-2, mediate full PI3K recruitment, suggesting that 
only a single PI3K heterodimer is recruited to Irs-1 (83).  Y734 and Y814 do not share 
homologous sites within Irs-1 and individual mutation of Y814 had the most significant 
impact on the association of Irs-2 with PI3K.  Therefore, Y734 and Y814 may be 
determining factors in the enhanced activation of PI3K by Irs-2.   
 Our study reveals a novel mechanism for how Irs-1 and Irs-2 differentially 
regulate tumor cell metabolism and contribute to breast cancer progression.  Both Irs-1 
and Irs-2 can recruit and activate PI3K to promote Akt signaling when stimulated with 
IGF-1, yet the functional outcomes that result from this activation are different.  Irs-1 and 
Irs-2 have distinct subcellular localization patterns in human tumors, with Irs-1 localized 
to both the cytoplasm and nucleus, and Irs-2 to the cytoplasm and at the cell membrane 
(96,97). Irs-2 membrane localization is a predictor of reduced breast cancer patient 
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 overall survival, while Irs-1 nuclear localization is associated with tumors that are more 
differentiated and non-metastatic, and more sensitive to tamoxifen response (96,98).  
These studies reveal that differences in the localization of Irs-1 and Irs-2 impact 
outcomes in human cancer and point toward localization as being a key determinant of 
the function of these adaptor proteins.  Localizing to distinct intracellular compartments 
would not only determine access to unique subsets of downstream effectors, but also to 
the substrates of these effectors to impact cell function. With regard to Irs-2, we 
hypothesize that activation of Akt at the plasma membrane would target inhibition of 
Gsk-3β where it could regulate glucose uptake.  We identify Gsk-3β as one Akt target 
that is preferentially regulated by Irs-2-dependent PI3K signaling. Additional Akt 
effectors that are selectively regulated by this signaling pathway may also play a role in 
metabolism and other functions regulated by Irs-2.  In this regard, Foxo1 is preferentially 
regulated by Irs-2 because PI3K is not sufficiently activated by Irs-1 to support this 
regulation (258).  The PI3K kinase signal is likely enhanced when activated through Irs-2 
because it has a greater potential for PI3K recruitment.   The enhanced activation of 
mTorc1, Gsk-3β and Foxo1, key regulators of metabolism, confirms the role of Irs-2 in 
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 The Insulin Receptor Substrate (IRS) proteins, IRS-1 and IRS-2, are the primary 
mediators of insulin-stimulated growth and glucose homeostasis.  Studies of IRS-1 and 
IRS-2 have shown that they do not function interchangeably in both normal cellular 
biology and in tumor progression.  Specifically in studies of breast cancer, IRS-1 
promotes growth and proliferation, while IRS-2 promotes motility, invasion, survival, 
aerobic glycolysis and metastasis.  However, many of these studies have been performed 
in model systems that limit the conclusions that can be drawn about the differences 
between IRS-1 and IRS-2.  We have generated a novel model system that allows for the 
rigorous comparison of IRS-1- and IRS-2-mediated signaling and functions in mammary 
tumor cells.  We have generated cells from PyMT:Irs-1fl/flIrs-2fl/fl mouse mammary 
tumors and knocked-out Irs-1 and Irs-2 expression in vitro using Cre-recombinase.   This 
made it possible to express IRS-1 or IRS-2 in a genetically matched background and 
allowed for the rigorous comparison of their function. Using these cells, we have 
confirmed a role for IRS-1 in tumor cell growth and a role for IRS-2 in tumor cell 
invasion.  Additionally, our data suggest that IRS-2 can more robustly stimulate Akt 
phosphorylation on Thr308 and Ser473.  This study supports that this model system is 








 The Insulin Receptor Substrate (IRS) proteins are cytoplasmic adaptors that 
function to recruit and activate downstream signaling effectors following upstream 
receptor stimulation (33).  The IRS family of proteins has four members, IRS-1-4, and 
only IRS-1 and IRS-2 are ubiquitously expressed in both humans and rodents (33).  In 
contrast, Irs-3 is expressed only in rodents and IRS-4 is expressed only in the brain, 
kidney, thymus, and liver (34-36).  Mouse models of whole body knockout of each of the 
Irs proteins suggest that despite having a similar structure they do not function 
interchangeably.  Irs-1-/- mice are born runted, develop insulin resistance, but do not go 
on to develop diabetes.  However, Irs-2-/- mice are infertile, display brain developmental 
defects and develop insulin resistance, ultimately progressing to diabetes due to β-cell 
failure (84-87).  In contrast to Irs-1 and Irs-2, Irs-3-/- mice are born normal size and do 
not display any abnormalities in glucose homeostasis, while Irs-4-/- mice display only 
mild effects on growth, reproduction and glucose homeostasis (259,260).  From these 
studies it has been concluded that Irs-1 and Irs-2 are the primary mediators of growth and 
insulin-dependent glucose homeostasis.      
 In vitro experiments have confirmed the distinct functions of the Irs proteins.  In 
Irs-1-/- mouse embryonic fibroblasts (MEFs), cell proliferation is reduced relative to wild 
type (WT) controls, suggesting that endogenous expression of Irs-2 in Irs-1-/- cells is 
insufficient to promote proliferation (88).  The role of Irs-1 in the regulation of 
proliferation has been confirmed in L6 myotubes, as knockdown of Irs-1, but not Irs-2, 
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 decreases proliferation.  Additionally, the effects of signaling mediated by the Irs proteins 
on metabolism have been shown to be cell context dependent.  For example, in 
adipocytes Irs-2 promotes Glut4 translocation to the plasma membrane, whereas in L6 
myotubes, Irs-1 promotes Glut4 translocation (89,91).  Together, these data suggest non-
redundant, cell context specific roles of the Irs proteins. 
 Studies of the IRS proteins in cancer have also suggested that they do not function 
interchangeably in all steps of tumor initiation and progression, with the most significant 
data coming from breast cancer.  Overexpression of either IRS-1 or IRS-2 leads to 
disrupted acini formation of MCF10A cells in 3D matrigel assays and in vivo, mammary 
specific, transgenic overexpression of either IRS-1 or IRS-2 promotes mammary tumor 
initiation and pulmonary metastasis (99).  Together, these experiments suggest that both 
IRS-1 and IRS-2 are capable of promoting tumor initiation.  However, in other stages of 
tumor progression, the IRS proteins function in a non-redundant manner as shown by in 
vivo experiments using Irs-1-/- and Irs-2-/- mice crossed with the PyMT mouse model of 
mammary tumor progression.  In this model, tumor growth was not impaired in 
PyMT:Irs-1-/- or PyMT:Irs-2-/- mice relative to their PyMT:WT counterparts (105,106).  
However, Irs-1-/- tumors had increased expression and activation of Irs-2 as well as 
increased angiogenesis and significantly increased pulmonary metastasis (105,107).  In 
contrast, Irs-2-/- tumors were more apoptotic and had decreased metastasis relative to 
their WT counterparts (105,106).  Additionally, in vitro studies using breast cancer cell 
lines have suggested that overexpression of IRS-1 promotes IGF-1-dependent growth and 
proliferation only in estrogen receptor + (ER+) breast cancer cell lines that predominantly 
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 express IRS-1, but not ER- cell lines that express predominantly IRS-2 (40,100-102).  In 
contrast, IGF-1 signaling mediated by IRS-2 promotes adhesion, motility, invasion, and 
aerobic glycolysis regardless of ER expression status (102,103,108).  These data show 
divergent functional outcomes of either IRS-1 or IRS-2-mediated signaling in breast 
cancer.  
 Despite their differential functions in normal biology and cancer, the mechanism 
by which the IRS proteins regulate these distinct functions remains unknown (93).  Both 
IRS-1 and IRS-2 mediate signal transduction downstream of the Insulin Receptor (IR) 
and the Insulin-Like Growth Factor-1 Receptor (IGF-1R) (42-50).  They have also both 
been shown to function downstream of additional receptors including the interleukin-4 
(IL-4) receptor and certain integrins (50-53).  Following either IR or IGF-1R activation, 
the IRS proteins are recruited via their Plextrin Homology (PH) and Phosphotyrosine 
Binding Domains (PTB) domains where they share the highest level of homology and are 
subsequently phosphorylated by the receptor on tyrosine residues in their C-termini 
(24,43,49,59-61).  This creates docking sites for downstream effectors including 
Phosphatidylinositol-3-Kinase (PI3K), Growth factor receptor-bound protein 2 (GRB2) 
and Src-Homology 2 Domain Containing Protein Tyrosine Phosphatase 2 (SHP2), 
leading to activation of the PI3K and Mitogen Activated Protein Kinase (MAPK) 
signaling pathways (59,65,67,68). In addition to tyrosine residues, the IRS proteins are 
also phosphorylated on serine residues, some of which inhibit their ability to recruit and 
activate PI3K signaling (75).  The outcome of serine phosphorylation on IRS-1 has been 
more extensively studied, while less is known about IRS-2 serine phosphorylation.  Not 
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 all tyrosine and serine residues are conserved between the IRS proteins and these 
differences may confer unique protein associations with IRS-1 and IRS-2 (81).  In fact, a 
phosphoproteomic study of all the tyrosine residues in IRS-1 and IRS-2 suggest that they 
have unique binding partners (74).  Together, these differences between IRS-1 and IRS-2 
may mediate the differential functional outcomes with which they have been associated.  
IRS-2 also contains a unique region called the kinase regulatory loop-binding (KRLB) 
region that associates with the IR and limits the receptor’s tyrosine kinase activity (62-
64).  IRS-1 does not contain a KRLB region and this difference may also contribute to 
the differences in functional outcomes of signaling downstream of IRS-1 and IRS-2.  
 The differential localization of the IRS proteins mediated by unique interacting 
partners may also play a role in determining some of their discrete functional outcomes.  
IRS-1 has been shown to localize to both the cytoplasm and nucleus, while IRS-2 strictly 
localizes to the cytoplasm with some studies reporting localization of IRS-2 at the plasma 
membrane (96,97).  These localization patterns have been shown to correlate with breast 
cancer patient prognosis.  Specifically, IRS-1 nuclear staining predicts increased response 
to tamoxifen treatment, while IRS-2 plasma membrane staining predicts decreased 
overall survival (96,98).   
 The current models that exist to study the IRS proteins are not ideal for rigorous 
comparison of IRS-1 and IRS-2 specific functions.  Cell lines derived from Irs-1-/- and 
Irs-2-/- mouse tissues and tumors have given great insight into the differential functions of 
the IRS proteins, but these cell lines are not genetically matched and limit the conclusions 
that can be made from their comparison (88,89,91,108).  The use of breast carcinoma cell 
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 lines has helped to define the roles of the IRS proteins in breast cancer (40,100-103).  
However, these discoveries have been based on either overexpression or knockdown of 
either IRS-1 or IRS-2.  It has been well established that protein overexpression studies 
are complicated by the fact that high levels of protein expression may promote functions 
that are not observed with endogenous levels of expression.  Additionally, many of these 
overexpression studies have been done in such a way that IRS-1 and IRS-2 expression 
cannot be compared (99,102).  Knockdown studies, while useful because either IRS-1 or 
IRS-2 expression can be knocked down in the same cell line, are limited by the fact that 
protein levels are only reduced, and not completely eliminated (101,103).  In addition, all 
experiments examining IRS-1 specific functions have been done in a background of IRS-
2 expression and vice-versa.  Therefore, the effects attributed to either IRS-1 or IRS-2 
have not been shown independently of expression of the other IRS protein.   
 The purpose of the current study was to generate a model system that would allow 
for the rigorous comparison of IRS-1 and IRS-2 signaling and functions.  This model can 
be used for future identification of novel mechanisms of IRS-1 and IRS-2 action that 










Generation of a model system to compare IRS-1 and IRS-2 function 
 
 To establish a genetically matched model system to investigate IRS-1 and IRS-2-
mediated signaling and functions independent of the other, we derived cell lines from 
PyMT:Irs-1fl/fl/Irs-2fl/fl mammary tumors and acutely deleted Irs-1 and Irs-2 expression in 
vitro by transient adenoviral infection of Cre-recombinase.  The resulting population of 
PyMT:Irs-1-/-/Irs-2-/- cells were single-cell subcloned to generate cell lines with complete 
loss of Irs-1 and Irs-2 expression.  HA-tagged IRS-1 (IRS-1-HA) and IRS-2 (IRS-2-HA) 
were stably expressed in five distinct PyMT:Irs-1-/-/Irs-2-/- subclones.  IRS-1, IRS-2 and 
HA protein expression were assessed by western blot (Figure 4.1). The use of HA-tagged 
IRS constructs allowed for direct comparison of IRS expression levels.  Levels of IRS-1 
and IRS-2 expression were equivalent in all five subclones (Figure 4.1).  PyMT:Irs-1-/-
/Irs-2-/- subclones A and D were chosen for further analysis, as they have the highest 
level of Igf-1r expression (Figure 2.3E).  
 
IRS-mediated PI3K Activation in Response to IGF-1 stimulation 
 
 In response to IGF-1 stimulation, the IRS proteins are phosphorylated on tyrosine 
residues in their C-termini to facilitate recruitment and activation of downstream 




















































Figure 4.1. Stable expression of IRS-1-HA or IRS-2-HA in 
PyMT:Irs-1-/-/Irs-2-/- cells.  
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 Figure 4.1. Stable expression of IRS-1-HA or IRS-2-HA in PyMT:Irs-1-/-/Irs-2-/- cells.  
Five PyMT:Irs-1-/-/Irs-2-/- clones (A-E) were engineered to stably express empty vector 
(EV), IRS-1-HA or IRS-2-HA.  Following selection, aliquots of cell extracts that 
contained equivalent amounts of total protein were immunoblotted with antibodies that 






















 PyMT:Irs-1-/-/Irs-2-/- subclones A and D stably expressing either IRS-1-HA or IRS-2-HA 
were stimulated with IGF-1 (Figure 4.2A).   Each displayed tyrosine phosphorylation 
within two minutes of IGF-1 stimulation.  Phosphorylation levels began to decrease after 
10 minutes of stimulation for both IRS-1 and IRS-2.  Relative tyrosine phosphorylation 
of IRS-1 was higher when compared with IRS-2 over the time course of IGF-1 
stimulation, however this difference was not statistically significant (Figure 4.2B).  
 Specific phosphorylated tyrosines within consensus PI3K binding motifs (YxxM) 
are required for association of the IRS proteins with PI3K following insulin and IGF-1 
stimulation (83,261).  The interaction of src homology-2 (SH2) domains within the p85 
regulatory subunit of PI3K with pYxxM motifs in the IRS proteins leads to disinhibition 
of the p110 catalytic subunit and renders the kinase active (72,73,122,124-126).  This 
leads to generation of the phosphoinositide-3,4,5-P3 (PtdIns-3,4,5-P3) at the plasma 
membrane, promoting recruitment and phosphorylation of the PI3K effector Akt (132-
134,165).  Our previous study identified four tyrosine residues in Irs-2 that participate in 
its interaction with PI3K, while IRS-1 requires only two tyrosines to mediate full PI3K 
activity (261).   However, a side-by-side comparison of the ability of the IRS proteins to 
recruit PI3K has yet to be undertaken (83,261).  To rigorously compare the ability of the 
IRS proteins to recruit PI3K, IRS-1 and IRS-2 were assayed for their recruitment of p85, 
the regulatory subunit of PI3K.  p85 co-immunoprecipitated (co-IP) with both IRS-1 and 
IRS-2 following IGF-1 stimulation (Figure 4.2A).  p85 was recruited to IRS-1 and IRS-2 
within 2 minutes of IGF-1 stimulation and began to decrease following 10 minutes of 
stimulation. Consistent with its higher level of tyrosine phosphorylation, IRS-1 also 
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 Figure 4.2. Comparison of the ability of IRS-1 and IRS-2 to associate with PI3K.  
(A-C) Irs-1-/-/Irs-2-/- D cells stably expressing IRS-1-HA or IRS-HA were serum 
deprived and then stimulated with IGF-1 (100ng/ml) for 2, 10, 30, 60, and 120 minutes.  
Aliquots of cell extracts that contained equivalent amounts of total protein were 
immunoprecipitated with HA-specific antibodies conjugated to agarose beads and the 
immune complexes were immunoblotted with antibodies that recognize either 
phosphotyrosine (p-Tyr) or p85α. The p-Tyr blots were stripped and re-probed for Irs-2. 
The data shown represent the mean (+SEM) of three (B; Tyrosine phosphorylation) or 




















 exhibted higher levels of p85 association relative to IRS-2, but this increase was also not 
statistically significant (Figure 4.2C).   
 
Akt activation downstream of IRS-1 or IRS-2 
 
 Previous experiments have demonstrated that Irs-1 can compensate for the loss of 
Irs-2-mediated PI3K activation of Akt following Cre-mediated knockout of Irs-2 
expression, as these cells do not display reduced IGF-1-mediated Akt phosphorylation 
(261). To compare the ability of IRS-1 and IRS-2 to mediate Akt activation, cells 
expressing vector control, IRS-1-HA or IRS-2-HA were stimulated with IGF-1 and 
assayed for their ability to promote Akt activation.  Regardless of IRS expression status, 
Igf-1r phosphorylation was equivalent across the panel of cells lines following IGF-1 
stimulation and was sustained during the time course of stimulation (Figure 4.3A and D).  
Following IGF-1 simulation, phosphorylation of Akt at Ser473 or Thr308 was not 
induced in vector control cells (Figure 4.3A and D).  This confirms that the Igf-1r 
requires the IRS proteins to mediate activation of PI3K/Akt signaling (129,130).  In 
contrast, IRS-1-HA and IRS-2-HA expressing cells show an increase in both Ser473 and 
Thr308 phosphorylation in response to IGF-1 stimulation (Figure 4.3A-F).  However, 
phosphorylation of both sites is higher in both subclones expressing IRS-2-HA relative to 
cells expressing IRS-1-HA and these data are statistically significant for subclone D 
(Figure 4.3A-F).  In addition to Akt phosphorylation, S6 Kinase (S6k) phosphorylation 
was increased in cells expressing IRS-2-HA relative to cells expressing  
100











































































































































































 Figure 4.3. Comparison of IRS-1- and IRS-2-mediated signaling.  (A,D) Irs-1-/-/Irs-2-
/- A and D subclones stably expressing pcDNA vector, IRS-1-HA or IRS-HA were serum 
deprived and then stimulated with IGF-1 (100ng/ml) for 30, 60, and 120 minutes. 
Aliquots of cell extracts containing equivalent amounts of total protein were 
immunoblotted with antibodies that recognize Irs-1, Irs-2, pIgf-IR (Tyr1135/1136), Igf-
1R, pS6k (Thr389), S6k, pAkt (Thr308, Ser473), Akt, pGsk-3β (Ser9), Gsk-3β, and 
Tubulin.  The data shown in (B) and (C) represent the mean (+SEM) of three independent 
experiments.  The data shown in (E) and (F) represent the mean (+SEM) of four 




















 IRS-1-HA (Figure 4.3A and D).  These data show that the increased phosphorylation of 
Akt downstream of IRS-2 correlates with its increased kinase activity, as S6k is a 
downstream effector of Akt and the mechanistic target of rapamycin complex-1 
(mTorc1).  Additionally, we previously identified Glycogen synthase kinase-3β (Gsk-3β) 
as an Irs-2-specific Akt substrate (261).  While IRS-1 mediated signaling induced a 
modest phosphorylation of Gsk-3β in response to IGF-1 stimulation, phosphorylation of 
this Akt effector downstream of IRS-2 was significantly more robust (Figure 4.3A and 
D). 
 Akt exists as three isoforms, Akt 1-3, which are highly homologous but, not 
unlike the IRS proteins, do not function interchangeably in cancer (262).  Previous 
studies of IRS-1 and IRS-2 signaling have suggested that the IRS proteins may 
differentially regulate Akt1 and Akt2 (89,263).  One study suggested that IRS-1 and Akt2 
may function together to regulate glucose metabolism, while IRS-2 and Akt1 function to 
regulate lipid metabolism (263).  However, in an independent study, Irs-1 was shown to 
regulate Akt1, while Irs-2 regulated Akt2 (89).  To determine if the IRS proteins 
differentially activate either Akt1 or Akt2, each of these isoforms were 
immunoprecipitated following IGF-1 stimulation and the level of phosphorylation of 
Thr308 and Ser473 was measured.  As had been observed for the analysis of total Akt 
phosphorylation (Figure 4.4), IGF-1-stimulated phosphorylation of Akt requires 
expression of the IRS proteins. However, phosphorylation of Akt1 on Thr308 is higher 
downstream of IRS-1 than downstream of IRS-2.  These results are preliminary and 















Figure 4.4. Akt1 and Akt2 phosphorylation mediated by IRS-1 or IRS-2.  
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 Figure 4.4. Akt1 and Akt2 phosphorylation mediated by IRS-1 or IRS-2.  Irs-1-/-/Irs-
2-/- D subclones stably expressing pcDNA vector, IRS-1-HA or IRS-HA were serum 
deprived and then stimulated with IGF-1 (100ng/ml) for 30, 60, and 120 minutes. 
Aliquots of cell extracts that contained equivalent amounts of total protein were 
immunoprecipitated with Akt1 or Akt2 specific antibodies and the immune complexes 
were immunoblotted with antibodies that recognize either pAkt (Thr308, Ser473), Akt1 




















 expression of either IRS-1 or IRS-2 is sufficient to promote phosphorylation of either 
Akt1 or Akt2 in response to IGF-1 stimulation.     
  
IRS-1 promotes growth in 3D Matrigel 
 
 Previous studies of the IRS proteins have suggested that IRS-1, but not IRS-2, 
functions to promote growth and proliferation. Only one of these studies directly 
compared of the ability of IRS-1 and IRS-2 to promote proliferation (102).  However, this 
study used expression of untagged IRS proteins and thus relative IRS expression could 
not be determined.  Therefore, these experiments do not exclude the possibility that the 
ability of IRS-1 to promote proliferation was dependent on its expression being higher 
than expression of IRS-2.  Using our model system where IRS expression is equivalent, 
we sought to compare the ability of IRS-1 and IRS-2 to regulate cell growth.  Standard 
2D assays showed no difference in growth rates when comparing PyMT:Irs-1-/-/Irs-2-/- 
subclones expressing vector control, IRS-1-HA or IRS-2-HA (data not shown).  
However, the ability of IRS-1 to stimulate IGF-1 dependent growth is this type of assay 
has been previously shown to be dependent on ER expression (40).  Given that MMTV-
PyMT mammary tumors and cell lines derived from these tumors are ER-, our results 
recapitulate these prior experiments (107,242).   
 To further assess the role of the IRS proteins in the regulation of cell growth, 
PyMT:Irs-1-/-/Irs-2-/- cells expressing vector control, IRS-1-HA or IRS-2-HA were 
subjected to 3D-matrigel growth assays in the presence IGF-1.  Following nine days in 
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 culture, the number and size of the colonies formed was determined.   In both PyMT:Irs-
1-/-/Irs-2-/- subclones expressing IRS-1-HA, but not IRS-2-HA, the size of the colonies 
relative to vector control cells was significantly increased (Figure 4.5A and B).  
However, the number of colonies formed under IGF-1 stimulated conditions was similar 
in cells expressing vector control, IRS-1-HA or IRS-2-HA (Figure 4.5A and C).  Despite 
observing no difference in the proliferative ability of these cells in a 2D growth assay, 3D 
growth assays clearly show that IRS-1 promotes mammary tumor cell growth. 
 
IRS-2 promotes invasion 
 
 Multiple studies have suggested that IRS-2, but not IRS-1, positively regulates 
motility and invasion (102,103,108).  Similar to experiments that suggested a role for 
IRS-1 in proliferation, studies of the regulation of motility and invasion by IRS-2 were 
done using untagged versions of the IRS proteins (102).  Therefore, these experiments do 
not exclude the possibility that the ability of IRS-2 to promote motility and invasion was 
dependent on its expression being higher than expression of IRS-1.  Other experiments 
have also shown increased invasion in cells derived from PyMT:Irs-1-/- tumors relative to 
those derived from PyMT:Irs-2-/- tumors (108).  However, these cell lines are not 
genetically matched and it is possible that additional factors could mediate these 
differences.  One additional study using metastatic variants of breast cancer cell lines 
determined that there was a correlation between increased IRS-2 tyrosine 

























































































































Figure 4.5. IRS-1 expression promotes cell growth in 3D. 
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 Figure 4.5. IRS-1 expression promotes cell growth in 3D. (A) Equivalent numbers of 
Irs-1-/-/Irs-2-/- A and D subclones stably expressing pcDNA vector, IRS-1-HA or IRS-HA 
were grown in a 3D matrix composed of Matrigel in the presence of IGF-1 (10ng/ml). 
The data shown for colony size (B) and colony number (B) represents the mean (+SEM) 






















 never addressed (103).  To assess the ability of the IRS proteins to promote invasion, 
PyMT:Irs-1-/-/Irs-2-/- cells expressing vector control, IRS-1-HA or IRS-2-HA were 
assayed using a matrigel transwell invasion assay.  Expression of IRS-2, but not IRS-1, 
significantly increased the invasive ability of cells relative to vector control cells (Figure 
4.6A).  These data confirm a role for IRS-2 in mediating invasion in mammary tumor 
cells.  
 IRS-2 also preferentially increases aerobic glycolysis in mouse mammary tumor 
cell lines (108).  As described above, the original WT, Irs-1-/- and Irs-2-/-cell lines used 
for these studies were not genetically identical. To directly compare the contribution of 
the IRS proteins to the regulation of aerobic glycolysis, glucose uptake and lactate 
production were measured in our genetically matched model system.  Expression of IRS-
2-HA, but not IRS-1-HA, significantly increased glucose uptake, while both IRS-1-HA 
and IRS-2-HA significantly increased lactate production (Figure 4.6B and C).  Of note, in 
prior studies in which we expressed murine Irs-2 in subclone A, a more significant 
increase in both glucose uptake and lactate production were observed in response to Irs-2 
expression (Chapter 3, Figure 3.5D and E).  These data suggest that there may be species 









Figure 4.6.  IRS-2 expression promotes invasion.  (A) Equivalent numbers of Irs-1-/-
/Irs-2-/- D cells stably expressing pcDNA vector, IRS-1-HA or IRS-2-HA were subjected 
to a Transwell invasion assay for 4hrs.  The data shown represent the mean (+SEM) of 
five independent experiments. *, p<0.0003. Irs-1-/-/Irs-2-/- A (B) and D (C) subclones 
stably expressing pcDNA vector, IRS-1-HA or IRS-HA were grown in 0.1% 
BSA/DMEM supplemented with IGF-1 (20ng/mL) for 24 hrs.  Glucose uptake and 
lactate production were measured and normalized to total protein concentration.  The data 
shown are expressed as a rate measurement (mM/mg/hr) and represent the mean (+SEM) 






















 In the study presented here, we have performed a rigorous comparative study of 
IRS-1 and IRS-2-mediated signaling and functions.  This study has confirmed that IRS-1 
and IRS-2 do not function interchangeably in the activation of PI3K signaling and in the 
regulation of growth and invasion.  Despite IRS-1 sustaining a marginally increased 
ability to recruit PI3K, Akt phosphorylation and activity are significantly increased 
downstream of IRS-2.  These data suggest that IRS-2 is a more potent activator of Akt 
and this may contribute to the functional differences associated with the IRS proteins.  
Both IRS-1 and IRS-2 can mediate activation of Akt, but specific functions regulated by 
Akt can be attributed either to IRS-1 or IRS-2 in breast cancer.  For example, IRS-1 
stimulates growth and IRS-2 stimulates invasion and metabolism, but Akt can regulate all 
of these functions.  Interestingly, the Akt effector FOXO1 is preferentially 
phosphorylated downstream of IRS-2, as the magnitude of Akt activation downstream of 
IRS-1 is insufficient to promote its phosphorylation (258).  This increased level of Akt 
phosphorylation downstream of IRS-2 is then sufficient to promote glucose uptake.  
These findings suggests that some of the specific functions associated with IRS-2 may 
correlate with the magnitude of Akt activation when signals are initiated through this 
adaptor.  
 Differential phosphorylation of Akt1 may allow IRS-1 and IRS-2 to promote 
discrete functions.  While both IRS-1 and IRS-2 are capable of facilitating Akt1 and Akt2 
phosphorylation, IRS-1 promotes a higher level of Akt1 Thr308 phosphorylation.  This 
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 result is exciting as correlations can clearly be made between functions that are 
associated with IRS-1 and Akt1.  Specifically, Irs-1-/- or Akt1-/- mice are born runted and 
both Irs-1 and Akt1 have been suggested to suppress metastasis in mouse models of 
breast cancer (85,105,194,212).  Therefore, it is interesting to consider that both the 
magnitude of Akt activation as well as the regulation of specific Akt isoforms are 
mechanisms by which IRS-1 and IRS-2 can regulate differential functions.  
 Based on our previous work, we hypothesized that IRS-2 would have an increased 
ability to recruit PI3K.  We suggested that Irs-2 may have the ability to associate with 
two PI3K heterodimers, while studies from another laboratory suggested that Irs-1 has 
the ability to recruit only one PI3K heterodimer (261).  In the current study IRS-1 
displayed a slight increase in the ability to recruit PI3K relative to IRS-2.  Despite this 
increase, Akt signaling is significantly increased downstream of IRS-2 relative to IRS-1.  
Following ligand binding, the IGF-1R is known to be internalized and traffic through the 
endosomal compartment, leading to its degradation or recycling back to the cell surface 
(264).  Recycling of the IGF-1R back to the cell surface promotes sustained Akt 
activation in response to IGF-1 stimulation. IGF-1R association with IRS-2 may promote 
its recycling back to the cell surface, facilitating increased Akt phosphorylation.  In 
contrast, IRS-1 may not promote this recycling step and therefore Akt activation may not 
be sustained.  A differential ability of IRS-1 and IRS-2 to regulate the trafficking of the 
IGF-1R and elevate Akt signaling could be one of the determining factors in the 
differential outcomes of IRS-mediated signaling. 
114
  Recent studies have implicated the differential localization of the IRS proteins in 
mediating some of their discrete functional outcomes.  IRS-1 localizes to both the 
cytoplasm and nucleus, while IRS-2 strictly localizes to the cytoplasm with some studies 
reporting localization of IRS-2 at the plasma membrane (96,97).  These localization 
patterns have been shown to correlate with breast cancer patient prognosis.  Specifically, 
IRS-1 nuclear staining predicts increased response to tamoxifen treatment, while IRS-2 
plasma membrane staining predicts decreased overall survival (96,98).  We have shown 
that IRS-1, and not IRS-2, promotes growth in 3D and the ability of IRS-1 to regulate 
growth may be due to its localization to the nucleus.  It has been suggested that IRS-1 
regulates growth through increased transcription of factors that are involved in cell cycle 
progression.  IRS-1 been shown to associate with ERα in the nucleus and to promote 
Cyclin D1 transcription (265,266).  The specific localization of IRS-1 to the nucleus, and 
not IRS-2, may explain how IRS-1 promotes growth, as it alone has the ability to 
promote transcription of cell cycle related genes.  Previous studies investigating the role 
of IRS induced growth have been limited by the model systems that were used to address 
this question.  Specifically, one study addressed the contribution of IRS-1 and Shc, but 
not IRS-2, in the regulation of human breast carcinoma cell growth (101).  Here we have 
shown that IRS-1 promotes growth in a genetically matched model system in which we 
can confirm that the level of IRS-1 and IRS-2 expression are equivalent.   
 A role for IRS-2, but not IRS-1, in the regulation of invasion has been reported 
previously.  Like the studies of the involvement of the IRS proteins in growth regulation, 
investigations of invasion have been limited by the model systems that were available at 
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 the time the studies were undertaken.  Specifically, the same study that used 
overexpression to show IRS-1 promotes proliferation while IRS-2 is unable to, 
additionally suggested that IRS-2, and not IRS-1, promotes invasion (102).  Here we have 
confirmed these findings using a system where the ability of IRS-1 and IRS-2 to 
stimulate invasion could be compared with known equivalent expression levels.  It is 
possible that for invasion to occur, a higher level of Akt phosphorylation is required, thus 
IRS-2 alone is sufficient to promote this function.  As is the case with FOXO1-mediated 
glucose uptake, invasion may only be stimulated by the high levels of Akt activation that 
IRS-2, but not IRS-1, can stimulate (258).  
 We were unable to draw rigorous conclusions about the differential role of IRS-1 
and IRS-2 in aerobic glycolysis.  Specifically, we observed only a small increase in 
glucose uptake and lactate production in cells expressing either IRS-1 or IRS-2.  
Although this effect of the IRS proteins on lactate production was modest, it was 
statistically significant. However, expression of murine Irs-2 in subclone A increased 
glucose uptake and lactate production more robustly (Chapter 3).  The use of HA-tagged 
human versions of the IRS proteins in this study could impact their subcellular 
localization or association with interacting proteins, which may influence their ability to 
regulate aerobic glycolysis in mammary tumor cells.  Additional studies comparing 
murine Irs-1 and Irs-2 would resolve this question. 
           Here we have presented a novel model system to compare IRS-1 and IRS-2 
specific functions in mammary tumor cells.  In this system, IRS-1 and IRS-2 can be 
studied on a genetically identical background and this is superior to previous models used 
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 to compare the IRS proteins.  Using these cells we have confirmed that IRS-1 functions 
to promote tumor cell growth, while IRS-2 promotes invasion and glucose uptake, 
suggesting that this model system is suitable for future use in characterizing the distinct 
roles of the IRS proteins.  In this system the specific roles of the IRS proteins in breast 
cancer can be addressed in a genetically matched background where the other IRS protein 
is not expressed (i.e. only IRS-1 or only IRS-2 expression).  This prevents the 
contribution of negative feedback loops that could be initiated by either IRS-1 or IRS-2 
that could confound results attributing specific functions to the IRS proteins.   These cells 
will be a valuable tool for future comparison of IRS-1 and IRS-2 function and their role 
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 Summary of Findings 
 
 In the studies presented in this dissertation, I have investigated the role of Insulin 
receptor subsrate-2 (Irs-2)-dependent Phosphatidylinositol-3-Kinase (PI3K) signaling in 
breast cancer and more rigorously demonstrated that IRS-1 and IRS-2 do not act 
interchangeably in cellular functions that are associated with mammary tumor growth and 
progression.  Specifically, I have determined that tyrosines 649, 671, 734, and 814 
significantly contribute to the ability of Irs-2 to recruit and activate PI3K signaling in 
response to Insulin-like growth factor-1 (IGF-1) or insulin stimulation.  This information 
allowed me to generate a PI3K binding-deficient Irs-2 mutant with a significantly 
impaired ability to recruit and activate PI3K signaling.  Using this mutant, I determined 
that Irs-2-dependent PI3K signaling regulates glucose uptake and lactate production 
through the inhibition of the Akt effector, Glycogen Synthase Kinase-3β (Gsk-3β).  In 
response to IGF-1 stimulation, Gsk-3β is preferentially phosphorylated downstream of 
PI3K/Akt signaling mediated by Irs-2, but not Irs-1.  Additionally, I determined that the 
regulation of aerobic glycolysis is not mediated through Gsk-3β-dependent modulation of 
Glut1 protein expression or cell surface localization.  
 I also generated and characterized a novel model system that allowed me to 
perform a controlled comparison of IRS-1 and IRS-2 signaling and function.  Using this 
model, I have demonstrated that in response to IGF-1 stimulation, tyrosine 
phosphorylation and PI3K association of IRS-1 are marginally higher than they are for 
IRS-2.  However, in response to IGF-1 stimulation, Akt phosphorylation and activation 
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 downstream of IRS-2 are enhanced relative to that observed downstream of IRS-1.  
Additionally, only expression of IRS-1 is sufficient to mediate increased cell growth, 
while only IRS-2 expression is sufficient to promote invasive potential.  This new model 
system confirms previous reports regarding IRS-1 and IRS-2 function, but does so in a 
more rigorous and controlled manner.  This model system will allow for future studies to 
investigate IRS-1 and IRS-2 function in a genetically matched tumor cell background to 
further characterize and understand the mechanisms of IRS function in tumor 
progression.  
 
Differential Akt Activation by IRS-1 and IRS-2 
 
 I have discovered novel ways in which IRS-1 and IRS-2 differ in their function.  I 
have shown that IRS-2 promotes aerobic glycolysis and invasion and has increased 
ability to activate PI3K/Akt signaling, while IRS-1 promotes growth and stimulates lower 
levels of Akt activity.  In addition, specific Akt effectors are differentially phosphorylated 
downstream of IRS-1 and IRS-2.  Case in point, Gsk-3β, which is predominantly 
phosphorylated in response to Irs-2-mediated Akt activation. 
 In early studies of the IRS proteins, IRS-1 was thought to be the predominant 
substrate phosphorylated in response to insulin and was the primary regulator of insulin 
functions (267).  This was suggested because loss of IRS-1 expression increased the level 
of IRS-2 tyrosine phosphorylation and IRS-2 phosphorylation was lower in the 
background of IRS-1 expression.  The studies presented here suggest that in mouse 
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 mammary tumor cells IRS-1 only has a slightly increased tyrosine phosphorylation and 
ability to recruit PI3K when compared directly with IRS-2.  Furthermore, increased PI3K 
recruitment by IRS-1 does not translate into increased phosphorylation of its downstream 
effector Akt.  I hypothesize that one mechanism by which the differential magnitude of 
Akt phosphorylation is achieved is through differential regulation of Insulin-Like Growth 
Factor-1 Receptor (IGF-1R) receptor trafficking by IRS-1 and IRS-2.  The IGF-1R 
traffics through the recycling compartment of the endosomal pathway and upon ligand 
stimulation, it is internalized and eventually recycled back to the cell surface (264).  
Inhibition of receptor internalization blocks Akt phosphorylation, while inhibition of 
receptor trafficking blocks receptor recycling and does not promote sustained Akt 
activation.  These results suggest that factors that inhibit the recycling of the IGF-1R 
through the endosomal compartment could decrease Akt phosphorylation.  The IRS 
proteins could differentially effect this transition and based on the observed increase in 
Akt phosphorylation, I suggest that IRS-2 could increase recycling of the IGF-1R back to 
the cell surface.   
 Following ligand-mediated activation of the IGF-1R, phosphorylation of IRS-2 
may preferentially recruit factors involved in trafficking through the recycling 
compartment of the endosomal pathway that IRS-1 is unable to recruit.  Interestingly, the 
p85 regulatory subunit of PI3K contains a Rab binding domain that associates with the 
Rab GTPase Rab5 and functions as a Rab GTPase Activating Protein (GAP) (268,269).  
Rab5-GTP promotes endocytosis and recycling of receptor tyrosine kinases (RTKs) in 
response to ligand binding (270,271).  The GAP activity of p85 would serve to limit 
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 Rab5 activity by promoting the hydrolysis of GTP to GDP; however, Guanine Nucleotide 
Exchange Factors (GEFs) are also recruited to these vesicles, promoting nucleotide 
exchange and increased Rab5 activity (269).   It would be interesting to investigate the 
possibility that IRS-2, but not IRS-1, can preferentially recruit GEFs to these 
compartments and thereby increase trafficking of the IGF-1R through the recycling 
pathway.  In addition to its role as a second messenger, PtdIns-3,4,5-P3 generated by 
PI3K serves as a substrate for the phosphatases PI4-Pase and PI5-Pase, generating 
PtdIns-3-P, which serves as a docking site for the early endosome antigen 1 (EEA1) 
(272).  Binding of EEA1 to early endosomes promotes soluble N-ethylmaleimide-
sensitive fusion attachment receptor (SNARE)-mediated endosome fusion (273,274).  
Perhaps IRS-2 promotes trafficking of the IGF-1R through the recruitment of these lipid 
phosphatases and thus promotes endosome maturation through recruitment of EEA1.  
Further studies of IRS-1 and IRS-2 interacting proteins would suggest if there is a 
differential recruitment of such factors.  Additionally, it would be interesting to follow 
the trafficking of the IGF-1R through the early endosomal compartment using total 
internal reflection fluorescence (TIRF) microscopy in cells expressing either IRS-1 or 
IRS-2.  Potentially, IRS-2 may increase the rate of IGF-1R trafficking, while IRS-1 may 
not have this ability.      
 A second possible mechanism for differences in IRS signaling is that Akt 
activation mediated by IRS-2 is less sensitive to the phosphatases PH domain Leucine-
rich repeat Protein Phosphatase (PHLPP)-1 and PHLPP2, which negatively regulate Akt 
activity through dephosphorylation of Ser473 (275).   It is possible Akt activation 
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 downstream of either IRS-1 or IRS-2 occurs in specific subcellular regions in which Akt 
phosphatases differentially localize.  Currently no studies have rigorously studied the 
localization of these phosphatases in the cell; however, PHLPP1 and PHLPP2 have been 
shown to co-immunprecipitate with specific Akt isoforms (275).  The data in Chapter IV 
do not exclude the possibility that downstream of IRS-1, Akt phosphorylation is more 
sensitive to dephosphorylation than Akt activated downstream of IRS-2.  This would lead 
to increased Akt phosphorylation and activity downstream of IRS-2, which was observed 
in response to IGF-1 signaling. 
 In addition to Akt phosphatases, the lipid phosphatase Phosphatase and Tensin 
Homolog (PTEN) antagonizes the action of PI3K by converting PtdIns-3,4,5-P3 to 
PtdIns-4,5-P2 (276).  This decreases the level of PtdIns-3,4,5-P3 at the plasma membrane 
and the subsequent recruitment and activation of Akt.  It is possible that IRS-1 and IRS-2 
may differentially recruit PTEN to the membrane and based on my data, I would suggest 
that IRS-1 may have an increased ability to recruit PTEN.  Interestingly, PTEN also 
functions as a tyrosine phosphatase for IRS-1 and has been shown to decrease IRS-1-
mediated Mitogen Activated Protein Kinase (MAPK) activation by perturbing its ability 
to associate with Grb-2 and Sos (277,278).  However, no studies have addressed the 
ability of PTEN to act as a phosphatase for IRS-2.  PTEN can also directly bind to p85 
and in this way, p85 can served to limit the production of PtdIns-3,4,5-P3 (279).  My 
studies do not exclude the possibility that p85 bound to IRS-1 may recruit a higher level 
of PTEN relative IRS-2.   Co-immunoprecipitation assays could be used to determine if 
there is a differentially ability of IRS-1 and IRS-2 to associate with PTEN following IGF-
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 1 stimulation.  Additionally, measuring the levels of PtdIns-3,4,5-P3 and PtdIns-4,5-P2 
following either IRS-1 or IRS-2-mediated PI3K signaling would suggest if there is a 
differential potential for Akt recruitment and activation. 
 With regard to the level of PtdIns-3,4,5-P3 produced, PI3K effectors other than 
Akt may be differentially regulated by IRS-1 and IRS-2.  Specifically, activation of the 
Rac signaling pathway would promote actin cytoskeleton rearrangement, adhesion and 
cell-to-cell contacts, all of which affect the motile and invasive ability of cells (139,140).  
Therefore, if higher levels of PtdIns-3,4,5-P3 are generated downstream of IRS-2, this 
could be one mechanism by which IRS-2 promotes invasion.  
  
Functional Differences Mediated by IRS-1 and IRS-2 
 
 My data demonstrate that IRS-2 is a more potent stimulator of Akt activation and 
I hypothesize that the differential ability of IRS-1 and IRS-2 to stimulate PI3K/Akt 
activity underlies the differences in functional outcomes associated with IRS-1 and IRS-2 
signal transduction.  Based on my studies and what is known about the IRS proteins, I 
suggest that multiple layers of regulation affect the specificity of IRS-1 and IRS-2 
signaling.  The first layer of this regulation is the role that the differential localization of 
the IRS proteins may play in regulating the phosphorylation of Akt effectors, specifically 
GSK-3β.  Studies have shown that both IRS-1 and IRS-2 can localize to the cytoplasm, 
while IRS-1 also localizes to the nucleus and IRS-2 to the plasma membrane(96-98).  
These differences in localization patterns have been correlated with patient prognosis 
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 with IRS-1 nuclear localization correlating with increased patient response to tamoxifen 
treatment and IRS-2 plasma membrane localization correlating with reduced overall 
patient survival (96,98).  Together, these data suggest that the subcellular localization of 
the IRS proteins impacts the functional outcomes of the signaling they mediate.  In 
response to IGF-1 or insulin stimulation, Akt can undergo translocation into the 
mitochondria where it mediates GSK-3β phosphorylation (280).  This finding suggests 
that signaling originating from plasma membrane RTKs facilitates the activation of Akt 
which is then translocated to specific subcellular locations.  Studies in our lab have 
shown that IRS-2-mediated Akt activation is dependent on an intact microtubule 
cytoskeleton, as treatment with microtubule disrupting agents inhibits Akt activation 
downstream of IRS-2 (unpublished data).   It is interesting to speculate that activation of 
Akt mediated by IRS-2 may direct its localization in the cell through a microtubule 
dependent mechanism.  However, the question of whether Akt co-localizes with a 
complex containing IRS-2 or if IRS-2 merely directs this localization would be important 
to fully understand the mechanism of this regulation.  
 The data described above suggest a role for trafficking in the regulation of IRS-2-
mediated Akt activation. Interestingly, GSK-3β activity has been shown to correlate with 
its location within the cell and GSK-3β is more active in the nucleus and mitochondria, 
while displaying decreased activity in the cytoplasm (281).  Putting this in context of 
what is known about IRS-1 and its localization to the nucleus, it is possible that Akt 
activation mediated by IRS-1 does not promote GSK-3β phosphorylation, as GSK-3β 
activity is high in the nucleus where IRS-1, and not IRS-2, has been shown to localize.  
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 Therefore, I would suggest a rigorous study to compare the localization of Akt and GSK-
3 phosphorylation in response to either IRS-1 or IRS-2-mediated signaling, as these 
experiments would suggest if and where the IRS proteins direct localization of Akt 
activity.    
 Another mechanism that I hypothesize contributes to the disparate functions 
associated with the IRS proteins is a differential ability to regulate Akt isoform 
activation.  My data suggest that IRS-1 and IRS-2 are both capable of promoting 
phosphorylation of Akt1 and Akt2, but IRS-1 promotes increased Thr308 
phosphorylation of Akt1 relative to IRS-2.  Interestingly, studies of isoform specific 
functions of Akt1, Akt2 and Akt3 correlate well with the specific functions that have 
been attributed to either IRS-1 or IRS-2.  Studies of either Irs-1-/- or Akt1-/- mice have 
shown both genotypes are born runted, while Irs-2-/- or Akt2-/- mice develop diabetes 
(85,86,194-196).  Further, Irs-2-/- or Akt3-/- mice both display impaired brain development 
(87,197).  These correlations extend to the role of the IRS proteins or Akt isoforms in 
tumor initiation and progression.  Akt1 has been shown to suppress migration through 
phosphorylation of the actin bundling protein palladin and inhibits metastasis in vivo 
(215).  Irs-1 has been suggested to negatively regulate metastasis in vivo, as PyMT:Irs-1-/- 
mice have significantly increased pulmonary metastasis relative to PyMT:wildtype mice, 
while PyMT:Irs-1-/+ mice display an intermediate level of metastasis (105).  Additionally, 
both Akt2 and Irs-2 have been shown to promote metastasis (105,214). Although, Akt 
isoform-specific regulation downstream of the IRS proteins is not completely discrete, 
the fact that IRS-1 mediates a higher level of Akt1 phosphorylation in response to IGF-1 
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 stimulation does correspond with the functional comparisons of IRS-1 and Akt1.  
Additionally, like the IRS proteins, the Akt isoforms have been shown to adopt different 
subcellular localization patterns.  Specifically, Akt1 localizes to the cytoplasm, Akt2 to 
the mitochondria, and Akt3 to the nucleus (198).  It is interesting to speculate that the 
IRS-specific regulation of Akt isoforms may be dependent on their subcellular 
localization.    
 Fluorescent reporters for global Akt activity have been developed and recently an 
Akt1-specific reporter has been characterized (170,282,283).  These reporters function as 
substrates for Akt and upon phosphorylation, a conformational change is induced that 
modulates their fluorescence wavelength and the localization of Akt activity can be 
determined (282).   I suggest using these reporters to determine if IRS-1 and IRS-2 
mediate Akt activation in a specific region of the cell.  Using PyMT:Irs-1-/-/Irs-2-/- cells 
expressing either IRS-1 or IRS-2, the localization of Akt activation could be assessed 
with these reporters and co-localization of the IRS proteins to these regions could also be 
determined.  In regard to isoform specificity, the Akt1 fluorescent reporter would be 
useful in determining if IRS-1 or IRS-2 preferentially mediate Akt1 activation and if this 
occurs in a specific subcellular compartment.  In the future, development of Akt2 and 
Akt3 fluorescent reporters will also be very useful in characterizing IRS-specific 
regulation of the Akt isoforms. 
 I would like to additionally hypothesize that the magnitude and dynamics of Akt 
amplification downstream of either IRS-1 or IRS-2 act as another level of regulation that 
contributes to their differences in functional outcomes.  Consistent with my findings, the 
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 magnitude of Akt activation downstream of IRS-2, and not IRS-1, has been shown to be 
sufficient to promote FOXO1 phosphorylation and increase glucose uptake (258).  As is 
the case for FOXO1, it is possible that a greater magnitude of localized Akt activity is 
required for GSK-3β phosphorylation and IRS-1 cannot sufficiently mediate this level of 
Akt activation.  Additionally, IRS-1 mediates a higher magnitude of Akt1 
phosphorylation despite the ability of IRS-2 to mediate a more robust level of global Akt 
phosphorylation.  These data suggest that global Akt activation may not be indicative of a 
particular isoforms’s activity.  I suggest that to fully understand signal transduction 
downstream of IRS-1 and IRS-2, the magnitude and dynamics of each isoform must be 
evaluated and considered.  In regard to dynamics of Akt activation, it is possible that 
IRS-1-mediated Akt activation is sustained longer relative to IRS-2 and that specific Akt 
effectors are phosphorylated only after sustained Akt activation.  In response to insulin 
stimulation, the Akt signaling pathway has been shown to encode temporal patterns of 
insulin stimulus in the dynamics of Akt phosphorylation (284).  These temporal patterns 
of Akt activation are subsequently decoded into the level of phosphorylation of Akt 
effectors.  However, this study did not correlate these temporal patterns of stimulation 
with functional responses or look at IRS-1 or IRS-2 involvement.  Studies have suggested 
that IRS-1 mediated growth is dependent on the sustained activation of signaling 
downstream of IRS-1.  Therefore, longer time courses of IGF-1 stimulation should be 




 IRS Negative Feedback Regulatory Loops 
 
 One interesting mechanism of regulation that my studies do not directly address, 
but indirectly suggest could impact differential functions, is the potential for IRS-1 or 
IRS-2 to mediate negative feedback loops that negatively impact their ability to mediate 
PI3K/Akt signaling.  It is well established that downstream of Akt and Mechanistic 
Target of Rapamycin Complex 1 (mTORC1), Ribosomal Protein S6 Kinase (S6K) will 
phosphorylate IRS-1 on serine residues that inhibit its ability to mediate PI3K signaling 
(285).   Based on my data, I hypothesize that IRS-2 promotes feedback regulation on 
IRS-1 and that when both IRS-1 and IRS-2 are expressed, IRS-2 promotes serine 
phosphorylation of IRS-1, dampening PI3K and Akt activation. Consistent with this idea, 
despite a higher level of Akt phosphorylation downstream of IRS-2 relative to IRS-1 as 
shown in Chapter IV, in Chapter III loss of Irs-2 expression did not decrease Akt 
activation in response to IGF-1 stimulation.  These data suggest that Irs-1 compensates 
for the loss of Irs-2-mediated PI3K activity.  In the context of only IRS-1 or IRS-2 
expression, it is clear that the level of Akt and S6K activation mediated by IRS-2 is much 
greater than that downstream of IRS-1.  Therefore these data suggest that IRS-2 more 
effectively activates this negative feedback loop.  Studies comparing the sensitivity of 
IRS-1 and IRS-2 to S6K-mediated serine phosphorylation have yet to be undertaken and 
will be helpful in determining if IRS-2 is potentially less sensitive to this feedback 
regulation.  These data do not exclude the possibility that IRS-1 may also promote 
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 negative feedback on IRS-2 or that IRS-2 can mediate this feedback on itself, as studies 
have suggested that IRS-2 can also be phosphorylated by S6K (286,287). 
 In addition to the negative feedback loop initiated by S6K, GSK-3β 
phosphorylation of IRS-1 has also been shown to negatively regulate IRS-1-mediated Akt 
activation.  GSK-3β phosphorylates Irs-1 on Ser332 and phosphorylation of this serine 
requires an additional priming phosphorylation of Ser336 (288).  Mutation of these 
serines to alanine leads to increased tyrosine phosphorylation of IRS-1 as well as 
increased phosphorylation of Akt on both Thr308 and Ser473 in response to insulin 
stimulation.   I hypothesize that Irs-2-specific inhibition of Gsk-3β would decrease 
phosphorylation of Irs-1 on Ser332, increasing the ability of IRS-1 to activate Akt.  This 
contrasts with the potential role of IRS-2 in the S6K feedback loop, where IRS-2 would 
negatively regulate IRS-1-mediated signaling.  A phospho-specific Ser332 IRS-1 
antibody is commercially available and will be of significant use in determining if IRS-2-
mediated GSK-3β inhibition promotes decreased phosphorylation of this site.  Together, 
these data suggest that IRS-2 can both inhibit IRS-1 activity through S6K activation, as 
well as promote IRS-1 activity through inhibition of GSK-3β.   It is likely the balance of 
these feedback loops that determines the outcome on IRS mediated functions. 
 
Intrinsically Disordered Proteins 
 
 Both IRS-1 and IRS-2 are considered intrinsically disordered proteins (IDPs), as 
only their N-terminal plextrin homology (PH) and phosphotyrosine binding (PTB) 
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 domains have been shown to adopt stable tertiary structure while their central and C-
terminal regions do not adopt any discernable structure (256).  IDPs are commonly 
involved in cellular signaling and are often associated with human cancer (289).  
Structural analysis of IDPs are limited as this class of proteins are poor candidates for X-
ray crystallography. However recent advances in nuclear magnetic resonance (NMR) 
spectroscopy have allowed for more informative study of these proteins (290).  These 
studies have suggested that IDPs may adopt some secondary like structures that are not 
picked up by structural prediction programs (256).  In the case of Gab1, another IDP that 
is also an adaptor protein, Ser552 directly binds to the C-terminal PH domain (256).  
From these studies the “N-terminal folding nucleation (NFN) hypthothesis” was 
suggested by Stephen Feller as a mechanism by which IDPs adopt structure and escape 
aggregation and degradation (256).  This hypothesis suggests that during translation, the 
N-terminal region folds as it leaves the ribosome.  As translation continues, regions of 
IDPs that are relatively unstructured associate with specific regions of the folded N-
terminus, increasing the stability of the IDP as well as preventing any non-specific 
interactions from occurring.  It has been suggested that these intramolecular interactions 
between different regions of the same protein would create loops that may serve as 
docking sites for downstream effectors.  In this case, loops are beneficial as they confine 
the protein to a more defined region while still allowing for binding of multiple factors.  
It is interesting to speculate how the intrinsically disordered structure of IRS-1 and IRS-2 
contributes to their differences.  IRS-1 and IRS-2 share the greatest level of homology in 
the N-terminal regions, while they are less homologous in their C-termini (81).  I 
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 hypothesize that these non-homologous regions of IRS-1 or IRS-2 differentially interact 
with either their PH or PTB domains, promoting differential formation of looped 
structures that mediate unique interactions of the IRS proteins.  To test this hypothesis, 
peptides of both IRS-1 and IRS-2 C-terminal regions could be assessed for their ability to 
associate with constructs of IRS-1 or IRS-2 PH and PTB domains.  This would reveal if 
there are specific C-terminal regions of the IRS proteins that make contacts with the PH 
and PTB domains.   Further, if a specific region is shown to associate with the PH or PTB 
domain, it would be important to consider the phosphorylation status of serine or tyrosine 
residues it that region.  Mutation of these sites could suggest if these interactions are 
phosphorylation dependent.   
 It has been suggested that posttranslational modifications such as tyrosine 
phosphorylation of IDPs modulate the conformations they adopt.  NMR studies of CD79a 
and CD79b before and after phosphorylation have shown tyrosine phosphorylation will 
shift their propensity to adopt helical-like secondary structure (291).  In the case of 
CD79a, tyrosine phosphorylation decreases helical propensity, while the opposite is true 
of CD79b.  It is interesting to consider the possibility that IRS-1 and IRS-2 may adopt 
different conformations depending on their phosphorylation status and this may serve to 
inhibit or promote association with binding partners.   
 As suggested from the work done in Chapter III, Irs-2 has four tyrosine residues 
(Tyr649, Tyr671, Tyr734, Tyr814) that mediate the recruitment and activation of PI3K.  
In comparing Irs-1 and Irs-2 protein primary sequence, Tyr734 and Tyr814 do not have 
homologous sites in YxxM motifs in this region of Irs-1.  Therefore, tyrosine 
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 phosphorylation in this particular region of the IRS proteins is dissimilar and could 
differentially effect the structural conformation the IRS proteins would adopt in response 
to phosphorylation.  Currently, mass spec studies of differential interacting proteins of 
IRS-1 and IRS-2 do suggest that proteins differentially associate with them under basal 
and IGF-1 stimulated conditions (unpublished data).  It may be possible that these 
differential regions of tyrosine phosphorylation in IRS-1 and IRS-2 may induce unique 
conformational changes that function as determinants of the protein interactions that IRS 
proteins can then mediate.  Further along these lines, it has been suggested that protein 
interactions can also mediate structural changes within IDPs (292).  So it will be 
important to consider how unique protein associations of IRS-1 and IRS-2 may impact 
their structure, as well as the functional outcomes of these possible conformational 
changes.  While it is difficult to speculate exactly how IRS-1 and IRS-2 may structurally 
differ, I hypothesize that despite overall homology, non-homologous, unstructured 
regions of the IRS proteins allow for them to adopt different conformations and 
ultimately lead to different functional outcomes through unique protein interactions.   
 
IRS-2-Mediated Aerobic Glycolysis 
 
 IRS-2 is a key mediator of aerobic glycolysis (108).  I have confirmed and 
extended the understanding of this regulation to include the requirement for direct PI3K 
recruitment and activation by IRS-2 and GSK-3β inactivation.  Previous studies of GSK-
3β action have suggested that it inhibits glucose uptake through inhibition of Glut1 
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 protein expression plasma membrane localization (232,254).  However, in the studies 
presented here, I have not found any indication that Gsk-3β regulates Glut1 expression or 
trafficking to the cell surface.  I hypothesize that GSK-3β increases the rate of glucose 
transport by Glut1, thereby increasing glucose uptake.  A mechanism for increased 
catalytic activity of Glut1 has yet to be described.  However, one group has reported that 
AMPK is similar to GSK-3β in that it does not promote increased Glut1 expression or 
surface localization and instead increases the catalytic turnover of the transporter (293).  
To date, no studies have shown that kinase-mediated direct phosphorylation regulates the 
activity of Glut1, but it remains a possibility.  It is also possible that GSK-3β regulates 
other members of this glucose transporter family, such as Glut3 or Glut4; however 
expression of these proteins has not been determined in our model systems and should be 
assessed.  Further, the studies here do not exclude the possibility that GSK-3α, an 
additional isoform of GSK-3, may regulate glucose uptake through a yet to be described 
mechanism (294).  GSK-3 inhibitors are not isoform specific, so both isoforms are 
blocked following inhibitor treatment.  Less is currently known about GSK-3α, but 
mouse models do not suggest a role for GSK-3α in growth, development, metabolism, or 
insulin sensitivity (295). 
 In previous studies from our lab, it was determined that Irs-2 promoted increased 
glucose uptake through mTorc-1-dependent Glut1 surface expression (108).   I have 
confirmed the role of IRS-2 in the regulation of Glut1 surface expression, but was unable 
to rigorously tie IRS-2-dependent PI3K signaling to this regulation.  The ability of the 
Irs-2 mutant to recruit PI3K was not completely inhibited and it is possible that the level 
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 of residual PI3K association that the IRS-2 mutant was sufficient to promote Glut1 
surface localization.  Generating an Irs-2 mutant in which PI3K association is completely 
abolished will be required to fully address the contribution of Irs-2-dependent PI3K 
signaling to Glut1 surface expression. 
 
Aerobic Glycolysis and Metastasis 
 
 The specific contribution of IRS-2-dependent regulation of aerobic glycolysis in 
promoting metastasis has yet to be determined.  I hypothesize that increased aerobic 
glycolysis downstream of IRS-2 may promote metastasis through cell autonomous effects 
as well as effects on the tumor microenvironment.  With regard to cell autonomous 
effects, previous studies in erythrocytes, lymphocytes and smooth muscle cells have 
suggested that specific proteins recruit and associate with multiple glycolytic enzymes at 
the plasma membrane (296-299).  In the case of lymphocytes and smooth muscle cells, 
Caveolin-1 (Cav-1) functions as a scaffolding protein, recruiting multiple glycolytic 
enzymes to the plasma membrane (297,298).  It is thought that this co-localization of 
glycolytic enzymes increases pathway flux through channeling of metabolic 
intermediates and can also localize ATP production at sites of high-energy utilization.    It 
would be interesting to investigate the possibility that IRS-2 functions to recruit these 
enzymes to regions that require high levels of ATP production, such as the leading edge 
of an invading cell.  Invasive protrusions undergo constant changes in adhesion and 
rearrangements in their actin cytoskeleton, which require rapid and constant production 
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 of energy (300).  Recent, unpublished mass spec studies from our lab suggest that IRS-2, 
but not IRS-1, associates with metabolic enzymes.  Therefore, it is possible that IRS-2 
may serve a key function in localization of these enzymes at local sites of invasion.  
However, further characterization of these IRS-2 interactions as well as localization 
studies of both IRS-2 and glycolytic enzymes must be undertaken.  Interestingly, IRS-2, 
and not IRS-1, has been shown to localize to the plasma membrane, which further 
suggests an important role for IRS-2 plasma membrane localization. 
 In addition to generating energy and biomass for rapidly dividing cells, much of 
the lactate produced in tumor cells is secreted into the microenvironment (5).  This lactate 
lowers the pH, activating MMPs which function to degrade the ECM, allowing for the 
invasion of tumor cells through the basement membrane where they gain access to the 
vasculature, promoting metastasis.  It is therefore possible that IRS-2-stimulated lactate 
production can promote invasion of cells through the basement membrane, increasing the 
potential for metastasis.   
 Interesting studies have also suggested that the lactate secreted by tumor cells can 
promote angiogenesis through multiple mechanisms.  Lactate can engage specific cell 
surface receptors such as Axl and Tie of endothelial cells to promote angiogenesis (301).  
Additionally, lactate increases the level of VEGF in endothelial cells and stabilizes 
HIF1α, leading to increased VEGF expression (302-306).  Interestingly, Irs-2-/- tumors 
display decreased vascularization relative to their WT counterparts, while vascularization 
is increased in Irs-1-/- tumors.  This difference suggests a role for Irs-2 in promoting 
angiogenesis, and this may occur in part through its ability to regulate lactate production. 
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 Together these studies suggest that the effects of IRS-2-mediated aerobic glycolysis in 
tumor cells are more than just cell autonomous and extend into the tumor 
microenvironment. 
Future Contributions of Model System 
 
 In addition to the insight that my studies have provided into the role of Irs-2-
dependent PI3K signaling and the specific functions that are associated with either IRS-1 
or IRS-2, a novel model system has been generated to rigorously characterize signaling 
by, and functions of, the IRS proteins.  The studies that were done prior to the work 
presented here contributed to our understanding of the roles of the IRS proteins in breast 
cancer.  However, many conclusions of these studies were limited by the model systems 
that were available at the time of the study.  In studies done using Irs knockout mice, a 
true comparison of Irs-1-/- and Irs-2-/- tumor derived cells could not be made as these cells 
came from different tumors from different mice (108).  However, here we have generated 
Irs-1-/-/Irs-2-/- mammary tumor derived cells in which a rigorous comparison of IRS-1 
and IRS-2 can be performed in a genetically matched background.  Going forward, it will 
be interesting to further investigate IRS-specific functions in this model system.  The 
studies done here comparing IRS-1 and IRS-2 have confirmed previous results and 
suggest that this model system is suitable for further study of the IRS proteins.   
 One of the most interesting experiments going forward will be re-introducing 
IRS-2 expression in Irs-1-/-/Irs-2-/- cells that express IRS-1 and vice versa. These types of 
experiments are key to understanding how IRS-1 and IRS-2 either work together or 
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 impede the other’s function.  It has been suggested that IRS-1 may negatively regulate 
metastasis, as PyMT:Irs-1-/- mice show greater levels of pulmonary metastasis relative to 
their PyMT:WT counterparts, while PyMT:Irs-1-/+ mice display an intermediate level of 
metastasis (105).  Re-introducing IRS-1 expression to cells Irs-1-/-/Irs-2-/- cells that only 
express IRS-2 and determining the level of invasion compared to cells that just express 
IRS-2, will determine if IRS-1 can function to inhibit the actions of IRS-2. Additionally, 
similar in vivo studies using these cell lines could help to address the potential role for 
IRS-1 in the inhibition of metastasis.  This interplay between IRS-1 and IRS-2 could 
occur through their competition for binding sites at receptors.  The study of these 
IRS/IGF-1R interactions when one or both IRS protein are expressed would further the 
mechanistic understanding of IRS-mediated signaling.  
 Addtionally, Irs-1-/- and Irs-2-/- cells will be of great use in future studies of the Irs 
proteins in mouse models of breast cancer.  For example, comparing tumor growth and 
metastasis in mice with mammary fat pad injections of either Irs-2fl/fl or Irs-2-/- cells is the 
most ideal system to determine the contribution of Irs-2 to tumor progression and 
metastasis.  The same can be said for similar studies using Irs-1fl/fl and Irs-1-/- cells.  
Using these genetically matched cell lines, the true contribution of Irs-1 and Irs-2 to 
tumor progression and metastsis can be determined and it will be interesting to see how 
these studies compare to those done in PyMT:Irs-1-/- and PyMT:Irs-2-/- mice.   Further, 
tumor progression studies following injection of Irs-2-/- cells expressing WT IRS-2 or 
IRS-2 Y5F will help define the role of Irs-2-dependent PI3K signaling tumor progression 
and metastasis.  Based on my work, I hypothesize that Irs-2 Y5F expressing tumors 
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 would show a significant decrease in their ability to metastasize relative to WT Irs-2 
expressing tumors.  I further suggest that Irs-2 Y5F tumors would have fewer invasive 
cells and the tumor would display decreased angiogenesis, due to a reduction in aerobic 
glycolysis.  This type of study is required to fully understand how Irs-2-mediated PI3K 




 In this dissertation I have focused on the role of IRS-2-dependent PI3K signaling 
in mammary tumor cell biology. When compared with IRS-1, IRS-2-dependent PI3K 
signaling preferentially leads to the phosphorylation of the Akt effector GSK-3β.  This 
finding shows that specific downstream effectors are differentially regulated by IRS-1 
and IRS-2 and suggests a mechanism that would promote functional differences when 
signals are initiated downstream of either IRS-1 or IRS-2. Additionally, my studies 
demonstrate that IRS-1 and IRS-2 do not function interchangeably.  IRS-1 promotes 
growth, while IRS-2 promotes invasion, aerobic glycolysis and a more robust activation 
of Akt.  The studies presented here recapitulate prior studies of the IRS proteins, but do 
so in a more rigorous and controlled manner.  
 There is significant evidence to support a role for IRS-2 in promoting metastasis 
as it regulates many functions associated with metastatic potential such as motility, 
invasion and aerobic glycolysis (102,103,108).  Additionally, studies using mouse models 
have suggested that IRS-2, but not IRS-1, promotes metastasis (105).  The studies 
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 presented here elucidate the underlying mechanisms that specifically allow for IRS-2 to 
positively regulate metastasis.  I would suggest that the ability of IRS-2-dependent PI3K 
signaling to promote aerobic glycolysis is one of the most important mechanisms by 
which IRS-2 drives metastasis.  This shift in metabolism affects multiple functions that 
promote metastasis.  Specifically, it drives the growth and survival of cells under hypoxic 
conditions as well as promotes the invasive ability of cells.  It additionally primes the 
microenvironment for invasion and metastasis.  Figure 5.1 summarizes my hypothesized 
role of the contribution Irs-2-dependent PI3K signaling makes to invasion and 
angiogenesis, both of which would promote metastasis.   I believe it is important to 
consider IRS-2 expression status in breast cancer patients and more specifically, evalute 
the phosphorylation status of tyrosines that I have implicated in the recruitment of PI3K.  
Together with localization and expression, understanding the level of IRS-2 activity may 
allow for a better determination of which patients have tumors that may be likely to 
metastasize.  My studies suggest that not all PI3K and Akt activation is equal, and it is 










 Figure 5.1. Hypothesized Role of IRS-2 in Invasion and Angiogenesis.  (A) IRS-2 can 
mediate a higher level of Akt activation through recycling of the IGF-1R back to the cell 
surface.  (B) IRS-2-mediated PI3K signaling preferentially regulates the phosphorylation 
of the Akt effector GSK-3β.  This stimulates increased glucose uptake and supports 
increased aerobic glycolysis.  (C) IRS-2 specifically localizes to regions of localized 
invasion while subsequently recruiting glycolytic enzymes.  This allows for localized 
aerobic glycolysis and ATP production, promoting actin cytoskeleton rearrangement and 
cell motility.  (D) The lactate produced is secreted into the microenvironment resulting in 
acidification and the subsequent activation of matrix metalloproteases (MMPs).  MMP 
activation promotes degradation of the extracellular matrix and cell invasion.  (E) The 



























 Antibody Isolation and Verification 
 
 We sought to generate rabbit polyclonal phosphotyrosine-specific IRS-2 
antibodies to further investigate IRS-2 function.  We chose to generate antibodies 
directed at the human sequences of IRS-2 for potential use in applications with human 
tissues such as immunohistochemistry and western blotting.  Using sequence alignment 
tools, the sequence surrounding Tyr734 (Human: Tyr742) and Tyr814 (Human: Tyr823) 
were similar between mouse and human IRS-2 and could potentially allow for species 
cross reactivity (Figure A.1A).  Additionally, the sequence surrounding these tyrosine 
residues was determined to have the least amount of sequence homology between IRS-1 
and IRS-2 when compared with Tyr649  (Human: Tyr653) and Tyr671 (Human: Tyr675) 
(Figure A.1B).  The sequences of the IRS-2 peptides that were used for immunization are 
shown in Figure A.1C.  The company ProSci (Poway, CA) was selected to generate the 
peptides and perform the antibody production and purification.   
 A total of four rabbits (two per peptide) were immunized with KLH-conjugated 
peptides every two weeks for a total of six weeks.  Three different bleeds were performed 
on each rabbit and serum was purified by a two-step immuno-affinity purification.  First, 
serum was purified through a non-phospho-IRS-2 peptide column to remove antibodies 
that recognize unphosphorylated IRS-2.  The flow through was then purified over a 
phospho-IRS-2 peptide column to isolate phospho-specific antibodies.  For each site, two 




 Figure A.1. IRS sequence alignment and peptide sequence.  (A) Sequence alignment 
of human and mouse IRS-2 protein sequence.  Red squares indicate tyrosines chosen for 
phospho-specific antibody generation. (B) Sequence alignment of human IRS-1 and IRS-
2 protein sequence.  Red squares indicate tyrosines chosen for phospho-specific antibody 






















 2, p823-1, p823-2).  Both non-phospho-specific and phospho-specific antibodies were 
eluted from the columns and sent to us for subsequent verification and testing. 
 To determine if the phospho-specific antibodies that recognize Tyr742 and 
Tyr823 are IRS-2 specific, Irs-1-/-/Irs-2-/- cells expressing either IRS-1-HA or IRS-2-HA 
were serum starved and stimulated with IGF-1 (Figure A.2a).  Little reactivity was 
observed for p823-1 with either human or mouse IRS-2, suggesting that this rabbit did 
not have a robust immune response.  The other three antibodies showed cross reactivity 
with IRS-1.  However, these antibodies are truly phospho-specific as there is no 
recognition of IRS-1 or IRS-2 under serum starved conditions.  Further optimization of 
antibody and protein lysate concentrations suggests that p832-1 does recognize the 
phosphorylated form of IRS-2 (Figure A.2b).  Additionally, both Tyr742 and Tyr823 are 
phosphorylated over a time course of IGF-1 stimulation, with phosphorylation of both 
sites decreasing after 10 min of stimulation.  Further testing is required to verify that 
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Figure A.2. Initial screening of pTyr742-IRS-2 and pTyr823-IRS-2 
antibodies. 
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 Figure A.2. Initial screening of pTyr742-IRS-2 and pTyr823-IRS-2 antibodies. (A) 
Irs-1-/-/Irs-2-/- cells expressing either IRS-1-HA or IRS-2-HA were serum starved and 
then stimulated with IGF-1 (100ng/ml, 10min).  Aliquots of cell extracts that contained 
equivalent amounts of total protein were immunoblotted with the phospho-specific IRS-2 
antibodies pTyr742-1, pTyr742-2 and pTyr823-1.  (B) Irs-1-/-/Irs-2-/- cells expressing 
IRS-2-HA were serum starved and then stimulated with IGF-1 (100ng/ml, 2, 10, 30, 60 
min).  Aliquots of cell extracts that contained equivalent amounts of total protein were 
immunoblotted with the phospho-specific IRS-2 antibodies pTyr742-1, pTyr742-2 and 
pTyr823-1 and pTyr823-2.      
































1. ACS. (2013) Breast Cancer Facts and Figures 2013-2014. American Cancer 
Society, Inc., Atlanta 
2. Siegel, R., Ma, J., Zou, Z., and Jemal, A. (2014) Cancer statistics, 2014. CA: a 
cancer journal for clinicians 64, 9-29 
3. Steeg, P. S. (2003) Metastasis suppressors alter the signal transduction of cancer 
cells. Nature reviews. Cancer 3, 55-63 
4. Hanahan, D., and Weinberg, R. A. (2011) Hallmarks of cancer: the next 
generation. Cell 144, 646-674 
5. Gatenby, R. A., and Gillies, R. J. (2004) Why do cancers have high aerobic 
glycolysis? Nature reviews. Cancer 4, 891-899 
6. Anandappa, G., and Turner, N. C. (2013) Targeting receptor tyrosine kinases in 
HER2-negative breast cancer. Current opinion in oncology 25, 594-601 
7. Brown-Glaberman, U., Dayao, Z., and Royce, M. (2014) HER2-targeted therapy 
for early-stage breast cancer: a comprehensive review. Oncology 28, 281-289 
8. Pollak, M. N., Perdue, J. F., Margolese, R. G., Baer, K., and Richard, M. (1987) 
Presence of somatomedin receptors on primary human breast and colon 
carcinomas. Cancer letters 38, 223-230 
9. Surmacz, E. (2000) Function of the IGF-I receptor in breast cancer. Journal of 
mammary gland biology and neoplasia 5, 95-105 
10. Resnik, J. L., Reichart, D. B., Huey, K., Webster, N. J., and Seely, B. L. (1998) 
Elevated insulin-like growth factor I receptor autophosphorylation and kinase 
activity in human breast cancer. Cancer research 58, 1159-1164 
11. Hankinson, S. E., Willett, W. C., Colditz, G. A., Hunter, D. J., Michaud, D. S., 
Deroo, B., Rosner, B., Speizer, F. E., and Pollak, M. (1998) Circulating 
concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 
351, 1393-1396 
12. Turner, B. C., Haffty, B. G., Narayanan, L., Yuan, J., Havre, P. A., Gumbs, A. A., 
Kaplan, L., Burgaud, J. L., Carter, D., Baserga, R., and Glazer, P. M. (1997) 
Insulin-like growth factor-I receptor overexpression mediates cellular 
radioresistance and local breast cancer recurrence after lumpectomy and radiation. 
Cancer research 57, 3079-3083 
13. Baserga, R. (2013) The decline and fall of the IGF-I receptor. Journal of cellular 
physiology 228, 675-679 
14. Liu, J. P., Baker, J., Perkins, A. S., Robertson, E. J., and Efstratiadis, A. (1993) 
Mice carrying null mutations of the genes encoding insulin-like growth factor I 
(Igf-1) and type 1 IGF receptor (Igf1r). Cell 75, 59-72 
15. O'Connor, R. (2003) Regulation of IGF-I receptor signaling in tumor cells. 
Hormone and metabolic research = Hormon- und Stoffwechselforschung = 
Hormones et metabolisme 35, 771-777 
16. Jones, J. I., and Clemmons, D. R. (1995) Insulin-like growth factors and their 
binding proteins: biological actions. Endocrine reviews 16, 3-34 
152
 17. Slaaby, R., Schaffer, L., Lautrup-Larsen, I., Andersen, A. S., Shaw, A. C., 
Mathiasen, I. S., and Brandt, J. (2006) Hybrid receptors formed by insulin 
receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin 
and high IGF-1 affinity irrespective of the IR splice variant. The Journal of 
biological chemistry 281, 25869-25874 
18. Belfiore, A. (2007) The role of insulin receptor isoforms and hybrid insulin/IGF-I 
receptors in human cancer. Current pharmaceutical design 13, 671-686 
19. Firth, S. M., and Baxter, R. C. (2002) Cellular actions of the insulin-like growth 
factor binding proteins. Endocrine reviews 23, 824-854 
20. Ullrich, A., Gray, A., Tam, A. W., Yang-Feng, T., Tsubokawa, M., Collins, C., 
Henzel, W., Le Bon, T., Kathuria, S., Chen, E., and et al. (1986) Insulin-like 
growth factor I receptor primary structure: comparison with insulin receptor 
suggests structural determinants that define functional specificity. The EMBO 
journal 5, 2503-2512 
21. Sepp-Lorenzino, L. (1998) Structure and function of the insulin-like growth factor 
I receptor. Breast cancer research and treatment 47, 235-253 
22. O'Connor, R. (1998) Survival factors and apoptosis. Advances in biochemical 
engineering/biotechnology 62, 137-166 
23. Tartare-Deckert, S., Sawka-Verhelle, D., Murdaca, J., and Van Obberghen, E. 
(1995) Evidence for a differential interaction of SHC and the insulin receptor 
substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the 
yeast two-hybrid system. The Journal of biological chemistry 270, 23456-23460 
24. Craparo, A., O'Neill, T. J., and Gustafson, T. A. (1995) Non-SH2 domains within 
insulin receptor substrate-1 and SHC mediate their phosphotyrosine-dependent 
interaction with the NPEY motif of the insulin-like growth factor I receptor. The 
Journal of biological chemistry 270, 15639-15643 
25. Pietrzkowski, Z., Sell, C., Lammers, R., Ullrich, A., and Baserga, R. (1992) Roles 
of insulinlike growth factor 1 (IGF-1) and the IGF-1 receptor in epidermal growth 
factor-stimulated growth of 3T3 cells. Molecular and cellular biology 12, 3883-
3889 
26. Sell, C., Dumenil, G., Deveaud, C., Miura, M., Coppola, D., DeAngelis, T., 
Rubin, R., Efstratiadis, A., and Baserga, R. (1994) Effect of a null mutation of the 
insulin-like growth factor I receptor gene on growth and transformation of mouse 
embryo fibroblasts. Molecular and cellular biology 14, 3604-3612 
27. Miura, M., Li, S., and Baserga, R. (1995) Effect of a mutation at tyrosine 950 of 
the insulin-like growth factor I receptor on the growth and transformation of cells. 
Cancer research 55, 663-667 
28. Dunn, S. E., Ehrlich, M., Sharp, N. J., Reiss, K., Solomon, G., Hawkins, R., 
Baserga, R., and Barrett, J. C. (1998) A dominant negative mutant of the insulin-
like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of 
breast cancer. Cancer research 58, 3353-3361 
29. Sachdev, D., Hartell, J. S., Lee, A. V., Zhang, X., and Yee, D. (2004) A dominant 
negative type I insulin-like growth factor receptor inhibits metastasis of human 
cancer cells. The Journal of biological chemistry 279, 5017-5024 
153
 30. Kim, H. J., Litzenburger, B. C., Cui, X., Delgado, D. A., Grabiner, B. C., Lin, X., 
Lewis, M. T., Gottardis, M. M., Wong, T. W., Attar, R. M., Carboni, J. M., and 
Lee, A. V. (2007) Constitutively active type I insulin-like growth factor receptor 
causes transformation and xenograft growth of immortalized mammary epithelial 
cells and is accompanied by an epithelial-to-mesenchymal transition mediated by 
NF-kappaB and snail. Molecular and cellular biology 27, 3165-3175 
31. Bartucci, M., Morelli, C., Mauro, L., Ando, S., and Surmacz, E. (2001) 
Differential insulin-like growth factor I receptor signaling and function in 
estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast 
cancer cells. Cancer research 61, 6747-6754 
32. Doerr, M. E., and Jones, J. I. (1996) The roles of integrins and extracellular 
matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human 
breast cancer cells. The Journal of biological chemistry 271, 2443-2447 
33. White, M. F. (2002) IRS proteins and the common path to diabetes. American 
journal of physiology. Endocrinology and metabolism 283, E413-422 
34. Bjornholm, M., He, A. R., Attersand, A., Lake, S., Liu, S. C., Lienhard, G. E., 
Taylor, S., Arner, P., and Zierath, J. R. (2002) Absence of functional insulin 
receptor substrate-3 (IRS-3) gene in humans. Diabetologia 45, 1697-1702 
35. Lavan, B. E., Fantin, V. R., Chang, E. T., Lane, W. S., Keller, S. R., and 
Lienhard, G. E. (1997) A novel 160-kDa phosphotyrosine protein in insulin-
treated embryonic kidney cells is a new member of the insulin receptor substrate 
family. The Journal of biological chemistry 272, 21403-21407 
36. Lavan, B. E., Lane, W. S., and Lienhard, G. E. (1997) The 60-kDa 
phosphotyrosine protein in insulin-treated adipocytes is a new member of the 
insulin receptor substrate family. The Journal of biological chemistry 272, 11439-
11443 
37. Lee, A. V., Jackson, J. G., Gooch, J. L., Hilsenbeck, S. G., Coronado-Heinsohn, 
E., Osborne, C. K., and Yee, D. (1999) Enhancement of insulin-like growth factor 
signaling in human breast cancer: estrogen regulation of insulin receptor 
substrate-1 expression in vitro and in vivo. Molecular endocrinology 13, 787-796 
38. Vassen, L., Wegrzyn, W., and Klein-Hitpass, L. (1999) Human insulin receptor 
substrate-2 (IRS-2) is a primary progesterone response gene. Molecular 
endocrinology 13, 485-494 
39. Molloy, C. A., May, F. E., and Westley, B. R. (2000) Insulin receptor substrate-1 
expression is regulated by estrogen in the MCF-7 human breast cancer cell line. 
The Journal of biological chemistry 275, 12565-12571 
40. Jackson, J. G., and Yee, D. (1999) IRS-1 expression and activation are not 
sufficient to activate downstream pathways and enable IGF-I growth response in 
estrogen receptor negative breast cancer cells. Growth hormone & IGF research : 
official journal of the Growth Hormone Research Society and the International 
IGF Research Society 9, 280-289 
41. Mardilovich, K., and Shaw, L. M. (2009) Hypoxia regulates insulin receptor 
substrate-2 expression to promote breast carcinoma cell survival and invasion. 
Cancer research 69, 8894-8901 
154
 42. White, M. F., Maron, R., and Kahn, C. R. (1985) Insulin rapidly stimulates 
tyrosine phosphorylation of a Mr-185,000 protein in intact cells. Nature 318, 183-
186 
43. Sun, X. J., Rothenberg, P., Kahn, C. R., Backer, J. M., Araki, E., Wilden, P. A., 
Cahill, D. A., Goldstein, B. J., and White, M. F. (1991) Structure of the insulin 
receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352, 
73-77 
44. Araki, E., Lipes, M. A., Patti, M. E., Bruning, J. C., Haag, B., 3rd, Johnson, R. S., 
and Kahn, C. R. (1994) Alternative pathway of insulin signalling in mice with 
targeted disruption of the IRS-1 gene. Nature 372, 186-190 
45. Tobe, K., Tamemoto, H., Yamauchi, T., Aizawa, S., Yazaki, Y., and Kadowaki, 
T. (1995) Identification of a 190-kDa protein as a novel substrate for the insulin 
receptor kinase functionally similar to insulin receptor substrate-1. The Journal of 
biological chemistry 270, 5698-5701 
46. Patti, M. E., Sun, X. J., Bruening, J. C., Araki, E., Lipes, M. A., White, M. F., and 
Kahn, C. R. (1995) 4PS/insulin receptor substrate (IRS)-2 is the alternative 
substrate of the insulin receptor in IRS-1-deficient mice. The Journal of biological 
chemistry 270, 24670-24673 
47. Izumi, T., White, M. F., Kadowaki, T., Takaku, F., Akanuma, Y., and Kasuga, M. 
(1987) Insulin-like growth factor I rapidly stimulates tyrosine phosphorylation of 
a Mr 185,000 protein in intact cells. The Journal of biological chemistry 262, 
1282-1287 
48. Myers, M. G., Jr., Sun, X. J., Cheatham, B., Jachna, B. R., Glasheen, E. M., 
Backer, J. M., and White, M. F. (1993) IRS-1 is a common element in insulin and 
insulin-like growth factor-I signaling to the phosphatidylinositol 3'-kinase. 
Endocrinology 132, 1421-1430 
49. He, W., Craparo, A., Zhu, Y., O'Neill, T. J., Wang, L. M., Pierce, J. H., and 
Gustafson, T. A. (1996) Interaction of insulin receptor substrate-2 (IRS-2) with 
the insulin and insulin-like growth factor I receptors. Evidence for two distinct 
phosphotyrosine-dependent interaction domains within IRS-2. The Journal of 
biological chemistry 271, 11641-11645 
50. Sun, X. J., Wang, L. M., Zhang, Y., Yenush, L., Myers, M. G., Jr., Glasheen, E., 
Lane, W. S., Pierce, J. H., and White, M. F. (1995) Role of IRS-2 in insulin and 
cytokine signalling. Nature 377, 173-177 
51. Vuori, K., and Ruoslahti, E. (1994) Association of insulin receptor substrate-1 
with integrins. Science 266, 1576-1578 
52. Shaw, L. M. (2001) Identification of insulin receptor substrate 1 (IRS-1) and IRS-
2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of 
phosphoinositide 3-OH kinase and promotion of invasion. Molecular and cellular 
biology 21, 5082-5093 
53. Goel, H. L., Fornaro, M., Moro, L., Teider, N., Rhim, J. S., King, M., and 
Languino, L. R. (2004) Selective modulation of type 1 insulin-like growth factor 
receptor signaling and functions by beta1 integrins. The Journal of cell biology 
166, 407-418 
155
 54. Yamauchi, T., Kaburagi, Y., Ueki, K., Tsuji, Y., Stark, G. R., Kerr, I. M., 
Tsushima, T., Akanuma, Y., Komuro, I., Tobe, K., Yazaki, Y., and Kadowaki, T. 
(1998) Growth hormone and prolactin stimulate tyrosine phosphorylation of 
insulin receptor substrate-1, -2, and -3, their association with p85 
phosphatidylinositol 3-kinase (PI3-kinase), and concomitantly PI3-kinase 
activation via JAK2 kinase. The Journal of biological chemistry 273, 15719-
15726 
55. Liang, L., Zhou, T., Jiang, J., Pierce, J. H., Gustafson, T. A., and Frank, S. J. 
(1999) Insulin receptor substrate-1 enhances growth hormone-induced 
proliferation. Endocrinology 140, 1972-1983 
56. Senthil, D., Ghosh Choudhury, G., Bhandari, B. K., and Kasinath, B. S. (2002) 
The type 2 vascular endothelial growth factor receptor recruits insulin receptor 
substrate-1 in its signalling pathway. The Biochemical journal 368, 49-56 
57. Morgillo, F., Woo, J. K., Kim, E. S., Hong, W. K., and Lee, H. Y. (2006) 
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor 
receptor and induction of survivin expression counteract the antitumor action of 
erlotinib. Cancer research 66, 10100-10111 
58. Knowlden, J. M., Jones, H. E., Barrow, D., Gee, J. M., Nicholson, R. I., and 
Hutcheson, I. R. (2008) Insulin receptor substrate-1 involvement in epidermal 
growth factor receptor and insulin-like growth factor receptor signalling: 
implication for Gefitinib ('Iressa') response and resistance. Breast cancer research 
and treatment 111, 79-91 
59. Myers, M. G., Jr., Backer, J. M., Sun, X. J., Shoelson, S., Hu, P., Schlessinger, J., 
Yoakim, M., Schaffhausen, B., and White, M. F. (1992) IRS-1 activates 
phosphatidylinositol 3'-kinase by associating with src homology 2 domains of 
p85. Proceedings of the National Academy of Sciences of the United States of 
America 89, 10350-10354 
60. Gustafson, T. A., He, W., Craparo, A., Schaub, C. D., and O'Neill, T. J. (1995) 
Phosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 
with the NPEY motif of the insulin receptor via a novel non-SH2 domain. 
Molecular and cellular biology 15, 2500-2508 
61. Voliovitch, H., Schindler, D. G., Hadari, Y. R., Taylor, S. I., Accili, D., and Zick, 
Y. (1995) Tyrosine phosphorylation of insulin receptor substrate-1 in vivo 
depends upon the presence of its pleckstrin homology region. The Journal of 
biological chemistry 270, 18083-18087 
62. Sawka-Verhelle, D., Tartare-Deckert, S., White, M. F., and Van Obberghen, E. 
(1996) Insulin receptor substrate-2 binds to the insulin receptor through its 
phosphotyrosine-binding domain and through a newly identified domain 
comprising amino acids 591-786. The Journal of biological chemistry 271, 5980-
5983 
63. Wu, J., Tseng, Y. D., Xu, C. F., Neubert, T. A., White, M. F., and Hubbard, S. R. 
(2008) Structural and biochemical characterization of the KRLB region in insulin 
receptor substrate-2. Nature structural & molecular biology 15, 251-258 
156
 64. Sawka-Verhelle, D., Baron, V., Mothe, I., Filloux, C., White, M. F., and Van 
Obberghen, E. (1997) Tyr624 and Tyr628 in insulin receptor substrate-2 mediate 
its association with the insulin receptor. The Journal of biological chemistry 272, 
16414-16420 
65. Myers, M. G., Jr., Grammer, T. C., Wang, L. M., Sun, X. J., Pierce, J. H., Blenis, 
J., and White, M. F. (1994) Insulin receptor substrate-1 mediates 
phosphatidylinositol 3'-kinase and p70S6k signaling during insulin, insulin-like 
growth factor-1, and interleukin-4 stimulation. The Journal of biological 
chemistry 269, 28783-28789 
66. Lee, C. H., Li, W., Nishimura, R., Zhou, M., Batzer, A. G., Myers, M. G., Jr., 
White, M. F., Schlessinger, J., and Skolnik, E. Y. (1993) Nck associates with the 
SH2 domain-docking protein IRS-1 in insulin-stimulated cells. Proceedings of the 
National Academy of Sciences of the United States of America 90, 11713-11717 
67. Myers, M. G., Jr., Wang, L. M., Sun, X. J., Zhang, Y., Yenush, L., Schlessinger, 
J., Pierce, J. H., and White, M. F. (1994) Role of IRS-1-GRB-2 complexes in 
insulin signaling. Molecular and cellular biology 14, 3577-3587 
68. Myers, M. G., Jr., Mendez, R., Shi, P., Pierce, J. H., Rhoads, R., and White, M. F. 
(1998) The COOH-terminal tyrosine phosphorylation sites on IRS-1 bind SHP-2 
and negatively regulate insulin signaling. The Journal of biological chemistry 
273, 26908-26914 
69. Beitner-Johnson, D., Blakesley, V. A., Shen-Orr, Z., Jimenez, M., Stannard, B., 
Wang, L. M., Pierce, J., and LeRoith, D. (1996) The proto-oncogene product c-
Crk associates with insulin receptor substrate-1 and 4PS. Modulation by insulin 
growth factor-I (IGF) and enhanced IGF-I signaling. The Journal of biological 
chemistry 271, 9287-9290 
70. Karas, M., Koval, A. P., Zick, Y., and LeRoith, D. (2001) The insulin-like growth 
factor I receptor-induced interaction of insulin receptor substrate-4 and Crk-II. 
Endocrinology 142, 1835-1840 
71. Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B., Graziani, A., 
Kapeller, R., and Soltoff, S. (1991) Oncogenes and signal transduction. Cell 64, 
281-302 
72. Escobedo, J. A., Kaplan, D. R., Kavanaugh, W. M., Turck, C. W., and Williams, 
L. T. (1991) A phosphatidylinositol-3 kinase binds to platelet-derived growth 
factor receptors through a specific receptor sequence containing phosphotyrosine. 
Molecular and cellular biology 11, 1125-1132 
73. Backer, J. M., Myers, M. G., Jr., Shoelson, S. E., Chin, D. J., Sun, X. J., 
Miralpeix, M., Hu, P., Margolis, B., Skolnik, E. Y., Schlessinger, J., and et al. 
(1992) Phosphatidylinositol 3'-kinase is activated by association with IRS-1 
during insulin stimulation. The EMBO journal 11, 3469-3479 
74. Hanke, S., and Mann, M. (2009) The phosphotyrosine interactome of the insulin 
receptor family and its substrates IRS-1 and IRS-2. Molecular & cellular 
proteomics : MCP 8, 519-534 
157
 75. Copps, K. D., and White, M. F. (2012) Regulation of insulin sensitivity by 
serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and 
IRS2. Diabetologia 55, 2565-2582 
76. Hancer, N. J., Qiu, W., Cherella, C., Li, Y., Copps, K. D., and White, M. F. 
(2014) Insulin and metabolic stress stimulate multisite serine/threonine 
phosphorylation of insulin receptor substrate 1 and inhibit tyrosine 
phosphorylation. The Journal of biological chemistry 289, 12467-12484 
77. Paz, K., Hemi, R., LeRoith, D., Karasik, A., Elhanany, E., Kanety, H., and Zick, 
Y. (1997) A molecular basis for insulin resistance. Elevated serine/threonine 
phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane 
region of the insulin receptor and impairs their ability to undergo insulin-induced 
tyrosine phosphorylation. The Journal of biological chemistry 272, 29911-29918 
78. Liu, Y. F., Paz, K., Herschkovitz, A., Alt, A., Tennenbaum, T., Sampson, S. R., 
Ohba, M., Kuroki, T., LeRoith, D., and Zick, Y. (2001) Insulin stimulates 
PKCzeta -mediated phosphorylation of insulin receptor substrate-1 (IRS-1). A 
self-attenuated mechanism to negatively regulate the function of IRS proteins. 
The Journal of biological chemistry 276, 14459-14465 
79. Aguirre, V., Werner, E. D., Giraud, J., Lee, Y. H., Shoelson, S. E., and White, M. 
F. (2002) Phosphorylation of Ser307 in insulin receptor substrate-1 blocks 
interactions with the insulin receptor and inhibits insulin action. The Journal of 
biological chemistry 277, 1531-1537 
80. Delahaye, L., Mothe-Satney, I., Myers, M. G., White, M. F., and Van Obberghen, 
E. (1998) Interaction of insulin receptor substrate-1 (IRS-1) with 
phosphatidylinositol 3-kinase: effect of substitution of serine for alanine in 
potential IRS-1 serine phosphorylation sites. Endocrinology 139, 4911-4919 
81. White, M. F. (1996) The IRS-signalling system in insulin and cytokine action. 
Philosophical transactions of the Royal Society of London. Series B, Biological 
sciences 351, 181-189 
82. Schmelzle, K., Kane, S., Gridley, S., Lienhard, G. E., and White, F. M. (2006) 
Temporal dynamics of tyrosine phosphorylation in insulin signaling. Diabetes 55, 
2171-2179 
83. Esposito, D. L., Li, Y., Cama, A., and Quon, M. J. (2001) Tyr(612) and Tyr(632) 
in human insulin receptor substrate-1 are important for full activation of insulin-
stimulated phosphatidylinositol 3-kinase activity and translocation of GLUT4 in 
adipose cells. Endocrinology 142, 2833-2840 
84. Araki, E., Haag, B. L., 3rd, and Kahn, C. R. (1994) Cloning of the mouse insulin 
receptor substrate-1 (IRS-1) gene and complete sequence of mouse IRS-1. 
Biochimica et biophysica acta 1221, 353-356 
85. Tamemoto, H., Kadowaki, T., Tobe, K., Yagi, T., Sakura, H., Hayakawa, T., 
Terauchi, Y., Ueki, K., Kaburagi, Y., Satoh, S., and et al. (1994) Insulin resistance 
and growth retardation in mice lacking insulin receptor substrate-1. Nature 372, 
182-186 
86. Withers, D. J., Gutierrez, J. S., Towery, H., Burks, D. J., Ren, J. M., Previs, S., 
Zhang, Y., Bernal, D., Pons, S., Shulman, G. I., Bonner-Weir, S., and White, M. 
158
 F. (1998) Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391, 900-
904 
87. Schubert, M., Brazil, D. P., Burks, D. J., Kushner, J. A., Ye, J., Flint, C. L., 
Farhang-Fallah, J., Dikkes, P., Warot, X. M., Rio, C., Corfas, G., and White, M. 
F. (2003) Insulin receptor substrate-2 deficiency impairs brain growth and 
promotes tau phosphorylation. The Journal of neuroscience : the official journal 
of the Society for Neuroscience 23, 7084-7092 
88. Bruning, J. C., Winnay, J., Cheatham, B., and Kahn, C. R. (1997) Differential 
signaling by insulin receptor substrate 1 (IRS-1) and IRS-2 in IRS-1-deficient 
cells. Molecular and cellular biology 17, 1513-1521 
89. Huang, C., Thirone, A. C., Huang, X., and Klip, A. (2005) Differential 
contribution of insulin receptor substrates 1 versus 2 to insulin signaling and 
glucose uptake in l6 myotubes. The Journal of biological chemistry 280, 19426-
19435 
90. Valverde, A. M., Lorenzo, M., Pons, S., White, M. F., and Benito, M. (1998) 
Insulin receptor substrate (IRS) proteins IRS-1 and IRS-2 differential signaling in 
the insulin/insulin-like growth factor-I pathways in fetal brown adipocytes. 
Molecular endocrinology 12, 688-697 
91. Fasshauer, M., Klein, J., Ueki, K., Kriauciunas, K. M., Benito, M., White, M. F., 
and Kahn, C. R. (2000) Essential role of insulin receptor substrate-2 in insulin 
stimulation of Glut4 translocation and glucose uptake in brown adipocytes. The 
Journal of biological chemistry 275, 25494-25501 
92. Sadagurski, M., Weingarten, G., Rhodes, C. J., White, M. F., and Wertheimer, E. 
(2005) Insulin receptor substrate 2 plays diverse cell-specific roles in the 
regulation of glucose transport. The Journal of biological chemistry 280, 14536-
14544 
93. Mardilovich, K., Pankratz, S. L., and Shaw, L. M. (2009) Expression and function 
of the insulin receptor substrate proteins in cancer. Cell communication and 
signaling : CCS 7, 14 
94. Chang, Q., Li, Y., White, M. F., Fletcher, J. A., and Xiao, S. (2002) Constitutive 
activation of insulin receptor substrate 1 is a frequent event in human tumors: 
therapeutic implications. Cancer research 62, 6035-6038 
95. Porter, H. A., Perry, A., Kingsley, C., Tran, N. L., and Keegan, A. D. (2013) IRS1 
is highly expressed in localized breast tumors and regulates the sensitivity of 
breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive 
breast tumors. Cancer letters 338, 239-248 
96. Clark, J. L., Dresser, K., Hsieh, C. C., Sabel, M., Kleer, C. G., Khan, A., and 
Shaw, L. M. (2011) Membrane localization of insulin receptor substrate-2 (IRS-2) 
is associated with decreased overall survival in breast cancer. Breast cancer 
research and treatment 130, 759-772 
97. Sisci, D., Morelli, C., Garofalo, C., Romeo, F., Morabito, L., Casaburi, F., 
Middea, E., Cascio, S., Brunelli, E., Ando, S., and Surmacz, E. (2007) Expression 
of nuclear insulin receptor substrate 1 in breast cancer. Journal of clinical 
pathology 60, 633-641 
159
 98. Migliaccio, I., Wu, M. F., Gutierrez, C., Malorni, L., Mohsin, S. K., Allred, D. C., 
Hilsenbeck, S. G., Osborne, C. K., Weiss, H., and Lee, A. V. (2010) Nuclear IRS-
1 predicts tamoxifen response in patients with early breast cancer. Breast cancer 
research and treatment 123, 651-660 
99. Dearth, R. K., Cui, X., Kim, H. J., Kuiatse, I., Lawrence, N. A., Zhang, X., 
Divisova, J., Britton, O. L., Mohsin, S., Allred, D. C., Hadsell, D. L., and Lee, A. 
V. (2006) Mammary tumorigenesis and metastasis caused by overexpression of 
insulin receptor substrate 1 (IRS-1) or IRS-2. Molecular and cellular biology 26, 
9302-9314 
100. Jackson, J. G., White, M. F., and Yee, D. (1998) Insulin receptor substrate-1 is the 
predominant signaling molecule activated by insulin-like growth factor-I, insulin, 
and interleukin-4 in estrogen receptor-positive human breast cancer cells. The 
Journal of biological chemistry 273, 9994-10003 
101. Nolan, M. K., Jankowska, L., Prisco, M., Xu, S., Guvakova, M. A., and Surmacz, 
E. (1997) Differential roles of IRS-1 and SHC signaling pathways in breast cancer 
cells. International journal of cancer. Journal international du cancer 72, 828-
834 
102. Byron, S. A., Horwitz, K. B., Richer, J. K., Lange, C. A., Zhang, X., and Yee, D. 
(2006) Insulin receptor substrates mediate distinct biological responses to insulin-
like growth factor receptor activation in breast cancer cells. British journal of 
cancer 95, 1220-1228 
103. Jackson, J. G., Zhang, X., Yoneda, T., and Yee, D. (2001) Regulation of breast 
cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants 
of human breast cancer cell lines. Oncogene 20, 7318-7325 
104. Guy, C. T., Cardiff, R. D., and Muller, W. J. (1992) Induction of mammary 
tumors by expression of polyomavirus middle T oncogene: a transgenic mouse 
model for metastatic disease. Molecular and cellular biology 12, 954-961 
105. Gibson, S. L., Ma, Z., and Shaw, L. M. (2007) Divergent roles for IRS-1 and IRS-
2 in breast cancer metastasis. Cell cycle 6, 631-637 
106. Nagle, J. A., Ma, Z., Byrne, M. A., White, M. F., and Shaw, L. M. (2004) 
Involvement of insulin receptor substrate 2 in mammary tumor metastasis. 
Molecular and cellular biology 24, 9726-9735 
107. Ma, Z., Gibson, S. L., Byrne, M. A., Zhang, J., White, M. F., and Shaw, L. M. 
(2006) Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary 
tumor metastasis. Molecular and cellular biology 26, 9338-9351 
108. Pankratz, S. L., Tan, E. Y., Fine, Y., Mercurio, A. M., and Shaw, L. M. (2009) 
Insulin receptor substrate-2 regulates aerobic glycolysis in mouse mammary 
tumor cells via glucose transporter 1. The Journal of biological chemistry 284, 
2031-2037 
109. Hokin, L. E., and Hokin, M. R. (1953) The incorporation of 32P into the 
nucleotides of ribonucleic acid in pigeon pancreas slices. Biochimica et 
biophysica acta 11, 591-592 
110. Lapetina, E. G., and Michell, R. H. (1973) A membrane-bound activity catalysing 
phosphatidylinositol breakdown to 1,2-diacylglycerol, D-myoinositol 1:2-cyclic 
160
 phosphate an D-myoinositol 1-phosphate. Properties and subcellular distribution 
in rat cerebral cortex. The Biochemical journal 131, 433-442 
111. Macara, I. G., Marinetti, G. V., and Balduzzi, P. C. (1984) Transforming protein 
of avian sarcoma virus UR2 is associated with phosphatidylinositol kinase 
activity: possible role in tumorigenesis. Proceedings of the National Academy of 
Sciences of the United States of America 81, 2728-2732 
112. Kaplan, D. R., Whitman, M., Schaffhausen, B., Pallas, D. C., White, M., Cantley, 
L., and Roberts, T. M. (1987) Common elements in growth factor stimulation and 
oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase 
activity. Cell 50, 1021-1029 
113. Whitman, M., Downes, C. P., Keeler, M., Keller, T., and Cantley, L. (1988) Type 
I phosphatidylinositol kinase makes a novel inositol phospholipid, 
phosphatidylinositol-3-phosphate. Nature 332, 644-646 
114. Coughlin, S. R., Escobedo, J. A., and Williams, L. T. (1989) Role of 
phosphatidylinositol kinase in PDGF receptor signal transduction. Science 243, 
1191-1194 
115. Whitman, M., Kaplan, D., Roberts, T., and Cantley, L. (1987) Evidence for two 
distinct phosphatidylinositol kinases in fibroblasts. Implications for cellular 
regulation. The Biochemical journal 247, 165-174 
116. Ruderman, N. B., Kapeller, R., White, M. F., and Cantley, L. C. (1990) 
Activation of phosphatidylinositol 3-kinase by insulin. Proceedings of the 
National Academy of Sciences of the United States of America 87, 1411-1415 
117. Auger, K. R., Serunian, L. A., Soltoff, S. P., Libby, P., and Cantley, L. C. (1989) 
PDGF-dependent tyrosine phosphorylation stimulates production of novel 
polyphosphoinositides in intact cells. Cell 57, 167-175 
118. Stephens, L. R., Hughes, K. T., and Irvine, R. F. (1991) Pathway of 
phosphatidylinositol(3,4,5)-trisphosphate synthesis in activated neutrophils. 
Nature 351, 33-39 
119. Stephens, L., Hawkins, P. T., and Downes, C. P. (1989) Metabolic and structural 
evidence for the existence of a third species of polyphosphoinositide in cells: D-
phosphatidyl-myo-inositol 3-phosphate. The Biochemical journal 259, 267-276 
120. Engelman, J. A., Luo, J., and Cantley, L. C. (2006) The evolution of 
phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature 
reviews. Genetics 7, 606-619 
121. Carpenter, C. L., Duckworth, B. C., Auger, K. R., Cohen, B., Schaffhausen, B. S., 
and Cantley, L. C. (1990) Purification and characterization of phosphoinositide 3-
kinase from rat liver. The Journal of biological chemistry 265, 19704-19711 
122. Yu, J., Zhang, Y., McIlroy, J., Rordorf-Nikolic, T., Orr, G. A., and Backer, J. M. 
(1998) Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization 
and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. 
Molecular and cellular biology 18, 1379-1387 
123. Escobedo, J. A., Navankasattusas, S., Kavanaugh, W. M., Milfay, D., Fried, V. 
A., and Williams, L. T. (1991) cDNA cloning of a novel 85 kd protein that has 
161
 SH2 domains and regulates binding of PI3-kinase to the PDGF beta-receptor. Cell 
65, 75-82 
124. Yu, J., Wjasow, C., and Backer, J. M. (1998) Regulation of the p85/p110alpha 
phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal 
SH2 domains. The Journal of biological chemistry 273, 30199-30203 
125. Carpenter, C. L., Auger, K. R., Chanudhuri, M., Yoakim, M., Schaffhausen, B., 
Shoelson, S., and Cantley, L. C. (1993) Phosphoinositide 3-kinase is activated by 
phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. The 
Journal of biological chemistry 268, 9478-9483 
126. Rordorf-Nikolic, T., Van Horn, D. J., Chen, D., White, M. F., and Backer, J. M. 
(1995) Regulation of phosphatidylinositol 3'-kinase by tyrosyl phosphoproteins. 
Full activation requires occupancy of both SH2 domains in the 85-kDa regulatory 
subunit. The Journal of biological chemistry 270, 3662-3666 
127. Seely, B. L., Reichart, D. R., Staubs, P. A., Jhun, B. H., Hsu, D., Maegawa, H., 
Milarski, K. L., Saltiel, A. R., and Olefsky, J. M. (1995) Localization of the 
insulin-like growth factor I receptor binding sites for the SH2 domain proteins 
p85, Syp, and GTPase activating protein. The Journal of biological chemistry 
270, 19151-19157 
128. Tartare-Deckert, S., Murdaca, J., Sawka-Verhelle, D., Holt, K. H., Pessin, J. E., 
and Van Obberghen, E. (1996) Interaction of the molecular weight 85K 
regulatory subunit of the phosphatidylinositol 3-kinase with the insulin receptor 
and the insulin-like growth factor-1 (IGF- I) receptor: comparative study using the 
yeast two-hybrid system. Endocrinology 137, 1019-1024 
129. Dong, X. C., Copps, K. D., Guo, S., Li, Y., Kollipara, R., DePinho, R. A., and 
White, M. F. (2008) Inactivation of hepatic Foxo1 by insulin signaling is required 
for adaptive nutrient homeostasis and endocrine growth regulation. Cell 
metabolism 8, 65-76 
130. Long, Y. C., Cheng, Z., Copps, K. D., and White, M. F. (2011) Insulin receptor 
substrates Irs1 and Irs2 coordinate skeletal muscle growth and metabolism via the 
Akt and AMPK pathways. Molecular and cellular biology 31, 430-441 
131. Harlan, J. E., Hajduk, P. J., Yoon, H. S., and Fesik, S. W. (1994) Pleckstrin 
homology domains bind to phosphatidylinositol-4,5-bisphosphate. Nature 371, 
168-170 
132. Coffer, P. J., and Woodgett, J. R. (1991) Molecular cloning and characterisation 
of a novel putative protein-serine kinase related to the cAMP-dependent and 
protein kinase C families. European journal of biochemistry / FEBS 201, 475-481 
133. Franke, T. F., Yang, S. I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. 
K., Kaplan, D. R., and Tsichlis, P. N. (1995) The protein kinase encoded by the 
Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-
kinase. Cell 81, 727-736 
134. Burgering, B. M., and Coffer, P. J. (1995) Protein kinase B (c-Akt) in 
phosphatidylinositol-3-OH kinase signal transduction. Nature 376, 599-602 
135. Manning, B. D., and Cantley, L. C. (2007) AKT/PKB signaling: navigating 
downstream. Cell 129, 1261-1274 
162
 136. Welch, H. C., Coadwell, W. J., Ellson, C. D., Ferguson, G. J., Andrews, S. R., 
Erdjument-Bromage, H., Tempst, P., Hawkins, P. T., and Stephens, L. R. (2002) 
P-Rex1, a PtdIns(3,4,5)P3- and Gbetagamma-regulated guanine-nucleotide 
exchange factor for Rac. Cell 108, 809-821 
137. Shinohara, M., Terada, Y., Iwamatsu, A., Shinohara, A., Mochizuki, N., Higuchi, 
M., Gotoh, Y., Ihara, S., Nagata, S., Itoh, H., Fukui, Y., and Jessberger, R. (2002) 
SWAP-70 is a guanine-nucleotide-exchange factor that mediates signalling of 
membrane ruffling. Nature 416, 759-763 
138. Welch, H. C., Coadwell, W. J., Stephens, L. R., and Hawkins, P. T. (2003) 
Phosphoinositide 3-kinase-dependent activation of Rac. FEBS letters 546, 93-97 
139. Bishop, A. L., and Hall, A. (2000) Rho GTPases and their effector proteins. The 
Biochemical journal 348 Pt 2, 241-255 
140. Etienne-Manneville, S., and Hall, A. (2002) Rho GTPases in cell biology. Nature 
420, 629-635 
141. Taniguchi, C. M., Emanuelli, B., and Kahn, C. R. (2006) Critical nodes in 
signalling pathways: insights into insulin action. Nature reviews. Molecular cell 
biology 7, 85-96 
142. Taniguchi, C. M., Kondo, T., Sajan, M., Luo, J., Bronson, R., Asano, T., Farese, 
R., Cantley, L. C., and Kahn, C. R. (2006) Divergent regulation of hepatic glucose 
and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. 
Cell metabolism 3, 343-353 
143. Luo, J., Sobkiw, C. L., Hirshman, M. F., Logsdon, M. N., Li, T. Q., Goodyear, L. 
J., and Cantley, L. C. (2006) Loss of class IA PI3K signaling in muscle leads to 
impaired muscle growth, insulin response, and hyperlipidemia. Cell metabolism 3, 
355-366 
144. Kurlawalla-Martinez, C., Stiles, B., Wang, Y., Devaskar, S. U., Kahn, B. B., and 
Wu, H. (2005) Insulin hypersensitivity and resistance to streptozotocin-induced 
diabetes in mice lacking PTEN in adipose tissue. Molecular and cellular biology 
25, 2498-2510 
145. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., 
Gazdar, A., Powell, S. M., Riggins, G. J., Willson, J. K., Markowitz, S., Kinzler, 
K. W., Vogelstein, B., and Velculescu, V. E. (2004) High frequency of mutations 
of the PIK3CA gene in human cancers. Science 304, 554 
146. Bachman, K. E., Argani, P., Samuels, Y., Silliman, N., Ptak, J., Szabo, S., 
Konishi, H., Karakas, B., Blair, B. G., Lin, C., Peters, B. A., Velculescu, V. E., 
and Park, B. H. (2004) The PIK3CA gene is mutated with high frequency in 
human breast cancers. Cancer biology & therapy 3, 772-775 
147. Samuels, Y., Diaz, L. A., Jr., Schmidt-Kittler, O., Cummins, J. M., Delong, L., 
Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., Vogelstein, B., 
and Velculescu, V. E. (2005) Mutant PIK3CA promotes cell growth and invasion 
of human cancer cells. Cancer cell 7, 561-573 
148. Kang, S., Bader, A. G., and Vogt, P. K. (2005) Phosphatidylinositol 3-kinase 
mutations identified in human cancer are oncogenic. Proceedings of the National 
Academy of Sciences of the United States of America 102, 802-807 
163
 149. Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline, R. 
V., Cantley, L. C., and Brugge, J. S. (2005) Breast cancer-associated PIK3CA 
mutations are oncogenic in mammary epithelial cells. Cancer research 65, 10992-
11000 
150. Sansal, I., and Sellers, W. R. (2004) The biology and clinical relevance of the 
PTEN tumor suppressor pathway. Journal of clinical oncology : official journal of 
the American Society of Clinical Oncology 22, 2954-2963 
151. Maehama, T., and Dixon, J. E. (1998) The tumor suppressor, PTEN/MMAC1, 
dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-
trisphosphate. The Journal of biological chemistry 273, 13375-13378 
152. Liaw, D., Marsh, D. J., Li, J., Dahia, P. L., Wang, S. I., Zheng, Z., Bose, S., Call, 
K. M., Tsou, H. C., Peacocke, M., Eng, C., and Parsons, R. (1997) Germline 
mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid 
cancer syndrome. Nature genetics 16, 64-67 
153. Yuan, T. L., and Cantley, L. C. (2008) PI3K pathway alterations in cancer: 
variations on a theme. Oncogene 27, 5497-5510 
154. Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W. L., 
Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., Symmans, W. F., Pusztai, L., 
Nolden, L. K., Horlings, H., Berns, K., Hung, M. C., van de Vijver, M. J., Valero, 
V., Gray, J. W., Bernards, R., Mills, G. B., and Hennessy, B. T. (2008) An 
integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT 
mutations in breast cancer. Cancer research 68, 6084-6091 
155. Ghayad, S. E., and Cohen, P. A. (2010) Inhibitors of the PI3K/Akt/mTOR 
pathway: new hope for breast cancer patients. Recent patents on anti-cancer drug 
discovery 5, 29-57 
156. Cidado, J., and Park, B. H. (2012) Targeting the PI3K/Akt/mTOR pathway for 
breast cancer therapy. Journal of mammary gland biology and neoplasia 17, 205-
216 
157. Soltoff, S. P., Carraway, K. L., 3rd, Prigent, S. A., Gullick, W. G., and Cantley, L. 
C. (1994) ErbB3 is involved in activation of phosphatidylinositol 3-kinase by 
epidermal growth factor. Molecular and cellular biology 14, 3550-3558 
158. Baselga, J. (2011) Targeting the phosphoinositide-3 (PI3) kinase pathway in 
breast cancer. The oncologist 16 Suppl 1, 12-19 
159. Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., 
Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, 
M., Beijersbergen, R. L., Mills, G. B., van de Vijver, M. J., and Bernards, R. 
(2007) A functional genetic approach identifies the PI3K pathway as a major 
determinant of trastuzumab resistance in breast cancer. Cancer cell 12, 395-402 
160. Saal, L. H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., Yu, J. S., 
Malmstrom, P. O., Mansukhani, M., Enoksson, J., Hibshoosh, H., Borg, A., and 
Parsons, R. (2005) PIK3CA mutations correlate with hormone receptors, node 
metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human 
breast carcinoma. Cancer research 65, 2554-2559 
164
 161. Boyault, S., Drouet, Y., Navarro, C., Bachelot, T., Lasset, C., Treilleux, I., 
Tabone, E., Puisieux, A., and Wang, Q. (2012) Mutational characterization of 
individual breast tumors: TP53 and PI3K pathway genes are frequently and 
distinctively mutated in different subtypes. Breast cancer research and treatment 
132, 29-39 
162. Campbell, I. G., Russell, S. E., Choong, D. Y., Montgomery, K. G., Ciavarella, 
M. L., Hooi, C. S., Cristiano, B. E., Pearson, R. B., and Phillips, W. A. (2004) 
Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer research 64, 
7678-7681 
163. Klippel, A., Reinhard, C., Kavanaugh, W. M., Apell, G., Escobedo, M. A., and 
Williams, L. T. (1996) Membrane localization of phosphatidylinositol 3-kinase is 
sufficient to activate multiple signal-transducing kinase pathways. Molecular and 
cellular biology 16, 4117-4127 
164. Didichenko, S. A., Tilton, B., Hemmings, B. A., Ballmer-Hofer, K., and Thelen, 
M. (1996) Constitutive activation of protein kinase B and phosphorylation of 
p47phox by a membrane-targeted phosphoinositide 3-kinase. Current biology : 
CB 6, 1271-1278 
165. Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., 
and Hemmings, B. A. (1996) Mechanism of activation of protein kinase B by 
insulin and IGF-1. The EMBO journal 15, 6541-6551 
166. Andjelkovic, M., Alessi, D. R., Meier, R., Fernandez, A., Lamb, N. J., Frech, M., 
Cron, P., Cohen, P., Lucocq, J. M., and Hemmings, B. A. (1997) Role of 
translocation in the activation and function of protein kinase B. The Journal of 
biological chemistry 272, 31515-31524 
167. Kohn, A. D., Takeuchi, F., and Roth, R. A. (1996) Akt, a pleckstrin homology 
domain containing kinase, is activated primarily by phosphorylation. The Journal 
of biological chemistry 271, 21920-21926 
168. Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R., Reese, 
C. B., and Cohen, P. (1997) Characterization of a 3-phosphoinositide-dependent 
protein kinase which phosphorylates and activates protein kinase Balpha. Current 
biology : CB 7, 261-269 
169. Sarbassov, D. D., Guertin, D. A., Ali, S. M., and Sabatini, D. M. (2005) 
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. 
Science 307, 1098-1101 
170. Kunkel, M. T., Ni, Q., Tsien, R. Y., Zhang, J., and Newton, A. C. (2005) Spatio-
temporal dynamics of protein kinase B/Akt signaling revealed by a genetically 
encoded fluorescent reporter. The Journal of biological chemistry 280, 5581-5587 
171. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. 
(1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein 
kinase B. Nature 378, 785-789 
172. Alessi, D. R., Caudwell, F. B., Andjelkovic, M., Hemmings, B. A., and Cohen, P. 
(1996) Molecular basis for the substrate specificity of protein kinase B; 
comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS letters 399, 333-
338 
165
 173. Chin, Y. R., and Toker, A. (2009) Function of Akt/PKB signaling to cell motility, 
invasion and the tumor stroma in cancer. Cellular signalling 21, 470-476 
174. Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., 
Qin, J., and Su, B. (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity 
and regulates Akt phosphorylation and substrate specificity. Cell 127, 125-137 
175. Kim, A. H., Yano, H., Cho, H., Meyer, D., Monks, B., Margolis, B., Birnbaum, 
M. J., and Chao, M. V. (2002) Akt1 regulates a JNK scaffold during excitotoxic 
apoptosis. Neuron 35, 697-709 
176. Jahn, T., Seipel, P., Urschel, S., Peschel, C., and Duyster, J. (2002) Role for the 
adaptor protein Grb10 in the activation of Akt. Molecular and cellular biology 22, 
979-991 
177. Basso, A. D., Solit, D. B., Chiosis, G., Giri, B., Tsichlis, P., and Rosen, N. (2002) 
Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 
and is destabilized by inhibitors of Hsp90 function. The Journal of biological 
chemistry 277, 39858-39866 
178. Anai, M., Shojima, N., Katagiri, H., Ogihara, T., Sakoda, H., Onishi, Y., Ono, H., 
Fujishiro, M., Fukushima, Y., Horike, N., Viana, A., Kikuchi, M., Noguchi, N., 
Takahashi, S., Takata, K., Oka, Y., Uchijima, Y., Kurihara, H., and Asano, T. 
(2005) A novel protein kinase B (PKB)/AKT-binding protein enhances PKB 
kinase activity and regulates DNA synthesis. The Journal of biological chemistry 
280, 18525-18535 
179. Varsano, T., Dong, M. Q., Niesman, I., Gacula, H., Lou, X., Ma, T., Testa, J. R., 
Yates, J. R., 3rd, and Farquhar, M. G. (2006) GIPC is recruited by APPL to 
peripheral TrkA endosomes and regulates TrkA trafficking and signaling. 
Molecular and cellular biology 26, 8942-8952 
180. Schenck, A., Goto-Silva, L., Collinet, C., Rhinn, M., Giner, A., Habermann, B., 
Brand, M., and Zerial, M. (2008) The endosomal protein Appl1 mediates Akt 
substrate specificity and cell survival in vertebrate development. Cell 133, 486-
497 
181. Yang, L., Lin, H. K., Altuwaijri, S., Xie, S., Wang, L., and Chang, C. (2003) 
APPL suppresses androgen receptor transactivation via potentiating Akt activity. 
The Journal of biological chemistry 278, 16820-16827 
182. Mao, X., Kikani, C. K., Riojas, R. A., Langlais, P., Wang, L., Ramos, F. J., Fang, 
Q., Christ-Roberts, C. Y., Hong, J. Y., Kim, R. Y., Liu, F., and Dong, L. Q. 
(2006) APPL1 binds to adiponectin receptors and mediates adiponectin signalling 
and function. Nature cell biology 8, 516-523 
183. Lin, D. C., Quevedo, C., Brewer, N. E., Bell, A., Testa, J. R., Grimes, M. L., 
Miller, F. D., and Kaplan, D. R. (2006) APPL1 associates with TrkA and GIPC1 
and is required for nerve growth factor-mediated signal transduction. Molecular 
and cellular biology 26, 8928-8941 
184. Martelli, A. M., Tabellini, G., Bressanin, D., Ognibene, A., Goto, K., Cocco, L., 
and Evangelisti, C. (2012) The emerging multiple roles of nuclear Akt. 
Biochimica et biophysica acta 1823, 2168-2178 
166
 185. Bavelloni, A., Santi, S., Sirri, A., Riccio, M., Faenza, I., Zini, N., Cecchi, S., 
Ferri, A., Auron, P., Maraldi, N. M., and Marmiroli, S. (1999) 
Phosphatidylinositol 3-kinase translocation to the nucleus is induced by 
interleukin 1 and prevented by mutation of interleukin 1 receptor in human 
osteosarcoma Saos-2 cells. Journal of cell science 112 ( Pt 5), 631-640 
186. Follo, M. Y., Faenza, I., Piazzi, M., Blalock, W. L., Manzoli, L., McCubrey, J. A., 
and Cocco, L. (2014) Nuclear PI-PLCbeta1: an appraisal on targets and 
pathology. Advances in biological regulation 54, 2-11 
187. Follo, M. Y., Marmiroli, S., Faenza, I., Fiume, R., Ramazzotti, G., Martelli, A. 
M., Gobbi, P., McCubrey, J. A., Finelli, C., Manzoli, F. A., and Cocco, L. (2013) 
Nuclear phospholipase C beta1 signaling, epigenetics and treatments in MDS. 
Advances in biological regulation 53, 2-7 
188. Neri, L. M., Bortul, R., Tabellini, G., Borgatti, P., Baldini, G., Celeghini, C., 
Capitani, S., and Martelli, A. M. (2002) Erythropoietin-induced erythroid 
differentiation of K562 cells is accompanied by the nuclear translocation of 
phosphatidylinositol 3-kinase and intranuclear generation of phosphatidylinositol 
(3,4,5) trisphosphate. Cellular signalling 14, 21-29 
189. Scheid, M. P., Parsons, M., and Woodgett, J. R. (2005) Phosphoinositide-
dependent phosphorylation of PDK1 regulates nuclear translocation. Molecular 
and cellular biology 25, 2347-2363 
190. Rosner, M., and Hengstschlager, M. (2012) Detection of cytoplasmic and nuclear 
functions of mTOR by fractionation. Methods in molecular biology 821, 105-124 
191. Hanada, M., Feng, J., and Hemmings, B. A. (2004) Structure, regulation and 
function of PKB/AKT--a major therapeutic target. Biochimica et biophysica acta 
1697, 3-16 
192. Calleja, V., Laguerre, M., and Larijani, B. (2012) Role of the C-terminal 
regulatory domain in the allosteric inhibition of PKB/Akt. Advances in biological 
regulation 52, 46-57 
193. Mahadevan, D., Powis, G., Mash, E. A., George, B., Gokhale, V. M., Zhang, S., 
Shakalya, K., Du-Cuny, L., Berggren, M., Ali, M. A., Jana, U., Ihle, N., Moses, 
S., Franklin, C., Narayan, S., Shirahatti, N., and Meuillet, E. J. (2008) Discovery 
of a novel class of AKT pleckstrin homology domain inhibitors. Molecular 
cancer therapeutics 7, 2621-2632 
194. Chen, W. S., Xu, P. Z., Gottlob, K., Chen, M. L., Sokol, K., Shiyanova, T., 
Roninson, I., Weng, W., Suzuki, R., Tobe, K., Kadowaki, T., and Hay, N. (2001) 
Growth retardation and increased apoptosis in mice with homozygous disruption 
of the Akt1 gene. Genes & development 15, 2203-2208 
195. Cho, H., Thorvaldsen, J. L., Chu, Q., Feng, F., and Birnbaum, M. J. (2001) 
Akt1/PKBalpha is required for normal growth but dispensable for maintenance of 
glucose homeostasis in mice. The Journal of biological chemistry 276, 38349-
38352 
196. Garofalo, R. S., Orena, S. J., Rafidi, K., Torchia, A. J., Stock, J. L., Hildebrandt, 
A. L., Coskran, T., Black, S. C., Brees, D. J., Wicks, J. R., McNeish, J. D., and 
Coleman, K. G. (2003) Severe diabetes, age-dependent loss of adipose tissue, and 
167
 mild growth deficiency in mice lacking Akt2/PKB beta. The Journal of clinical 
investigation 112, 197-208 
197. Tschopp, O., Yang, Z. Z., Brodbeck, D., Dummler, B. A., Hemmings-Mieszczak, 
M., Watanabe, T., Michaelis, T., Frahm, J., and Hemmings, B. A. (2005) 
Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain 
development but not in glucose homeostasis. Development 132, 2943-2954 
198. Santi, S. A., and Lee, H. (2010) The Akt isoforms are present at distinct 
subcellular locations. American journal of physiology. Cell physiology 298, C580-
591 
199. Cho, H., Mu, J., Kim, J. K., Thorvaldsen, J. L., Chu, Q., Crenshaw, E. B., 3rd, 
Kaestner, K. H., Bartolomei, M. S., Shulman, G. I., and Birnbaum, M. J. (2001) 
Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the 
protein kinase Akt2 (PKB beta). Science 292, 1728-1731 
200. Gonzalez, E., and McGraw, T. E. (2009) Insulin-modulated Akt subcellular 
localization determines Akt isoform-specific signaling. Proceedings of the 
National Academy of Sciences of the United States of America 106, 7004-7009 
201. Jiang, Z. Y., Zhou, Q. L., Coleman, K. A., Chouinard, M., Boese, Q., and Czech, 
M. P. (2003) Insulin signaling through Akt/protein kinase B analyzed by small 
interfering RNA-mediated gene silencing. Proceedings of the National Academy 
of Sciences of the United States of America 100, 7569-7574 
202. Katome, T., Obata, T., Matsushima, R., Masuyama, N., Cantley, L. C., Gotoh, Y., 
Kishi, K., Shiota, H., and Ebina, Y. (2003) Use of RNA interference-mediated 
gene silencing and adenoviral overexpression to elucidate the roles of 
AKT/protein kinase B isoforms in insulin actions. The Journal of biological 
chemistry 278, 28312-28323 
203. Bruss, M. D., Arias, E. B., Lienhard, G. E., and Cartee, G. D. (2005) Increased 
phosphorylation of Akt substrate of 160 kDa (AS160) in rat skeletal muscle in 
response to insulin or contractile activity. Diabetes 54, 41-50 
204. Sano, H., Kane, S., Sano, E., Miinea, C. P., Asara, J. M., Lane, W. S., Garner, C. 
W., and Lienhard, G. E. (2003) Insulin-stimulated phosphorylation of a Rab 
GTPase-activating protein regulates GLUT4 translocation. The Journal of 
biological chemistry 278, 14599-14602 
205. Eguez, L., Lee, A., Chavez, J. A., Miinea, C. P., Kane, S., Lienhard, G. E., and 
McGraw, T. E. (2005) Full intracellular retention of GLUT4 requires AS160 Rab 
GTPase activating protein. Cell metabolism 2, 263-272 
206. Sun, M., Wang, G., Paciga, J. E., Feldman, R. I., Yuan, Z. Q., Ma, X. L., Shelley, 
S. A., Jove, R., Tsichlis, P. N., Nicosia, S. V., and Cheng, J. Q. (2001) 
AKT1/PKBalpha kinase is frequently elevated in human cancers and its 
constitutive activation is required for oncogenic transformation in NIH3T3 cells. 
The American journal of pathology 159, 431-437 
207. Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. 
M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., Uhlik, M., Lin, A., 
Du, J., Qian, Y. W., Zeckner, D. J., Tucker-Kellogg, G., Touchman, J., Patel, K., 
Mousses, S., Bittner, M., Schevitz, R., Lai, M. H., Blanchard, K. L., and Thomas, 
168
 J. E. (2007) A transforming mutation in the pleckstrin homology domain of AKT1 
in cancer. Nature 448, 439-444 
208. Bellacosa, A., de Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. 
A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., Ferrandina, G., Benedetti 
Panici, P., Mancuso, S., Neri, G., and Testa, J. R. (1995) Molecular alterations of 
the AKT2 oncogene in ovarian and breast carcinomas. International journal of 
cancer. Journal international du cancer 64, 280-285 
209. Nakatani, K., Thompson, D. A., Barthel, A., Sakaue, H., Liu, W., Weigel, R. J., 
and Roth, R. A. (1999) Up-regulation of Akt3 in estrogen receptor-deficient 
breast cancers and androgen-independent prostate cancer lines. The Journal of 
biological chemistry 274, 21528-21532 
210. Perez-Tenorio, G., Stal, O., and Southeast Sweden Breast Cancer, G. (2002) 
Activation of AKT/PKB in breast cancer predicts a worse outcome among 
endocrine treated patients. British journal of cancer 86, 540-545 
211. Liu, H., Radisky, D. C., Nelson, C. M., Zhang, H., Fata, J. E., Roth, R. A., and 
Bissell, M. J. (2006) Mechanism of Akt1 inhibition of breast cancer cell invasion 
reveals a protumorigenic role for TSC2. Proceedings of the National Academy of 
Sciences of the United States of America 103, 4134-4139 
212. Yoeli-Lerner, M., Yiu, G. K., Rabinovitz, I., Erhardt, P., Jauliac, S., and Toker, A. 
(2005) Akt blocks breast cancer cell motility and invasion through the 
transcription factor NFAT. Molecular cell 20, 539-550 
213. Irie, H. Y., Pearline, R. V., Grueneberg, D., Hsia, M., Ravichandran, P., Kothari, 
N., Natesan, S., and Brugge, J. S. (2005) Distinct roles of Akt1 and Akt2 in 
regulating cell migration and epithelial-mesenchymal transition. The Journal of 
cell biology 171, 1023-1034 
214. Arboleda, M. J., Lyons, J. F., Kabbinavar, F. F., Bray, M. R., Snow, B. E., Ayala, 
R., Danino, M., Karlan, B. Y., and Slamon, D. J. (2003) Overexpression of 
AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased 
invasion, and metastasis of human breast and ovarian cancer cells. Cancer 
research 63, 196-206 
215. Chin, Y. R., and Toker, A. (2010) The actin-bundling protein palladin is an Akt1-
specific substrate that regulates breast cancer cell migration. Molecular cell 38, 
333-344 
216. Cheng, G. Z., Chan, J., Wang, Q., Zhang, W., Sun, C. D., and Wang, L. H. (2007) 
Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to 
increased migration, invasion, and resistance to paclitaxel. Cancer research 67, 
1979-1987 
217. Hutchinson, J. N., Jin, J., Cardiff, R. D., Woodgett, J. R., and Muller, W. J. (2004) 
Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary 
tumorigenesis but suppresses tumor invasion. Cancer research 64, 3171-3178 
218. Maroulakou, I. G., Oemler, W., Naber, S. P., and Tsichlis, P. N. (2007) Akt1 
ablation inhibits, whereas Akt2 ablation accelerates, the development of 
mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-
169
 ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer research 67, 
167-177 
219. Ju, X., Katiyar, S., Wang, C., Liu, M., Jiao, X., Li, S., Zhou, J., Turner, J., Lisanti, 
M. P., Russell, R. G., Mueller, S. C., Ojeifo, J., Chen, W. S., Hay, N., and Pestell, 
R. G. (2007) Akt1 governs breast cancer progression in vivo. Proceedings of the 
National Academy of Sciences of the United States of America 104, 7438-7443 
220. Warburg, O. (1956) On the origin of cancer cells. Science 123, 309-314 
221. Warburg, O. (1956) On respiratory impairment in cancer cells. Science 124, 269-
270 
222. Moreno-Sanchez, R., Rodriguez-Enriquez, S., Marin-Hernandez, A., and 
Saavedra, E. (2007) Energy metabolism in tumor cells. The FEBS journal 274, 
1393-1418 
223. Vander Heiden, M. G., Cantley, L. C., and Thompson, C. B. (2009) 
Understanding the Warburg effect: the metabolic requirements of cell 
proliferation. Science 324, 1029-1033 
224. Brand, K. (1985) Glutamine and glucose metabolism during thymocyte 
proliferation. Pathways of glutamine and glutamate metabolism. The Biochemical 
journal 228, 353-361 
225. Hedeskov, C. J. (1968) Early effects of phytohaemagglutinin on glucose 
metabolism of normal human lymphocytes. The Biochemical journal 110, 373-
380 
226. Loos, J. A., and Roos, D. (1973) Changes in the carbohydrate metabolism of 
mitogenically stimulated human peripheral lymphocytes. 3. Stimulation by 
tuberculin and allogenic cells. Experimental cell research 79, 136-142 
227. Wang, T., Marquardt, C., and Foker, J. (1976) Aerobic glycolysis during 
lymphocyte proliferation. Nature 261, 702-705 
228. Guppy, M., Greiner, E., and Brand, K. (1993) The role of the Crabtree effect and 
an endogenous fuel in the energy metabolism of resting and proliferating 
thymocytes. European journal of biochemistry / FEBS 212, 95-99 
229. Pfeiffer, T., Schuster, S., and Bonhoeffer, S. (2001) Cooperation and competition 
in the evolution of ATP-producing pathways. Science 292, 504-507 
230. Lunt, S. Y., and Vander Heiden, M. G. (2011) Aerobic glycolysis: meeting the 
metabolic requirements of cell proliferation. Annual review of cell and 
developmental biology 27, 441-464 
231. Krzeslak, A., Wojcik-Krowiranda, K., Forma, E., Jozwiak, P., Romanowicz, H., 
Bienkiewicz, A., and Brys, M. (2012) Expression of GLUT1 and GLUT3 glucose 
transporters in endometrial and breast cancers. Pathology oncology research : 
POR 18, 721-728 
232. Wieman, H. L., Wofford, J. A., and Rathmell, J. C. (2007) Cytokine stimulation 
promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of 
Glut1 activity and trafficking. Molecular biology of the cell 18, 1437-1446 
233. Wofford, J. A., Wieman, H. L., Jacobs, S. R., Zhao, Y., and Rathmell, J. C. 
(2008) IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated 
activation of Akt to support T-cell survival. Blood 111, 2101-2111 
170
 234. Lum, J. J., Bui, T., Gruber, M., Gordan, J. D., DeBerardinis, R. J., Covello, K. L., 
Simon, M. C., and Thompson, C. B. (2007) The transcription factor HIF-1alpha 
plays a critical role in the growth factor-dependent regulation of both aerobic and 
anaerobic glycolysis. Genes & development 21, 1037-1049 
235. Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., 
Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., Loda, M., Lane, H. A., 
and Sellers, W. R. (2004) mTOR inhibition reverses Akt-dependent prostate 
intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent 
pathways. Nature medicine 10, 594-601 
236. Semenza, G. L. (2003) Targeting HIF-1 for cancer therapy. Nature reviews. 
Cancer 3, 721-732 
237. Majewski, N., Nogueira, V., Bhaskar, P., Coy, P. E., Skeen, J. E., Gottlob, K., 
Chandel, N. S., Thompson, C. B., Robey, R. B., and Hay, N. (2004) Hexokinase-
mitochondria interaction mediated by Akt is required to inhibit apoptosis in the 
presence or absence of Bax and Bak. Molecular cell 16, 819-830 
238. Deprez, J., Vertommen, D., Alessi, D. R., Hue, L., and Rider, M. H. (1997) 
Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein 
kinase B and other protein kinases of the insulin signaling cascades. The Journal 
of biological chemistry 272, 17269-17275 
239. Vander Heiden, M. G., Plas, D. R., Rathmell, J. C., Fox, C. J., Harris, M. H., and 
Thompson, C. B. (2001) Growth factors can influence cell growth and survival 
through effects on glucose metabolism. Molecular and cellular biology 21, 5899-
5912 
240. Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., 
Maira, M., McNamara, K., Perera, S. A., Song, Y., Chirieac, L. R., Kaur, R., 
Lightbown, A., Simendinger, J., Li, T., Padera, R. F., Garcia-Echeverria, C., 
Weissleder, R., Mahmood, U., Cantley, L. C., and Wong, K. K. (2008) Effective 
use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA 
H1047R murine lung cancers. Nature medicine 14, 1351-1356 
241. Maglione, J. E., Moghanaki, D., Young, L. J., Manner, C. K., Ellies, L. G., 
Joseph, S. O., Nicholson, B., Cardiff, R. D., and MacLeod, C. L. (2001) 
Transgenic Polyoma middle-T mice model premalignant mammary disease. 
Cancer research 61, 8298-8305 
242. Lin, E. Y., Jones, J. G., Li, P., Zhu, L., Whitney, K. D., Muller, W. J., and Pollard, 
J. W. (2003) Progression to malignancy in the polyoma middle T oncoprotein 
mouse breast cancer model provides a reliable model for human diseases. The 
American journal of pathology 163, 2113-2126 
243. Lin, X., Taguchi, A., Park, S., Kushner, J. A., Li, F., Li, Y., and White, M. F. 
(2004) Dysregulation of insulin receptor substrate 2 in beta cells and brain causes 
obesity and diabetes. The Journal of clinical investigation 114, 908-916 
244. Withers, D. J., Burks, D. J., Towery, H. H., Altamuro, S. L., Flint, C. L., and 
White, M. F. (1999) Irs-2 coordinates Igf-1 receptor-mediated beta-cell 
development and peripheral insulin signalling. Nature genetics 23, 32-40 
171
 245. Yenush, L., Makati, K. J., Smith-Hall, J., Ishibashi, O., Myers, M. G., Jr., and 
White, M. F. (1996) The pleckstrin homology domain is the principal link 
between the insulin receptor and IRS-1. The Journal of biological chemistry 271, 
24300-24306 
246. Backer, J. M., Wjasow, C., and Zhang, Y. (1997) In vitro binding and 
phosphorylation of insulin receptor substrate 1 by the insulin receptor. Role of 
interactions mediated by the phosphotyrosine-binding domain and the pleckstrin-
homology domain. European journal of biochemistry / FEBS 245, 91-96 
247. Miller, T. W., Rexer, B. N., Garrett, J. T., and Arteaga, C. L. (2011) Mutations in 
the phosphatidylinositol 3-kinase pathway: role in tumor progression and 
therapeutic implications in breast cancer. Breast cancer research : BCR 13, 224 
248. Vivanco, I., and Sawyers, C. L. (2002) The phosphatidylinositol 3-Kinase AKT 
pathway in human cancer. Nature reviews. Cancer 2, 489-501 
249. DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., and Thompson, C. B. (2008) 
The biology of cancer: metabolic reprogramming fuels cell growth and 
proliferation. Cell metabolism 7, 11-20 
250. Robey, R. B., and Hay, N. (2009) Is Akt the "Warburg kinase"?-Akt-energy 
metabolism interactions and oncogenesis. Seminars in cancer biology 19, 25-31 
251. Obata, T., Yaffe, M. B., Leparc, G. G., Piro, E. T., Maegawa, H., Kashiwagi, A., 
Kikkawa, R., and Cantley, L. C. (2000) Peptide and protein library screening 
defines optimal substrate motifs for AKT/PKB. The Journal of biological 
chemistry 275, 36108-36115 
252. Nikoulina, S. E., Ciaraldi, T. P., Mudaliar, S., Carter, L., Johnson, K., and Henry, 
R. R. (2002) Inhibition of glycogen synthase kinase 3 improves insulin action and 
glucose metabolism in human skeletal muscle. Diabetes 51, 2190-2198 
253. Frame, S., and Cohen, P. (2001) GSK3 takes centre stage more than 20 years after 
its discovery. The Biochemical journal 359, 1-16 
254. Buller, C. L., Loberg, R. D., Fan, M. H., Zhu, Q., Park, J. L., Vesely, E., Inoki, 
K., Guan, K. L., and Brosius, F. C., 3rd. (2008) A GSK-3/TSC2/mTOR pathway 
regulates glucose uptake and GLUT1 glucose transporter expression. American 
journal of physiology. Cell physiology 295, C836-843 
255. Shaw, L. M. (2011) The insulin receptor substrate (IRS) proteins: at the 
intersection of metabolism and cancer. Cell cycle 10, 1750-1756 
256. Simister, P. C., Schaper, F., O'Reilly, N., McGowan, S., and Feller, S. M. (2011) 
Self-organization and regulation of intrinsically disordered proteins with folded 
N-termini. PLoS biology 9, e1000591 
257. De Meyts, P., and Whittaker, J. (2002) Structural biology of insulin and IGF1 
receptors: implications for drug design. Nature reviews. Drug discovery 1, 769-
783 
258. Guo, S., Dunn, S. L., and White, M. F. (2006) The reciprocal stability of FOXO1 
and IRS2 creates a regulatory circuit that controls insulin signaling. Molecular 
endocrinology 20, 3389-3399 
259. Fantin, V. R., Wang, Q., Lienhard, G. E., and Keller, S. R. (2000) Mice lacking 
insulin receptor substrate 4 exhibit mild defects in growth, reproduction, and 
172
 glucose homeostasis. American journal of physiology. Endocrinology and 
metabolism 278, E127-133 
260. Liu, S. C., Wang, Q., Lienhard, G. E., and Keller, S. R. (1999) Insulin receptor 
substrate 3 is not essential for growth or glucose homeostasis. The Journal of 
biological chemistry 274, 18093-18099 
261. Landis, J., and Shaw, L. M. (2014) Insulin Receptor Substrate-2 Mediated 
Phosphatidylinositol-3-kinase Signaling Selectively Inhibits Glycogen Synthase 
Kinase-3beta to Regulate Aerobic Glycolysis. The Journal of biological chemistry  
262. Gonzalez, E., and McGraw, T. E. (2009) The Akt kinases: isoform specificity in 
metabolism and cancer. Cell cycle 8, 2502-2508 
263. Bouzakri, K., Zachrisson, A., Al-Khalili, L., Zhang, B. B., Koistinen, H. A., 
Krook, A., and Zierath, J. R. (2006) siRNA-based gene silencing reveals 
specialized roles of IRS-1/Akt2 and IRS-2/Akt1 in glucose and lipid metabolism 
in human skeletal muscle. Cell metabolism 4, 89-96 
264. Romanelli, R. J., LeBeau, A. P., Fulmer, C. G., Lazzarino, D. A., Hochberg, A., 
and Wood, T. L. (2007) Insulin-like growth factor type-I receptor internalization 
and recycling mediate the sustained phosphorylation of Akt. The Journal of 
biological chemistry 282, 22513-22524 
265. Sun, H., and Baserga, R. (2008) The role of insulin receptor substrate-1 in 
transformation by v-src. Journal of cellular physiology 215, 725-732 
266. Wu, A., Chen, J., and Baserga, R. (2008) Nuclear insulin receptor substrate-1 
activates promoters of cell cycle progression genes. Oncogene 27, 397-403 
267. Yamauchi, T., Tobe, K., Tamemoto, H., Ueki, K., Kaburagi, Y., Yamamoto-
Honda, R., Takahashi, Y., Yoshizawa, F., Aizawa, S., Akanuma, Y., Sonenberg, 
N., Yazaki, Y., and Kadowaki, T. (1996) Insulin signalling and insulin actions in 
the muscles and livers of insulin-resistant, insulin receptor substrate 1-deficient 
mice. Molecular and cellular biology 16, 3074-3084 
268. Chamberlain, M. D., Berry, T. R., Pastor, M. C., and Anderson, D. H. (2004) The 
p85alpha subunit of phosphatidylinositol 3'-kinase binds to and stimulates the 
GTPase activity of Rab proteins. The Journal of biological chemistry 279, 48607-
48614 
269. Mellor, P., Furber, L. A., Nyarko, J. N., and Anderson, D. H. (2012) Multiple 
roles for the p85alpha isoform in the regulation and function of PI3K signalling 
and receptor trafficking. The Biochemical journal 441, 23-37 
270. Hutagalung, A. H., and Novick, P. J. (2011) Role of Rab GTPases in membrane 
traffic and cell physiology. Physiological reviews 91, 119-149 
271. Stenmark, H. (2009) Rab GTPases as coordinators of vesicle traffic. Nature 
reviews. Molecular cell biology 10, 513-525 
272. Shin, H. W., Hayashi, M., Christoforidis, S., Lacas-Gervais, S., Hoepfner, S., 
Wenk, M. R., Modregger, J., Uttenweiler-Joseph, S., Wilm, M., Nystuen, A., 
Frankel, W. N., Solimena, M., De Camilli, P., and Zerial, M. (2005) An 
enzymatic cascade of Rab5 effectors regulates phosphoinositide turnover in the 
endocytic pathway. The Journal of cell biology 170, 607-618 
173
 273. Waters, M. G., and Pfeffer, S. R. (1999) Membrane tethering in intracellular 
transport. Current opinion in cell biology 11, 453-459 
274. Corvera, S., D'Arrigo, A., and Stenmark, H. (1999) Phosphoinositides in 
membrane traffic. Current opinion in cell biology 11, 460-465 
275. Brognard, J., and Newton, A. C. (2008) PHLiPPing the switch on Akt and protein 
kinase C signaling. Trends in endocrinology and metabolism: TEM 19, 223-230 
276. Cantley, L. C., and Neel, B. G. (1999) New insights into tumor suppression: 
PTEN suppresses tumor formation by restraining the phosphoinositide 3-
kinase/AKT pathway. Proceedings of the National Academy of Sciences of the 
United States of America 96, 4240-4245 
277. Weng, L. P., Smith, W. M., Brown, J. L., and Eng, C. (2001) PTEN inhibits 
insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 
phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer 
model. Human molecular genetics 10, 605-616 
278. Shi, Y., Wang, J., Chandarlapaty, S., Cross, J., Thompson, C., Rosen, N., and 
Jiang, X. (2014) PTEN is a protein tyrosine phosphatase for IRS1. Nature 
structural & molecular biology 21, 522-527 
279. Chagpar, R. B., Links, P. H., Pastor, M. C., Furber, L. A., Hawrysh, A. D., 
Chamberlain, M. D., and Anderson, D. H. (2010) Direct positive regulation of 
PTEN by the p85 subunit of phosphatidylinositol 3-kinase. Proceedings of the 
National Academy of Sciences of the United States of America 107, 5471-5476 
280. Bijur, G. N., and Jope, R. S. (2003) Rapid accumulation of Akt in mitochondria 
following phosphatidylinositol 3-kinase activation. Journal of neurochemistry 87, 
1427-1435 
281. Bijur, G. N., and Jope, R. S. (2003) Glycogen synthase kinase-3 beta is highly 
activated in nuclei and mitochondria. Neuroreport 14, 2415-2419 
282. Antal, C. E., and Newton, A. C. (2013) Spatiotemporal dynamics of 
phosphorylation in lipid second messenger signaling. Molecular & cellular 
proteomics : MCP 12, 3498-3508 
283. Shen, D., Bai, M., Tang, R., Xu, B., Ju, X., Pestell, R. G., and Achilefu, S. (2013) 
Dual fluorescent molecular substrates selectively report the activation, 
sustainability and reversibility of cellular PKB/Akt activity. Scientific reports 3, 
1697 
284. Kubota, H., Noguchi, R., Toyoshima, Y., Ozaki, Y., Uda, S., Watanabe, K., 
Ogawa, W., and Kuroda, S. (2012) Temporal coding of insulin action through 
multiplexing of the AKT pathway. Molecular cell 46, 820-832 
285. Tremblay, F., and Marette, A. (2001) Amino acid and insulin signaling via the 
mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to 
insulin resistance in skeletal muscle cells. The Journal of biological chemistry 
276, 38052-38060 
286. Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., 
Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., Gout, I., 
Downes, C. P., and Lamb, R. F. (2004) The TSC1-2 tumor suppressor controls 
174
 insulin-PI3K signaling via regulation of IRS proteins. The Journal of cell biology 
166, 213-223 
287. Shah, O. J., Wang, Z., and Hunter, T. (2004) Inappropriate activation of the 
TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and 
cell survival deficiencies. Current biology : CB 14, 1650-1656 
288. Liberman, Z., and Eldar-Finkelman, H. (2005) Serine 332 phosphorylation of 
insulin receptor substrate-1 by glycogen synthase kinase-3 attenuates insulin 
signaling. The Journal of biological chemistry 280, 4422-4428 
289. Iakoucheva, L. M., Brown, C. J., Lawson, J. D., Obradovic, Z., and Dunker, A. K. 
(2002) Intrinsic disorder in cell-signaling and cancer-associated proteins. Journal 
of molecular biology 323, 573-584 
290. Wright, P. E., and Dyson, H. J. (2009) Linking folding and binding. Current 
opinion in structural biology 19, 31-38 
291. Rosenlow, J., Isaksson, L., Mayzel, M., Lengqvist, J., and Orekhov, V. Y. (2014) 
Tyrosine phosphorylation within the intrinsically disordered cytosolic domains of 
the B-cell receptor: an NMR-based structural analysis. PloS one 9, e96199 
292. Lawrence, C. W., Kumar, S., Noid, W. G., and Showalter, S. A. (2014) Role of 
Ordered Proteins in the Folding-Upon-Binding of Intrinsically Disordered 
Proteins. J Phys Chem Lett 5, 833-838 
293. Barnes, K., Ingram, J. C., Porras, O. H., Barros, L. F., Hudson, E. R., Fryer, L. G., 
Foufelle, F., Carling, D., Hardie, D. G., and Baldwin, S. A. (2002) Activation of 
GLUT1 by metabolic and osmotic stress: potential involvement of AMP-activated 
protein kinase (AMPK). Journal of cell science 115, 2433-2442 
294. Doble, B. W., and Woodgett, J. R. (2003) GSK-3: tricks of the trade for a multi-
tasking kinase. Journal of cell science 116, 1175-1186 
295. McManus, E. J., Sakamoto, K., Armit, L. J., Ronaldson, L., Shpiro, N., Marquez, 
R., and Alessi, D. R. (2005) Role that phosphorylation of GSK3 plays in insulin 
and Wnt signalling defined by knockin analysis. The EMBO journal 24, 1571-
1583 
296. Raikar, L. S., Vallejo, J., Lloyd, P. G., and Hardin, C. D. (2006) Overexpression 
of caveolin-1 results in increased plasma membrane targeting of glycolytic 
enzymes: the structural basis for a membrane associated metabolic compartment. 
Journal of cellular biochemistry 98, 861-871 
297. Vallejo, J., and Hardin, C. D. (2004) Caveolin-1 functions as a scaffolding protein 
for phosphofructokinase in the metabolic organization of vascular smooth muscle. 
Biochemistry 43, 16224-16232 
298. Vallejo, J., and Hardin, C. D. (2005) Expression of caveolin-1 in lymphocytes 
induces caveolae formation and recruitment of phosphofructokinase to the plasma 
membrane. FASEB journal : official publication of the Federation of American 
Societies for Experimental Biology 19, 586-587 
299. Campanella, M. E., Chu, H., and Low, P. S. (2005) Assembly and regulation of a 
glycolytic enzyme complex on the human erythrocyte membrane. Proceedings of 
the National Academy of Sciences of the United States of America 102, 2402-2407 
175
 300. Insall, R. H., and Machesky, L. M. (2009) Actin dynamics at the leading edge: 
from simple machinery to complex networks. Developmental cell 17, 310-322 
301. Ruan, G. X., and Kazlauskas, A. (2013) Lactate engages receptor tyrosine kinases 
Axl, Tie2, and vascular endothelial growth factor receptor 2 to activate 
phosphoinositide 3-kinase/Akt and promote angiogenesis. The Journal of 
biological chemistry 288, 21161-21172 
302. Sonveaux, P., Copetti, T., De Saedeleer, C. J., Vegran, F., Verrax, J., Kennedy, K. 
M., Moon, E. J., Dhup, S., Danhier, P., Frerart, F., Gallez, B., Ribeiro, A., 
Michiels, C., Dewhirst, M. W., and Feron, O. (2012) Targeting the lactate 
transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation 
and tumor angiogenesis. PloS one 7, e33418 
303. De Saedeleer, C. J., Copetti, T., Porporato, P. E., Verrax, J., Feron, O., and 
Sonveaux, P. (2012) Lactate activates HIF-1 in oxidative but not in Warburg-
phenotype human tumor cells. PloS one 7, e46571 
304. Beckert, S., Farrahi, F., Aslam, R. S., Scheuenstuhl, H., Konigsrainer, A., 
Hussain, M. Z., and Hunt, T. K. (2006) Lactate stimulates endothelial cell 
migration. Wound repair and regeneration : official publication of the Wound 
Healing Society [and] the European Tissue Repair Society 14, 321-324 
305. Kumar, V. B., Viji, R. I., Kiran, M. S., and Sudhakaran, P. R. (2007) Endothelial 
cell response to lactate: implication of PAR modification of VEGF. Journal of 
cellular physiology 211, 477-485 
306. Lu, H., Dalgard, C. L., Mohyeldin, A., McFate, T., Tait, A. S., and Verma, A. 
(2005) Reversible inactivation of HIF-1 prolyl hydroxylases allows cell 
metabolism to control basal HIF-1. The Journal of biological chemistry 280, 
41928-41939 
 
176
